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Abstract
Canine Transmissible Venereal Tumour (CTVT) is a neoplastic disease occurring 
naturally in dogs. CTVT is usually sexually transmitted, but transmission may occur 
by licking, biting, or scratching tumour-affected areas. Cytogenetic studies directed 
to verify the cell transmissibility of the CTVT showed that the tumour cells are 
characterized by a rearranged karyotype, which is similar in tumours from in 
different parts of the world. Thus it was postulated that that the transmissible agent 
causing the CTVT is the tumour cell itself and that all worldwide CTVT have a 
clonal origin. Given the lack of a definitive proof of the cellular transmission and 
clonal origin of CTVT, in this PhD project, I tested this hypothesis by analysing the 
genetic distance between host and tumour and between tumours, using molecular 
genetic markers including major histocompatibility (MHC) genes, microsatellite 
loci, and mitochondrial (mt) DNA in matched tumour and normal tissues from 
naturally occurring tumours collected worldwide. Here I demonstrate that tumours 
are genetically distinct from their hosts and that the tumours obtained from 5 
different continents are derived from a single neoplastic clone. During its evolution 
CTVT has diverged into two distinct phylogenetic subclades. Although naturally 
occurring CTVTs are observed only in dogs, CTVT has been reported to be 
experimentally transmitted by inoculation of tumour cells in other species of the 
Canidae family such as foxes, coyotes and jackals, thus raising questions about its 
capacity to grow as an allograft or xenograft and its phylogenetic origin of CTVT. I 
therefore examined MHC gene transcription in a progressive growing tumour and 
observed MHC class I and II downregulation. In this study phylogenetic analyses 
indicate that CTVT most likely originated from a wolf or an East Asian breed of 
dog. CTVT has been described for the first time in 1876 by Novinsky, thus arguing 
for an age of at least 130 years old. Here phylogenetic analysis based on 
microsatellites suggests that CTVT originated between 250 and 2500 years ago.
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Chapter 1
Introduction
1.1 Historical perspective on cancer causation
The term "karkinos" (crab) was employed by Hippocrates as a metaphor to describe 
a variety of swelling conditions, with finger like spreading projections from a round 
nodule (Kenneth, 2003). Hippocratic and Galenic medicine attributed the spread of 
black bile (one of the four humours) in the tissue as the cause of the cancer 
(Diamandopolus, 1996). This idea survived intact through the Middle Ages and 
Renaissance. With the discovery of the lymphatic system by Gasparro Aselli in 
1662, the black bile theory was superseded by the idea that cancer was an 
inflammatory reaction to extravasated lymph; a theory modified 150 years later by 
John Hunter who introduced the notion that contaminated coagulating lymph was 
the origin of the cancer (Kenneth, 2003). In 1838, German pathologist Johannes 
Muller demonstrated that cancer is made up of cells and not lymph, but he believed 
that cancer cells did not originated from normal cells but from a budding element 
named Blastema (Kardinal and Yarbro, 1979). Following Schleiden and Schwann's 
cell theory of tissues, it was Rudolf Virchow (Muller's student) who in 1855 that 
demonstrated that every cell is derived from another cell (omnis cellula e cellula), 
including cancer cells (Mazzarello, 1999; Porter, 1999). In 1867 Wilhelm Waldeyer 
supported the theory of the normal cell for the origin of cancer and he believed that 
metastasis resulted from transportation of cancer cells by blood or lymph (Porter,
1999).
Around the turn of the twentieth century the beginning of tumour transplantation 
experiments led to the new view of the cancer cell as an autonomous cell. The first 
successful tumour transplants were described in 1876 by the Russian veterinarian 
Mstislav Aleksandrovich Novinski (Novinski, 1876). He reported in his thesis
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entitled On the Question o f  the Inoculation o f  Malignant Neoplasms the first 
successful serial passage of tumours through transplantation in dogs. Novinski's 
transplantation experiments were based on the inoculation of canine transmissible 
venereal tumour (CTVT) in puppies. Novinski stated that successful tumour 
transplantation depends on the inoculation o f a living element of the tumour and that 
the transplantation of the element of a cancerous tumour to healthy tissue acts as an 
infecting agent. In 1888 Wehr repeated Novinski's transplantation experiments in 
dogs with similar results (Shimkin, 1955). It is interesting to note that the dogs used 
for transplantation of CTVT did not come from a single breed and were therefore 
not highly inbred. The allo-transplantation of tumours seemed less surprising in the 
late 19th Century than it does today with our modem knowledge of histo- 
incompatibility.
The successful results obtained with CTVT served as model for tumour transmission 
in other animals. Hanau in 1898 inoculated two rats with vulvar epidermoid 
carcinoma and observed growth of the tumour in the recipients (Shimkin, 1955). In 
1901 Leo Loeb supported the transplantability of tumours in rats (Witkowski, 1983; 
Brent, 1997). In 1903 a Danish veterinarian Carl O. Jensen demonstrated that the 
successful growth of transplanted tumours in mice is determined by heredity (Brent, 
1997). The discovery that the tumour could be successfully transplanted into other 
mice, led to the idea of using the rodent system to supply tumours for experiments. 
The observation that a single tumour can be expanded through many generations 
exceeding the life span of the laboratory mouse led Leo Loeb to the "cancer 
immortality" concept (Witkowski, 1983).
One of the most important steps in the discovery of the mechanistic basis o f the 
origin of cancer is due to Theodor Boveri (Allan, 2001). The results of his 
experiment on the fertilization of the Ascaris megalocephala eggs first and 
Paracentrotus sea urchin later led to Boveri in 1902-1904 to postulate the 
chromosomal theory of heredity (Baltzer, 1964). The observation that the sea
urchin eggs carrying an abnormal number of chromosomes showed abnormal 
growth, and the observation made by David Von Hansemann of abnormal mitosis in 
tumour cells, led Boveri in 1914 to develop the theory that the malignant tumours 
originated by incorrect chromosome segregation (genome instability) and that this 
abnormality was passed to daughter cells (clonal origin (Allan, 2001; Rowley, 
2001 ).
The earliest observations reported by John Hill in 1759 and by Percival Pott in 1775 
on the association of a specific tumour to a specific profession or work, led to the 
idea that some chemicals can cause cancer (Greaves, 2000). In 1918 Yamagiwa and 
Ichikawa induced cancer by applying coal tar to rabbit skin (Greaves, 2000; Luch, 
2005).
After the discovery of the X rays by Wilhelm Conrad Roentgen in 1895, Frieben 
published data in 1902 indicating that cancer rates were increased among persons 
working with X-rays (Cassileth, 1983; Greaves, 2000)
The concept that cancer might be contagious also recurs throughout the past 300 
years. In the XVII and XVIII centuries, physicians Daniel Sennert and Zacutus 
Lusitanus supported the hypothesis that cancer was contagious. In fact in 1779 a 
hospital in Paris dedicated mainly to cancer patients was forced to move from the 
city because of fear of cancer spread to the population in the city (Cassileth, 1983; 
Kenneth, 2003). In 1844 the Italian physician Domenico Antonio Rigoni-Stem 
noted that cancer of the cervix was frequent among married ladies, rare among 
unmarried ladies and absent in Italians nuns. In contrast, breast cancer was more 
frequent among nuns (Greaves, 2000). These observations led to the hypothesis that 
cervical cancer was sexually transmitted, and we now know that the cause is a 
papilloma virus (zur Hausen, 2002). In 1908 Wilhelm Ellerman and Olaf Bang, 
studying leukaemia in chickens succeeded in transferring the disease from one 
animal to another by cell-free tissue filtrates (Wyke, 2003). In 1911 Peyton Rous
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demonstrated that viruses were the cause of solid tumours (Sarcoma) in chickens but 
it took many decades before his data were accepted (Dulbecco, 1976). The notion 
that viruses can cause cancer was a discovery that brought back the fear that cancer 
was a contagious disease.
With the discovery made by Hermann Muller in 1930, that exposure to X rays 
causes mutations in fruit flies, cancer scientists began a series of experiments to find 
the causal role of genetic alteration in cellular transformation (Weinberg, 2001). 
One of these experiments was made in the laboratory of Michael Bishop and Harold 
Varmus (Stehelin et al., 1976) with the demonstration that normal chicken DNA 
contains a homologue of the viral gene \-src  oncogene of Rous Sarcoma Virus. V- 
src is able to transform normal cells and the homologus sequence was present in all 
normal cells as a proto-oncogene. Robert Weinberg, and Michael Wigler, using the 
DNA transfer approach, demonstrated that DNA extracted from chemically induced 
tumours was able to induce transformation when transferred in to a normal cell 
(Shih et al., 1979; Perucho et al., 1981). This observation was soon confirmed with 
human tumours (Perucho et al., 1981). When the transforming DNA was cloned and 
sequenced, it was recognized as a mutated form of the k-ras gene, a gene first 
characterized in oncogenic retroviruses (Shimizu et al., 1983). These new 
discoveries had a profound effect in converging all the causation theories into a 
unified theory that sees the mutation of DNA of specific genes as a key target in 
carcinogenesis.
1.2 Tumour Progression
The first detailed characterization o f the dynamic nature of cancer was described by 
Leslie Foulds (Foulds, 1949). Foulds showed that tumours progress (evolve) 
through different stages, characterized by the acquisition of different phenotypic 
traits such as increased growth rate, hormone dependence, invasiveness, formation 
of metastasis (Foulds, 1949; Foulds, 1954; Foulds, 1957). With the progress of
15
molecular biology the phenotypic view has been replaced with the somatic mutation 
theory, where cancer evolves through the accumulation of different mutations in 
several genes (Greaves, 2000). The accumulation of mutations in somatic cells 
implicates the presence of different cells bearing different mutations and also the 
presence of natural selection, which selects the cells with advantageous mutations. 
One of the questions arising from the somatic mutation theory is whether a tumour 
has a single or a multiple origin.
To determine mono- or poly-clonality o f the tumour, Philip Fialkow used the X 
linked glucose 6-phosphate dehydrogenase (G-6-PD) gene as a genetic marker 
(Linder and Gartler, 1965; Fialkow et al., 1967). In females one of the two 
chromosomes X are randomly inactivated through methylation, therefore only genes 
present in the non-methylated X chromosome are expressed in a given somatic cell. 
The human population, especially African Americans, has two frequent G-6-PD 
variants called A and B. Therefore in accordance to the random X inactivation, in 
females heterozygous for G-6-PD we expect to have two bands with different 
electrophoretic mobilities. Analysis conducted in G-6-PD heterozygous female 
tumours indicate that in all tumours analyzed, the tumours were monoclonal 
(Fialkow, 1979).
This observation was supported by a karyotype analysis in chronic myelogenous 
leukaemia (CML) by Peter Nowell and David Hungerford in 1960 (Nowell, 2002). 
They described the presence of an unusually short chromosome 22 in all CML 
tumour cells analyzed, and the absence in the normal cells from the same patients. 
This observation suggested that this mutation was a somatic mutation that occurred 
in one cell in the bone marrow, which gave it a selective advantage to expand as a 
clone. Nowell postulated that a tumour develops by a Darwinian evolutionary 
process, where cells with mutations conferring a growth advantage are selected and 
expanded (Nowell, 1976; Greaves, 2002).
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Although the notion that cancer evolved in a multistep fashion has been determined 
by applying molecular biology techniques, the notion that cancer progresses through 
several events has been suggested during the 1950s by applying mathematical 
models (Weiss, 2004). In 1949 Isaac Berenblum and Philip Shubik developed the 
two stage model, which was based on the observation that cancer can be induced by 
the application of mutagens followed by a non-mutagenic promoter, such as phorbol 
ester (Berenblum and Shubik, 1949). In 1954 Peter Armitage and Richard Doll 
analyzed human cancer incidence over the age, and showed that the incidence of 
cancer increased with the sixth of power of age (Armitage and Doll, 1954). They 
postulated the multistage theory of cancer and inferred that before the clinical 
manifestation of cancer, the cellular lineage needs 6-7 independent sequential steps 
of transformation (Armitage and Doll, 2004). Based on the observation of the 
incidence of Retinoblastoma in children, Alfred Knudson postulated the two hit 
hypothesis (Knudson et al., 1975). Retinoblastoma is a tumour that becomes 
manifest early in life. Retinoblastoma can be inherited or sporadic. According to the 
two hit hypothesis in the inherited form a single mutation in the Retinoblastoma 
(Rb) gene is present in the germ line which gives the genetic predisposition to 
develop cancer, but a second mutation in the normal Rb allele which occurs in the 
retinoblast must be acquired to develop cancer (Knudson, 2001). In the sporadic 
form the two mutations in the Rb alleles occur in the somatic cells. Although the 
epidemiological and molecular observations have consolidated the multistage theory 
of cancer, the number of mutations and in which sequential order they have to be 
acquired to develop cancer is still an open question (Hanahan and Weinberg, 2000; 
Hahn and Weinberg, 2002b).
Early experiments involving transforming retroviruses and the transfer of genes 
from tumour cells into established rodent cells allowed the identification of several 
cancer causing genes called oncogenes. The result of these experiments suggested 
that cancer could be induced by the mutation of one proto-oncogene. However the 
rodent cells used as recipient in the gene transfer experiments were not normal, but 
were immortalized, thus acquiring the ability to proliferate indefinitely. When the
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normal rodent cells were used, the transfer of a single oncogene failed to induce 
transformation, while the transfer o f two oncogenes resulted in transformation. 
Recent evidence suggested that human cells require more mutations than rodent 
cells and that there are differences also between cell types within the same species 
(Rangarajan et al., 2004).
1.3 Cancer Hallmarks
Despite the enormous variety of tumours affecting different types of tissues in 
animals and humans, research over the past 50 years has revealed that all malignant 
cancer share the same essential alterations (Hanahan and Weinberg, 2000). These 
alterations are the result o f breaching specific barriers evolved by multicellular 
organisms through their evolution from unicellular organisms (Michod, 2002). 
These alterations include:
Immortalization
Evasion of programmed cell death (apoptosis)
Independence from growth stimulation 
Resistance to growth inhibition 
Angiogenesis 
Invasion and metastasis 
Genetic instability.
These hallmarks are briefly described below.
1.3.1 Immortalization
Early experiments performed by Hayflick in 1961 demonstrated that normal cells 
when propagated in culture possess a limited replication capacity (Hayflick and 
Moorhead, 1961). The replicative capacity differs between cells within species and 
between species (Hahn and Weinberg, 2002a). When cells reach the limit of 
division a specific cellular program called senescence is activated. Since senescence
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limits the number of cellular divisions it plays an important role in aging and tumour 
biology (Mathon and Lloyd, 2001; Hahn and Weinberg, 2002a). The observations 
that DNA polymerase is unable to copy the extremity of the chromosomal DNA 
called the telomere, thus shortening the telomere during each mitosis, led Olovnikov 
in 1970 to propose that since the mammalian cells are unable to duplicate the 
telomeres, during mitosis the telomere are eroded until the chromosome ends are 
fused, causing genomic abnormalities which result in cellular death (Olovnikov, 
1973; Olovnikov, 1996). Over the past 25 years the results of numerous experiments 
have supported Olovnikov's speculations.
Telomeres contain DNA sequence repeats and protein. The repeat sequence 
consists o f hexameric motifs such as GGGTTA in humans, extended for 10 -20  
kilobases. The 3’ end has a 100-400 nucleotide over-hang (Mathon and Lloyd, 
2001). Telomeric DNA is generated by a reverse transcriptase called telomerase, 
containing a RNA subunit and a catalytic protein subunit, Telomerase Reverse 
Transcriptase (TERT). The telomerase RNA binds the telomeres DNA ends thus 
acting as template for telomere elongation. The chromosome ends are protected by 
several proteins: TRF-1, TRF-2, and POT-1 (Mathon and Lloyd, 2001; Hahn and 
Weinberg, 2002a). Several experiments have shown that senescence is activated 
when the telomeres are shortened down to 5 kb and that senescence is triggered by 
the shortest telomere present in the cell (Hemann et al., 2001).
Recent reports have suggested that the replicative senescence is not activated by the 
erosion of the double strand repetitive sequence, but by the degradation of the 3’end 
single strand overhang, resulting in loss of protective capping (Stewart et al., 2003). 
Telomere length is maintained by the activation of telomerase or by an alternative 
mechanism called alternative lengthening of telomeres (ALT), where the telomeres 
are regenerated through recombination-based interchromosomal exchange of 
sequence information (Bryan et al., 1997; Dunham et al., 2000). In the normal cell 
telomerase is transiently expressed, since it can be detected only in S phase, but in
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neoplastic cells its expression is increased and is detectable throughout the cell cycle 
(Mathon and Lloyd, 2001).
Although ectopic expression of telomerase in fibroblast cells results in increased 
replication capacity (Bodnar et al., 1998), recent experiments reveal that not all cells 
can be immortalized by telomerase activity (Kiyono et al., 1998) and that 
senescence is not an intrinsic mechanism independent from extrinsic stress, but a 
protective mechanism that can be activated also by external factors such as oxygen 
and metabolic stress, and internal factors such as the overexpression of oncogenes, 
that occur in cells with normal telomere length (Ben-Porath and Weinberg, 2004). 
Senescence can be triggered by the activation o f the tumour suppressor proteins p53 
and or Rb (Hahn and Weinberg, 2002a). While telomere erosion is detected as 
double strand breaks, thus leading to the activation of the ATM/ATR and or p l4 /arf 
complexes, which activate the p53 cascade, the external stress activates the p i6 
protein causing activation of the Rb pathway (Mathon and Lloyd, 2001). The 
inactivation of p53 or Rb leads cells to bypass the senescence barrier with further 
erosion of telomeres, until the cells reach a second proliferative block known as the 
crisis barrier, activating programmed cellular death (Reddel, 2000).
In tumour cells the senescence and crisis barriers are avoided by the activation of 
telomerase regenerating the telomeres and by the inactivation of tumour suppressor 
and pro-apoptotic genes (Hanahan and Weinberg, 2000; Hahn and Weinberg, 
2002b).
1.3.2 Apoptosis.
Multicellular organisms are organized in tissues arranged to form organs. Behind 
this organization there are highly regulated processes acquired through evolution 
from unicellular to multicellular organisms (Michod, 2002). One of these processes, 
known as programmed cell death or apoptosis, plays a key role controlling the
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number of cells during development and adult life by inducing the superfluous and 
defective cells to commit suicide (Alberts et al., 2002i).
In adult tissues the number of cell divisions is balanced by cell death. In cancer this 
equilibrium is shifted toward proliferation. The apoptosis process is organized by 
sensors and effectors (Hanahan and Weinberg, 2000). The sensors detect the intra- 
and extra-cellular signals. The intracellular signals include DNA damage, hypoxia 
and oncogene overexpression (Evan and Littlewood, 1998). The extracellular 
signals monitor the cell-cell and cell-matrix homeostasis (Aoshiba et al., 1997; 
Alberts et al., 2002i; Prince et al., 2002). The signals detected by the sensor are 
mainly conveyed to the mitochondria, where a series of cytoplasmatic proteins of 
the Bcl2 family control the release of cytochrome C from the mitochondria (Alberts 
et al., 2002i). The release of cytochrome C activates an array of intracellular 
proteases called caspases causing protein and DNA degradation (Hanahan and 
Weinberg, 2000). The caspases can be directly activated by extracellular proteins 
such as FAS ligand, which binds to the death receptor FAS (Houston and O'Connell,
2004).
Once the caspase cascade is triggered it cannot be inactivated (Alberts et al., 2002i). 
It has been reported that the tumour suppressor p53 can trigger the caspase cascade 
by the overexpression of the Bax protein, a member of the Bcl2 family, which in 
turn increases cytochrome C release thus inducing apoptosis (Hanahan and 
Weinberg, 2000).
It has been observed that in over 50% of human tumours, the tumour suppressor p53 
gene is functionally altered. p53 plays a key role in the maintenance of the genome 
integrity (Harris, 1996). From these considerations it has been suggested that when 
the level of DNA damage exceeds the DNA repairing capacity, p53 activates the 
apoptosis pathway, thus avoiding the replication of mutated cells. In cancer, p53 
inactivation allows the neoplastic cell to proliferate with a mutated genome (Levine,
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1997). A number of genes encoding proteins involved in inhibiting or promoting 
apoptosis are found to be mutated in many different kinds o f cancer (Lowe and Lin, 
2000).
In CTVT, the subject of this thesis, it is likely that expression of c-myc is up- 
regulated, due to insertion of a LINE-1 element as discussed later. Ectopic c-myc 
expression can promote tumour growth and survival, as seen, for instance, in 
immunoglobulin gene c-myc chromosome rearrangements in Burkitt's lymphoma 
(Hemann et al., 2005).
1.3.3. Independence from growth stimulation
In complex, multicellular organisms, cells cooperate with each other for the survival 
of the whole organism. At the core o f the cooperation there is the dependence o f a 
single cell on other cells, so that cells are dependently evolving units (Lachmann et 
al., 2002). Normally the passage from the quiescent to the proliferative state requires 
the presence of mitogenic growth signals in the microenvironment surrounding the 
cells. Thus the proliferation of a cell is dictated by the needs of the cells around it 
(Hanahan and Weinberg, 2000). In contrast, a tumour cell escapes from the external 
dependence to become an autonomous evolving unit, by producing its own growth 
signals (Hanahan and Weinberg, 2000).
Although the proliferative stimuli that are exerted by soluble growth factors 
generally act in a paracrine fashion, where growth signals produced from one type 
o f cell are able to stimulate a different type of cell, a tumour cell may produce 
growth factor that activates itself (autocrine stimulation) generating a positive 
feedback (Reith and Panayotou, 2003). One of the growth factors produced by 
many tumours is platelet-derived growth factor (PDGF) that interacts with the 
PDGF receptor present on the tumour cell surface which in turn activates the
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transcription of c-myc and c-fos oncogenes (Rozengurt et al., 1985; Benito and 
Lorenzo, 1993; Pietras et al., 2003).
Another mechanism selected by tumour cells is the overexpression of growth factor 
receptors, which induce the tumour cells to become sensitive to concentrations of 
growth factor that normally do not trigger proliferation (Hanahan and Weinberg,
2000). Proliferation can also be induced by a mechanism independent of the growth 
factor, for example the alteration of the cytoplasmic tail of the epidermal growth 
factor receptor (EGFR) causes self-activation of the receptor, which therefore 
becomes independent from the external microenvironment (Alberts et al., 2002a).
The role of the external microenvironment in regulating cellular proliferation is 
progressively gaining evidence. Cells are connected with the extracellular matrix by 
receptors called integrins (Alberts et al., 2002h). Integrins not only attach cells to 
their external environment, but also activate intracellular signalling pathways in 
response to the extracellular matrix (Alberts et al., 2002h). The association between 
integrins and extracellular matrix can also be regulated by intracellular signals 
(Giancotti and Ruoslahti, 1999). Tumour cells are able to modify the relative 
expression of specific integrins that promote cellular proliferation (Danen, 2005).
Although tumour cells are generally described as independent evolving units, recent 
results suggest that tumour cells are able to stimulate stromal cells to produce 
growth factors that increase tumour proliferation (heterotypic stimulation) (Kinzler 
and Vogelstein, 1998; Skobe and Fusenig, 1998; Iyengar et al., 2003). It has been 
demonstrated that cells involved in the immune response to tumours may produce 
factors such as inflammatory chemokines that may also promote the tumour 
proliferation (Pollard, 2004; Wyckoff et al., 2004).
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1.3.4 Resistance of growth inhibition
To balance the activity of the growth signals, the multicellular organism possesses 
several mechanisms that regulate proliferation. Like growth signals, the anti­
proliferative signals derive from soluble factors or surface proteins that are produced 
by neighbouring cells, or are induced by components of the extracellular matrix 
(Hanahan and Weinberg, 2000; Alberts et al., 2002d). These external inhibitory 
signals activate different intracellular pathways that regulate the cell cycle (Alberts 
et al., 2002b).
The cells within a multicellular organism can be found in three different states: 
quiescent, proliferative, and post-mitotic (Alberts et al., 2002g). Normally the 
quiescent and proliferative states are reversible, whereas the post-mitotic status is 
irreversible (Alberts et al., 2002g). It is thought that the majority of the anti­
proliferative signals act in the transition from the cellular G1 to S phase of the cell 
cycle (Hanahan and Weinberg, 2000).
The Rb protein and its related proteins, p i07 and p i30, play a key role in controlling 
this transition (Weinberg, 1995). The association of Rb with the transcription factor 
E2F inhibits the transcription of genes involved in the G l-S progression (Alberts et 
al., 2002b). The hyper-phosphorylation of the Rb protein induces the dissociation 
with E2F, therefore allowing progression to S phase (Alberts et al., 2002b). 
Normally complexes of cyclin and cyclin dependent kinase (CDK) induce the 
phosphorylation of the Rb protein (Alberts et al., 2002b). Many tumours can avoid 
the antigrowth signals by altering Rb activity or the proteins involved in Rb 
phosphorylation (Mittnacht, 2005).
Retinoblastoma and osteosarcoma are examples of tumours where Rb activity is 
altered (Mittnacht, 2005). Some glioblastomas and breast cancers are found to have
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the CdK4 or cyclin D1 genes amplified, therefore increasing Rb phosphorylation 
and consequently cell proliferation (Alberts et al., 2002a).
1.3.5 Angiogenesis
All cells within tissues and organs are supplied with oxygen and nutrients by the 
vasculature system. During development cellular growth is coupled with the 
formation of new blood vessels (Cleaver and Melton, 2003). In adult tissues, new 
vessels are required in response to tissue damage and tissue remodelling (Carmeliet, 
2003). The small blood vessels consist o f only endothelial cells, whereas in larger 
vessel, pericytes or smooth muscle cells surround the endothelial cells (Carmeliet, 
2003). Although it is commonly believed that blood vessels in different tissues 
consist of endothelial cells with identical properties, recent results suggest that 
different organs are equipped with distinct and specialized endothelial cells (Cleaver 
and Melton, 2003). Although the majority of the new vessels in adult tissues are 
derived by sprouting from existing vessels, recent evidence indicates that progenitor 
endothelial cells are derived from the bone morrow contributing to the vessel 
growth (Zhang et al., 2002; Contreras et al., 2003; Nishimura and Asahara, 2005; 
Religa et al., 2005). The formation of new vessels is referred as vasculogenesis, 
when the endothelial cells are derived from endothelial progenitors to form a 
primitive vascular bed, and as angiogenesis and arteriogenesis, when new vessels 
result from the expansion of existing vessels (Carmeliet, 2003). Although 
endothelial cells are highly proliferative in response to several angiogenic factors, 
they have long half-lives up to several years (Carmeliet, 2003). Generally, all cells 
residing within 100 pm of a capillary blood vessel have access to oxygen and 
nutrients by diffusion, but when a new tissue grows beyond the diffusion limit, the 
formation of new vessels is triggered (Hanahan and Weinberg, 2000). In order to 
adapt the vascular system to the tissue's requirements, several mechanisms regulate 
the process of angiogenesis (Carmeliet, 2003).
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Numerous observations indicate that small tumours (less than 1 mm) can persist for 
a long period of time (from months to years) in an avascular, quiescent state 
(Folkman, 2002). Thus in order to grow, tumour cells must change the local 
equilibrium between positive and negative regulators of angiogenesis. Several 
studies demonstrated that a tumour acquires the ability to form its own vasculature 
system in mid-stage lesion, thus indicating that angiogenesis is essential for rapid 
clonal expansion (Hanahan and Weinberg, 2000). A key molecule involved in the 
angiogenesis process is the vascular endothelial growth factor (VEGF) (Carmeliet,
2003). Tumour cells are able to promote angiogenesis by over-expressing VEGF or 
by down-regulating angiogenic inhibitors like thrombospondin or beta-interferon 
(Folkman, 2002). In addition it has been demonstrated that tumours can activate or 
inactivate pro- and anti-angiogenic factors respectively present in the extracellular 
matrix by producing several proteases (Gately et al., 1997; Harlozinska, 2005). 
Recently it has been suggested that different organs and therefore different tumours 
use different promoting and inhibitory factors to trigger the formation of new blood 
vessel (Harlozinska, 2005).
1.3.6 Metastasis
The majority of the cells in multicellular organism are bound and organized in 
tissues and organs. Cells are held together indirectly by extra-cellular matrix and 
directly by cell-cell junctions (Alberts et al., 2002c). The extra-cellular matrix is 
composed of proteoglycans and fibrous proteins such as collagen, elastin, 
fibronectin and laminin (Alberts et al., 2002c). While the proteoglycans form a 
hydrated gel substance, the fibrous proteins have structural and adhesive functions. 
Cells are bound to the extra-cellular matrix and to their neighbours by several types 
of adhesion molecules; while transmembrane adhesion proteins called integrins 
mediate the interaction between cells and extra-cellular matrix, the transmembrane 
proteins that belong to the cadherin family mediate the interactions between cells 
(Alberts et al., 2002c). Although cell adhesion molecules have an essential structural
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role, they are also involved in the communication network between the extra- and 
intra-cellular microenvironment. While the majority of cells are immobile, cellular 
migration plays an important part during embryonic development, in adult tissue 
repair processes and in immunological processes. Cells of the haematopoietic 
system including tissue macrophages (or histiocytes) are naturally mobile (Imhof 
and Aurrand-Lions, 2004). In cancer during tumour progression, some tumour cells 
acquire the ability to migrate and form new colonies at secondary sites (Hanahan 
and Weinberg, 2000). Metastasis is the migration of tumour cells from their primary 
tumour formation site to secondary sites where they invade normal tissue and 
proliferate to form new tumours (Hanahan and Weinberg, 2000). It has been 
estimated that 90 % of mortality associated with cancer is due to metastasis (Spom, 
1996). Recent results show that few cells in the primary tumour acquire the ability 
to grow in the secondary sites and that the tendency to metastasise is acquired in the 
early steps of tumour progression (Van't Veer and Weigelt, 2003).
The ability of tumour cells to spread in new tissues or organs relies on overcoming a 
series of interdependent steps, which include: cell detachment, motility, local 
invasion, intravasation, circulation, adhesion, extravasation, proliferation and 
growth (Nguyen, 2004). In order to migrate, the tumour cell must alter the cell-cell 
and the cell-matrix interactions (Zigrino et al., 2005). It has been shown that in 
many tumours the transcription of E cadherin is reduced (Christofori and Semb, 
1999; Bogenrieder and Herlyn, 2003). This reduction can be induced by genetic or 
epigenetic events (mutations or transcriptional repression), increased proteolysis, 
and redistribution to a different cellular site (Bogenrieder and Herlyn, 2003). 
Another mechanism adopted by tumour cells is to switch the expression of cell 
adhesive molecules (CAMs) with high adhesive capacity to CAMs with poor 
adherence capacity, thus favouring cellular mobility (Hanahan and Weinberg, 2000; 
Bogenrieder and Herlyn, 2003). An essential step in the metastatic process is the 
degradation of the extra cellular matrix by the proteolytic activity of proteases 
produced directly by tumour cells, or indirectly by stromal or immune cells 
(Egeblad and Werb, 2002). The increase o f protease activity can be due to up-
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regulation of protease expression, down regulation of the expression of protease 
inhibitors and increased conversion of active forms (Egeblad and Werb, 2002).
Cell motility is a complex and highly coordinated process, therefore is likely that 
tumour cells acquire motile ability by altering the expression of genes implicated in 
the motility process (Bogenrieder and Herlyn, 2003). Although gene expression 
comparison between metastatic and non metastatic tumours suggest the requirement 
o f cell-intrinsic changes to confer the motile competency (Condeelis et al., 2005; 
Wang et al., 2005), other studies suggest that extrinsic factors present in the 
microenvironment are also required to trigger the motility responses (Zigrino et al.,
2005).
Progressive alteration of normal tissue homeostasis by tumour and stromal cells, 
allow tumour cells to move throughout degraded matrix, and to invade surrounding 
tissues (Hanahan and Weinberg, 2000). Tumour cells are also aided to migrate by 
soluble factors (chemotaxis) and bound adhesion molecules (haptotaxis) (Nguyen,
2004).
Tumour invasion can be also due to mechanical pressure induced on the nearest 
tissues by rapid tumour growth causing local tissue damage, thus favouring the 
tumour invasiveness (Hart, 2003). Progressive local invasion allows tumour cells to 
invade the systemic circulation (Hart, 2003). Although tumour cells may acquire the 
ability to form new blood or lymphatic vessels, tumour cells may invade a pre­
existing vessel or invade directly the blood vessel, or may penetrate first the 
lymphatic vessels and then invade the haematogenous system (Nguyen, 2004). 
Essential to this end is the ability of tumour cells to recognize different adhesive 
molecules present in lymphatic and haematogenous systems (Dua et al., 2005).
In order to invade new organs, circulating tumour cells need to stop and exit the 
systemic circulation. In an unspecific manner, the extravasation may be due to the
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fact that large arteries progressively narrow in to arterioles and then capillaries, and 
tumour cells can be trapped in this small vessel, thus allowing the migration in the 
new organ (Nguyen, 2004).
Although tumour cells may invade several organs, it has been shown that certain 
types of cancer form metastases in specific organs. In 1889 Stephen Paget suggested 
that the colonization of a new organ by tumour cells is the result of the interaction of 
circulating tumour cells (seed) and the target tissue (soil) (Fidler, 2003). Although 
the exact mechanism behind the tumour homing is not completely understood, 
recent results suggest that the selective homing of cancer cells may be due to three 
mechanisms: 1) presence in the target tissue of specific growth factors or 
appropriate extra-cellular matrix that favour the selective tumour growth, 2) 
presence in the target organ vessel endothelium of specific adhesive proteins that 
interact with the tumour cells, favouring the tumour invasion, 3) production of a 
chemotaxis soluble factor by the target tissue that attract the tumour cells (Fidler, 
2003). Recently it has been reported that tumour cells by secreting specific humoral 
factor(s) can mobilize haematopoietic bone marrow progenitors cells to specific 
organs, where they change the local environment to form a pre-metastatic niche that 
attracts and supports the incoming tumour cells thus favouring the development of 
metastasis (Kaplan et al., 2005).
Recently it has been shown that the gene expression pattern between tumour cells 
in primary and secondary tumours are similar, thus suggesting that the metastatic 
ability is acquired in the early steps of the tumour progression, and that the genetic 
alterations responsible for tumorigenesis are involved in the metastatic process 
(Bernards and Weinberg, 2002; Van't Veer and Weigelt, 2003).
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1.3.7 Genetic instability
Over the past 25 years numerous genetic alterations have been described in human 
and animal tumours. These genetic alterations can affect the DNA sequence and the 
chromosomes (Lengauer et al., 1998). The mutations of DNA include: substitution, 
deletion, translocation and insertion and they can affect one or more nucleotides. 
Although genetic variation is considered fundamental for evolution, the necessity to 
transmit genetic information faithfully between generations demands genetic 
stability (Eisen and Hanawalt, 1999). These two opposing demands are 
accomplished by controlling the genetic variation rate. In normal conditions the 
genome is affected by spontaneous mutations caused by physiological DNA 
instability and by imprecision of the DNA polymerase proofreading activity during 
the DNA replication (Alberts et al., 2002e).
DNA polymerases limit nucleotide misincorporation by two mechanisms: one 
mechanism acts before nucleotide incorporation because the DNA polymerase 
conformation changes when a nucleotide is misincorporated causing the dissociation 
between the polymerase and DNA (Alberts et al., 20020; the second mechanism, 
known as exonucleolytic proofreading acts after nucleotide misincorporation. DNA 
polymerase has two catalytic sites; the first is called the polymerization site and is 
active when the enzyme is adding the correct nucleotide in the 5’ to 3’ direction 
during DNA replication; however, once the incorrect nucleotide is covalently added, 
the nascent 3' end is moved to the second site, called the exonucleolytic site, where 
the unpaired nucleotide is removed, allowing to shift the growing strand back to the 
polymerization site where the correct nucleotide is then added (Alberts et al., 
20020 -
In eukaryotic cells, several enzymes have been described with DNA polymerization 
activity, and five are the most important DNA polymerases involved in DNA 
replication and repair: a (alpha) p (beta) y (gamma) 5 (delta) and s (epsilon). To date
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the only polymerase involved in mitochondrial DNA replication is polymerase 
gamma. In vitro studies on the fidelity o f DNA duplication has shown that the 
nucleotide misincorporation rate varies among polymerases, with one in 5000 bases 
for beta and one in 10 000 000 for delta an epsilon polymerases (Umar and Kunkel, 
1996; Loeb and Loeb, 2000). To avoid non-complementary nucleotide 
incorporation, polymerase delta, gamma and epsilon contain a proofreading activity 
(Kunkel and Alexander, 1986). Normally DNA replication is carried out by delta 
polymerase, but recent reports show that in some tumours this priority is shifted in 
favour of less accurate polymerases, thus increasing the mutation rate (Loeb and 
Loeb, 2000). Environmental agents such as ultraviolet light, ionizing radiations and 
toxic substances in the dietary uptake can induce mutations (Loeb and Loeb, 2000).
Spontaneous mutations also occur in the normal cellular environment, due to 
depurination and deamination processes and also to the formation of reactive 
oxygen species generated from the mitochondrial electron transfer process (Alberts 
et al., 2002e). In order to repair the mutated DNA, cells have evolved several repair 
mechanisms, which involve different pathways depending on the type and extension 
o f mutation.
1.3.7a Base excision repair
The base excision repair (BER) pathway is involved when a mutation affects a 
single nucleotide. BER employs enzymes called DNA glycosylases, which are 
specific in removing a specific mutated base (Krokan et al., 2000). The enzyme 
recognizes the altered base through a base flipping mechanism. Once the mutated 
base is recognized the enzymes hydrolyze the base-sugar linkage leaving a sugar 
without a base. This sugar is then recognized by an apurinic/apyrimidinic (AP) 
endonuclease and phosphodiesterase which remove the sugar from the
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phosphodiester backbone. The missing nucleotide is replaced by DNA polymerase 
beta and linked to the next nucleotide by DNA ligase I or III (Krokan et al., 2000).
1.3.7b Nucleotide excision repair
The nucleotide excision repair (NER) system is able to repair DNA damage induced 
by UV. In contrast to BER, the NER system recognizes altered nucleotides by 
scanning the DNA for a conformational alteration (bulky lesion) (Wood, 1996). The 
human NER system consists of several proteins called XP (labelled XP-A through 
XP-G) because they were identified by studying the defective repair process in 
individuals affected by Xeroderma Pigmentosum (Cleaver, 1968). This is a rare 
autosomal recessive disorder, characterized by mutation in at least one of the XP 
genes, which give a marked genetic predisposition to develop skin cancer (Cleaver, 
1968).
The repair process begins with the detection of DNA conformational alterations by 
the XP-C protein (Wood, 1996). The XP-C then recruits the transcription factor 
TFIIH, which subsequently interacts with XP-A protein and RPA proteins. This 
complex then interacts with the helicases XPB and XPD to unwind the double 
stranded DNA. Subsequently the 3’endonuclease XPG and XPF cut out from the 
altered region 2-9 or 16-25 nucleotides respectively. The new 3 free termini interact 
with PCNA and RFC proteins, which in turn allow DNA polymerase delta to fill the 
gap. The process is then completed by DNA ligase I.
Although the NER system is involved in repairing the total genome, NER seems to 
act more efficiently on transcriptionally active genes. This activity called 
transcriptional coupled repair (TCR), guarantees the genetic integrity of the most
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essential genes (Hanawalt et al., 2003). Recent observations suggest that TCR is 
also present in BER and mismatch repair pathways (Leadon, 1999).
1.3.7c Mismatch repair
The mismatch repair (MMR) pathway includes a series of proteins that are involved 
in correcting errors that escape the DNA polymerase proofreading activity during 
DNA replication. They are also involved in suppressing recombination between 
non-identical sequences both in mitosis and meiosis (Kolodner and Marsischky,
1999). Unlike BER and NER, MMR does not act on damaged or mutated sequences, 
but it targets only the newly synthesized DNA strand. In eukaryotes several MMR 
proteins have been described that are homologous to those characterized in 
prokaryotes and therefore have an ancient lineage (Kolodner, 1996; Eisen and 
Hanawalt, 1999).
The repair process commences with the recognition of the DNA mismatch region by 
a complex formed by the interaction of hMSH2 with hMSH6 or hMSH3 proteins 
(Kolodner, 1996; Kolodner and Marsischky, 1999). This heterodimer undergoes an 
ATP dependent conformational change, which enables it to move along the DNA 
backbone. The hMSH2/hMSH6 complex recruits a second complex composed of 
hMLHl and hPMS2. This ternary complex is able to move in both directions until it 
encounters the PCNA protein, which guides the MMR complex to the 3’ free DNA 
termini present in the newly synthesized strands. At this stage the MMR complex 
activates an exonuclease able to degrade the newly synthesized strand including the 
mismatched region, thus removing the MMR complex from the mismatched 
sequence. The sequence gap is then filled by the DNA polymerase delta (Kolodner, 
1996; Kolodner and Marsischky, 1999). It has been reported that the MMR system 
decreases the level of replicative errors down to 100-1000 fold (Modrich and Lahue, 
1996). The importance of the MMR activity has been also highlighted by the fact 
that individuals with inherited mutation of MMR loci are genetically predisposed to
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develop colon cancer (Lengauer et al., 1998). The most common form of colon 
cancer predisposition is the hereditary non-polyposis colon cancer (HNPCC), where 
mutations in MMR genes present in the germ line (MLH1 and MSH2 are the most 
common) are predisposed to develop colon cancer if a somatic mutation affects the 
normal allele with the Rb system (Lengauer et al., 1998). Given that MMR is 
important for repairing errors affecting repetitive sequences, inactivation of the 
MMR system produces microsatellite instability (MSI) (Atkin, 2001).
1.3.7d Recombinational repair
Double strand breaks (DSBs) are commonly caused by ionizing radiation, however 
they also occur during the rearrangement process o f the immunoglobulin and T cell 
receptor genes. In eukaryotes, two processes called homologous recombination 
(HR) and non-homologous end joining (NHEJ) can repair double strand breaks. 
Recent studies have shown that both processes can act simultaneously or 
alternatively and that their relative contribution varies during the cell cycle and 
development (Essers et al., 2000; Haber, 2000).
1.3.7e. 1 Homologous recombination
Homologous recombination repairs double strand breaks by using an intact and 
homologous DNA molecule as a template. In eukaryotes several proteins are 
involved in the homologous recombination process (Kanaar et al., 1998; Haber,
2000). Although Rad51 has a central role in the recombination process, others 
proteins are: RP-A protein, which binds single-stranded DNA, Rad52, which can 
bind DNA ends and anneal complementary single-stranded DNA molecules, and a 
number of Rad51 paralogs (in human: Rad51-B, Rad51-C, Rad51-D, XRCC2, 
XRCC3). The process begins with the formation of the 3' single-stranded tails. The
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3' ends are the substrate for the Rad51 monomers, which form a nucleoprotein 
filament. This filament joints the heteroduplex molecule formed between the 
damaged DNA and the undamaged template. In addition to Rad51, these steps 
require the coordinated action of the RP-A protein, Rad52 and Rad51 paralogs. The 
missing sequence in the heteroduplex is generated by DNA polymerase alpha. The 
continuity of the strands is established by a DNA ligase. The final step includes the 
separation of the intact duplex DNAs, in a process called 'resolution'. Recent studies 
have shown that in humans, other proteins called BRCA-1 and BRCA-2 are 
involved in the regulation of homologous recombination. It has been suggested that 
the BRCA proteins interact with Rad51 monomers to limit their association with 
double strand breaks (Zhang et al., 1998).
1.3.7e.2 Non-homologous end joining
Non-homologous end joining (NHEJ) is the more important double strand break 
repair mechanism in mammalian cells (Khanna and Jackson, 2001). The process 
starts with an association between the DNA ends and the protein kinase Ku. 
Subsequently the Ku protein recruits DNA dependent protein kinase. The ligase 
4/XCC4 complex then joins the DNA ends. During the NHEJ process small 
deletions are generated. Given that majority o f the mammalians genome is 
composed of non-coding regions, the probability that in normal situations the NHEJ 
process induces mutation in genes is low (Alberts et al., 2002e). However, if there 
are multiple break points NHEJ increases the occurrence of illegitimate 
recombination (Rothkamm et al., 2001).
35
1.3.7d Chromosome Instability (CIN)
The cell reproduces by a series of events that allow DNA replication and cell 
division in a process known as the cell cycle. In order to check the correct order of 
events that take place in the cell cycle, a complex cell-cycle control system has 
evolved (Alberts et al., 2002b). This system checks normal cell cycle progression by 
a series of stage-specific sensors known as checkpoints that are able to induce the 
arrest of the uncompleted stage until it is completed.
The two fundamental processes in the cell cycle are the duplication and the division 
o f the chromosomes, which take place during the Synthesis (S) and Mitosis (M) 
phase respectively. To prevent the possibility that two daughter cells have non­
identical genomes, there are two checkpoints known as DNA replication and DNA 
damage checkpoints before mitosis, and one known as spindle-attachment 
checkpoint during mitosis (Alberts et al., 2002b).
The DNA replication checkpoint stops the mitotic cycle until the total replication of 
the genomes is completed. The DNA damage checkpoint is present at two cell cycle 
stages; one in G l, which prevents entry in to S phase, and one in G2 preventing 
entry into mitosis (Alberts et al., 2002b). While the G2 checkpoint acts in the same 
manner as the DNA replication checkpoint, the damaged DNA activates a series of 
protein kinases that inactivate the Cdc25 phosphatase, blocking the activation of the 
cyclin B-cyclin dependent kinase 1 complex, known also as M-Cdk, which prevents 
entry into mitosis (Alberts et al., 2002b).
The Gl checkpoint acts by inhibiting the activation of the Gl/S-Cdk and S-Cdk 
complexes. This inactivation is mediated by the regulatory protein p53. The 
damaged DNA activates protein kinase ATM that by the phosphorylation of p53 
favours the dissociation of the ubiqitin ligase MDM2 from p53, thus decreasing p53 
degradation.
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Cells must pass the correct number o f chromosomes to their progeny. The spindle 
attachment checkpoint prevents the altered segregation of the chromosomes during 
mitosis by monitoring the kinetochore status (Amon, 1999; Hoyt, 2001) . The 
kinetochore is a chromosome region that allows chromosomes to bind to the 
spindle’s microtubules. The unattached chromosome binds to the mitotic checkpoint 
complex (MCC). This process is mediated by a ubiquitin protein ligase called the 
anaphase-promoting complex or cyclosome (APC/C), along with a protein called 
Cdc20 (Amon, 1999; Hoyt, 2001).
Aneuploidy is the presence of abnormal chromosome numbers within cell 
(Rajagopalan and Lengauer, 2004). Generally the degree of chromosomal 
abnormality increases with the tumour progression being higher in malignant 
tumours. Aneuploidy is the outcome o f diverse genetic and cellular alterations 
leading to unfaithful chromosome segregation during mitosis. Although it may be 
assumed that almost all steps during mitosis can, if altered, cause chromosome 
imbalance, mounting evidence indicates that the mitotic spindle checkpoint 
alteration is a crucial point for chromosomal instability (CIN) (Rajagopalan and 
Lengauer, 2004).
Chromosome instability (CIN) is also associated with structural alteration of 
chromosomes, which include, reciprocal and non-reciprocal translocations, 
amplifications, deletions and insertions (Gollin, 2005). Structural chromosome 
instability, resulting from DNA breaks and rearrangements, is due to alteration of 
cell cycle checkpoints, DNA damage response and telomere integrity (Gollin, 2005). 
Structural alterations may results in altered gene expression or produce fusion or 
chimeric proteins with dysregulated or new properties (Greaves and Wiemels, 
2003).
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Recent studies have shown that a large proportion of human tumours with 
chromosome instability have a high rate of loss of heterozygosity (Rajagopalan and 
Lengauer, 2004). Therefore it has been argued that chromosome instability could 
accelerate the rate of inactivation or activation of tumour suppressor genes or 
oncogenes respectively (Rajagopalan and Lengauer, 2004).
CIN-associated genes can be classified on the basis of the mutational events 
required to trigger instability (Michor et al., 2005). Class I CIN genes, such as 
MAD-2 (Mitotic Arrest Deficient) trigger CIN if one allele is mutated or lost. Class 
II CIN genes, such as hBUB-1 (human Budding Uninhibited by Benzimidazoles) 
trigger CIN if one allele is mutated in a dominant negative fashion. Both MAD-2 
and hBUB-1 are required at the spindle assembly checkpoint (Amon, 1999; Hoyt,
2001). Class III CIN genes, such as BRCA1 and BRCA2 (Breast Cancer), trigger 
CIN if both alleles are mutated. BRCA genes are involved in DNA repair and 
recombination and checkpoint control o f the cell cycle (Yarden et al., 2002).
1.4 Evolutionary Dynamics of Tumour Development
According to neo-Darwinism, evolution is a balance between inherited genetic 
changes and natural selection (Ridley, 2004b). Multicellular organisms develop 
from an initial diploid cell derived by the fusion of haploid germ cells in a process 
known as fertilization. This kind of development is called Weismannistic, after 
August Weismann who first expounded the distinction between somatic and germ 
cell lines (Ridley, 2004a). The separation between somatic and germ cells, which 
occurs early in development, focuses the action of natural selection on the germ 
cells, since only they transmit genetic information to future generations (Ridley, 
2004a). The sources of genetic changes in germ cells are predominantly due to 
recombination between parental chromosomes and minimally to random mutations.
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Numerous genes present in the germ line are selected because they restrain somatic 
conflict (Michod, 2002).
According to clonal evolution theory, cancer is the result of somatic mutations 
selected during tumour evolution (Nowell, 1976). It has been argued that tumour 
cells cannot acquire the mutations needed for tumour progression at a physiological 
mutation rate, but that the tumour cell must acquire an increased mutation rate 
(Cairns, 1998; Loeb and Loeb, 2000).
Given that cancer is the result o f the accumulation of somatic mutations selected 
during tumour evolution, the processes of mutation and natural selection play an 
essential role in cancer biology. In order to induce cancer the mutations must affect 
a variety of genes that restrain somatic conflict (Frank and Nowak, 2004). These 
genes are known as cancer related genes and can be subdivided in three categories: 
Gatekeeper, Caretaker, and Landscaper (Michor et al., 2004).
Gatekeeper mutations increase the cellular proliferation rate by the alteration of 
oncogenes, tumour suppressor genes and apoptotic genes (Michor et al., 2004). 
Caretaker mutations increase genome instability by inactivating genes involved in 
maintaining genome integrity (Lengauer et al., 1998). Landscaper mutations 
increase tumour proliferation by affecting genes involved in regulating the external 
cellular microenvironment (Bissel and Radisky, 2001).
According to the multistage theory o f cancer, tumours evolve by accumulating 
mutations not only in tumour initiating genes but also in genes involved in tumour 
progression (Michor et al., 2004). Although mutations in gatekeeper and landscaper 
genes induce a selective advantage because they increase the proliferation rate, the 
accumulation of mutations in caretaker genes are more problematic to explain 
(Breivik, 2005). Given that mutations of caretaker genes increase the mutation rate 
and that the majority of mutations are expected to be deleterious, natural selection
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should limit the fixation of caretaker mutations. It has been argued that an elevated 
mutation rate could be advantageous because it allows the accumulation of 
mutations in gatekeeper and landscaper genes (Michor et al., 2004).
Theoretical analysis argues that in asexual organisms the mutated allele responsible 
for the increase in the mutation rate could be fixed in a population by hitchhiking 
with an associated allele that increases individual fitness. In sexual organisms the 
recombination process limits the hitchhiking mechanism (Sniegowsky et al., 2000).
Recent reports have suggested that the increase o f the mutation rate in asexual 
organisms may be a mechanism of adaptation and that the mutation rate can increase 
in stressful situations, where more adaptation is required, and then decrease when 
the stress event is reduced (Cairns, 1998; Sniegowsky et al., 2000). Recent 
mathematical analysis shows that tissue organization and cell population size can 
influence the dynamics of tumour progression. In large populations natural selection 
favours the fixation of advantageous mutations, whereas in small populations, 
random genetic drift allows fixation of the deleterious and advantageous mutations 
at the same rate (Michor et al., 2003).
Tissues of multicellular organism are organized in compartments. The number of 
cells in each compartment is maintained constant by several mechanisms, and 
therefore the number of dead cells is replaced by new cells (Frank, 2003). In skin 
and intestinal epithelium the stem cells renew the compartment. In each division a 
stem cell generates one transit cell and a new stem cell. The transiting cell divides 
until it reaches the upper layer and later sloughs off. Therefore mutations occurring 
in the stem cells stay in the compartment and might accumulate, increasing the risk 
o f cancer, while mutations occurring in the transit cell are eliminated from the 
compartment (Cairns, 1975).
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These observations suggest that in rapidly renewing tissues organised into many 
small compartments, like skin and intestinal epithelium, where each compartment is 
renewed by few stem cells, there is little mixing of cell population between 
neighbour compartments, and mutations in caretaker genes are fixed by random 
genetic drift despite being disadvantageous (Michor et al., 2004). In contrast, in 
tissues with large compartments, where few stem cells produce large numbers of 
differentiated cells, such as bone marrow, or conditionally renewing tissues such as 
liver and kidney, natural selection favours the fixation o f mutations affecting the 
gatekeeper and landscaper genes (Michor et al., 2004) . While mutations affecting 
oncogenes behave in a dominant way, because only one mutated allele can induce a 
tumour phenotype, mutations affecting tumour suppressor genes can be neutral if 
the normal allele compensates the mutant allele, disadvantageous if the mutant allele 
triggers apoptosis, and advantageous if the mutated allele is inactivated and the 
second allele is insufficient to balance the wild type allele (Michor et al., 2004). In 
small compartments the inactivation of the two alleles of a tumour suppressor gene, 
is unlikely, unless the mutation rate is increased by genetic instability (Nowak et al., 
2005). Given that chromosome instability (CIN) increases the rate of loss of 
heterozygosity (LOH) it also increases the probability of inactivating two TSG 
alleles in a short time (Michor et al., 2004). Thus mutations in caretaker genes may 
occur at an early stage of tumorigenesis in tissues with small compartments (Michor 
et al., 2004).
1.5 Canine Transmissible Venereal Tumour
1.5.1 Geographical Distribution
Although no detailed epidemiological data are available about the prevalence of the 
CTVT in different countries, the tumour has been reported throughout the world. It 
has been recorded in France (Marchal et al., 1997), Spain (Mozos et al., 1996)
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Poland (Wasecki, 1977), Australia (Locke et al., 1975), Russia (Osipov and 
Golubeva, 1976), Japan (Oshimura et al., 1973), Africa (Jackson, 1936) 
(Vermooten, 1987), Israel (Cohen, 1978), India (Das and Das, 2000), Turkey 
(Guvenc et al., 2002), Brazil (Saliba, 1958), United States of America (Hayes et al., 
1983), Puerto Rico, Papua and New Guinea (Rust, 1949), and Bahamas (Higgins, 
1966). In Italy CTVT is more prevalent in the southern regions (Ajello, 1936).
CTVT is rare in Denmark and United Kingdom, where the tumour has been only 
described in imported dogs. CTVT has never been reported in Sweden (Das and 
Das, 2000). Although the tumour has been described in many countries, CTVT is 
more prevalent in temperate areas with a higher prevalence in stray and feral dogs.
1.5.2 Transmission
Although the tumour is usually transmitted by coitus, it may be also transmitted by 
licking, sniffing or scratching tumour-affected areas (Feldman, 1929). Under natural 
conditions venereal transmission is highly efficient. Smith and Washboum (1898) 
reported the transmission of the tumour to 12 bitches by one male dog. Ajello 
reported that in 590 cases, 400 were found in females (Ajello, 1980). It was 
hypothesised that extra-genital forms (skin) without genital involvement may be 
explained by the possibility of tumour cell transmission by an ectoparasite 
(Batamuzi and Bittegeko, 1991).
Although naturally occurring tumours have been described only in dogs, the tumour 
can be experimentally transmitted by inoculation in other species of the Canidae 
family such as: foxes (Sticker, 1906), wolves (Dungem, 1912), jackals (Samso, 
1965), and coyotes (Cockrill and Beasley, 1979). The tumour cannot be 
experimentally transmitted to immunocompetent animals such as: mice, rats, 
hamster, cats, rabbits, chicken, monkeys, or mules (Smith and Washboum, 1898;
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Sticker, 1905; Ajello, 1939; Cockrill and Beasley, 1979). The tumour has been 
experimentally transmitted as a xenograft in nude mice (Holmes, 1981), X- 
irradiated mice (Stubbs and Furth, 1934), cortisone-treated hamsters (Samso, 1965) 
and SCID (Severe Combined Immuno Deficient) mice (Harmelin et al., 2001).
1.5.3 Etiology
Since the first description of the CTVT by Novinski in 1876 (Novinski, 1876), 
numerous experiments have been carried out to determine the etiology of the 
tumour. Although CTVT was generally described as a tumour, Bashford, Murray, 
Cramer at the newly established Imperial Cancer Research Fund, suggested that 
CTVT was not a tumour but a connective tissue reaction to a virus (Bashford et al., 
1905). Also, the high reproducibility of the tumour in experimentally transplanted 
dogs was a strong argument for a viral aetiology of CTVT (Gross, 1983). While 
experimental transmission of the tumour by inoculation o f intact and living tumour 
cells was highly reproducible (Smith and Washboum, 1898; Sticker, 1904; Stubbs 
and Furth, 1934; Ajello, 1936; Karlson and Mann, 1952; Smith, 1976), in spite of 
numerous efforts, transmission of the tumour by inoculation of cell free filtrates was 
reported only by Thierry (1950), Ajello (1960) and Dozza and Torlone, (1960). 
Experimental transplantation using labelled tumour cells indicated that the tumour 
developed from the transplanted tumour cell (Kudo et al., 1974). Several 
cytogenetic studies showed that tumours from different countries are characterized 
by constant chromosome rearrangements (Makino, 1963; Weber et al., 1965; 
Murray et al., 1969).
To date there is no evidence indicating a specific pathogen that induces the tumour, 
and the only way to transmit the tumour remains the inoculation of living tumour 
cells.
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1.5.4 Anatomo-Pathological and Clinical Aspects
The tumour is located mainly in the external genital organs. In the male the tumour 
is usually located in the glans penis and occasionally in other parts of the penis and 
prepuce. In the female it is usually located in the posterior part of the vagina in 
proximity of the vestibule and occasionally may protrude from the vulva (Cohen, 
1985). The tumour on the external genitalia appears as a cauliflower-like, 
pedunculated or multilobulated mass that can reach up to 15 cm of diameter (Ajello, 
1980). In some cases the tumour mass may infiltrate the surrounding region: 
mammary gland, scrotum, rectum and peri-anal and perivulvar regions (Ajello, 
1980). Metastases have been frequently described in immunosuppressed dogs and 
puppies and are mainly located in the inguinal or iliac lymph nodes, and 
occasionally in spleen, liver, brain, lungs, oro-nasal cavity, and eyes (Prier and 
Johnson, 1964; Ajello, 1980; Padovan et al., 1987; Placke et al., 1987; Das and Das, 
2000; Pereira et al., 2000). Extra-genital localizations have been described in 
external organs like eyes, mouth, skin and nose, also without genital involvement 
and in virgin dogs (Feldman, 1929; Jackson, 1936; Ajello, 1939; Nayak and 
Samaddar, 1988; Batamuzi and Bittegeko, 1991; Zanghi et al., 1996).
In natural and experimental conditions the tumour starts to develop from the sub­
mucosal layer and grows toward the mucosal layer causing distension and 
subsequently ulceration of the mucosal surface, assuming the clinical appearances 
described below (Ajello, 1980; Cohen, 1985). Tumour growth beneath the 
submucosal tissue is slow, but in some cases may be more extended than the 
superficial one, specially when the tumour affects subcutaneous tissues, and in these 
cases the tumour grows rapidly under the skin and slowly infiltrates the skin tissue 
causing ulceration (Ajello, 1980). Usually clinical signs include serous or 
sanguineous discharge from the genital areas. Several CTVT cases associated with 
mechanical obstruction of the urethra and uterus have been reported (Rust, 1949; 
Batamuzi and Kristensen, 1996). From clinical observations it has been suggested
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that the tumour becomes clinically evident in a period ranging from 14 days to 3 
months after sexual intercourse (Ajello, 1939; Ajello, 1980). CTVT is usually 
described in adult (2-5 years old) and sexually active dogs (Rogers et al., 1998; Das 
and Das, 2000). Although both sexes are susceptible, in some studies the tumour 
was found to be more prevalent in females (Ajello, 1980). In endemic areas the 
tumour is more frequently observed in stray or feral dogs. However, naturally 
occurring CTVT has been described in many dog breeds.
Although experimentally induced tumours regress spontaneously after 3-6 month, 
the frequency and the period of regression has not been accurately determined in 
naturally occurring CTVT (Higgins, 1966; Ajello, 1980; Yang, 1987; Yang, 1988). 
Normally in healthy animals tumours regress after 3-9 months, but in some cases, 
particularly when the animals are aged or unhealthy, the tumours do not regress 
(Das and Das, 2000). CTVT has occasionally been reported in association with 
Leishmaniasis (Albanese et al., 2002; Catone et al., 2003) and recently the presence 
of the Leishmania infantum within the CTVT cells has been described (Catone et al.,
2003). In these cases the immune suppression caused by the Leishmania parasite 
appears to favours the diffusion of the tumour to external and internal organs.
1.5.5 Histological and Cytological Features
Despite extensive and detailed studies, the histogenesis of the tumour is still 
debated. Early histological observations described the tumour as myxosarcoma 
(Novinski, 1876), carcinoma (Wehr, 1888), lymphosarcoma (Sticker, 1905), round 
cell sarcoma (Smith and Washboum, 1898), infective granuloma (Bashford et al., 
1905), tumour o f neuro-ectodermal origin (Jackson, 1944), and histiocytoma 
(Mulligan, 1949). The tumour has been defined as a round cell tumour of 
reticuloendothelial origin (Cockrill and Beasley, 1975) but the term, reticulo­
endothelial cell, has fallen out of fashion. Similarly the term, histiocyte, is less
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frequently used today, but it denotes non-lymphocytic, phagocytic cells of 
haematropoietic origin that reside in solid tissues. Immunophenotypic studies 
showed that the tumour cells are alpha -1- antitrypsin, lysozyme and ACM1 
positive, suggesting a histiocytic origin of CTVT (Mozos et al., 1996; Marchal et 
al., 1997; Perez et al., 1998; Mukaratirwa and Gruys, 2003). The presence of 
Leishmania infantum within the CTVT cells, supports an histiocytic origin of CTVT 
(Catone et al., 2003) because this parasite invades phagocytic cells such as 
macrophages and dendritic cells. In the haematoxylin-eosin stained sections the 
tumour cells appear round with a diameter ranging from 15 to 30pm, with a round- 
oval nuclei containing coarsely aggregated chromatin and usually a prominent 
nucleolus (Cohen, 1985). The cytoplasm is abundant and is distinct in areas where 
the tumour cells are not densely packed; it is lightly basophilic and usually contains 
vacuoles. Histologically the tumour cells are packed and arranged in diffuse clusters 
intercalated by a delicate stroma (Ajello, 1980).
Fig 1. Histopathology of CTVT. Microscopic section of tumour in progressive 
stage. Hematoxylin-esoin stain. Bar = 60 pm
Ultrastructural studies showed that tumour cells contain an extensive network of 
granular endoplasmic reticulum, a prominent Golgi apparatus, and numerous 
ribosomes (Cockrill and Beasley, 1975; Kennedy et al., 1977; Otomo et al., 1981). 
A cytoplasmic lamellar array has also been described (Cockrill and Beasley, 1975).
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Several studies showed that tumour cells in culture undergo a morphological 
transformation from round cells to fibroblast-like cells (Adams et al., 1968; 
Kennedy et al., 1977). Several reports have shown the presence of crystalline virus­
like structures in the tumour cells (Ajello and Gimbo, 1965; Lombard and Cabanie, 
1967; Battistacci and Morriconi, 1974)
1.5.6 Cytogenetic Features
The normal diploid chromosome number in dogs, wolves, jackals and coyotes is 78. 
The autosomic chromosomes are acrocentric, whereas the X chromosome is large 
and submetacentric, and the Y chromosome is small and metacentric (Breen et al., 
2001)
In the 1960s Takayama and Makino analysed the CTVT karyotype from different 
locations in Japan and showed that this is characterized by 59 chromosomes, of 
which 17 were metacentric and 42 acrocentric (Takayama and Makino, 1961). 
Several observations showed that the karyotype of tumours from different countries 
are characterized by 57-59 chromosomes, with 15-17 metacentric and 42-44 
acrocentric chromosomes (Makino, 1963; Weber et al., 1965; Barski and Comefert- 
Jensen, 1966; Kakpakova ES et al., 1968; Murray et al., 1969; Idowu, 1977; 
Richardson et al., 1987) (Figure 1.2).
Cytogenetic studies performed in tumour cells grown in vitro revealed the same 
chromosomal rearrangements (Adams and Slaughter, 1981). It has been also 
reported that the number of the chromosome arms and the DNA content in the 
tumour are approximately the same as in the normal diploid karyotype, and thus it 
was proposed that the metacentric chromosomes observed in CTVT arose from 
centric fusion (Weber et al., 1965; Barski and Cornefert-Jensen, 1966; Wright et al., 
1970). From these cytogenetic studies it was postulated that all CTVT tumours
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worldwide might have been derived from a single tumour clone expansion through 
tumour transplantation.
Figure 1.2. CTVT karyotype. Reproduced with permission from Max Murray 
(Murray et al, 1969)
1.5.7 Molecular M arkers
In a study on the involvement of oncogenes in the genesis of the tumour, a Long 
Interspersed Nuclear Element (LINE-1) was found to be inserted 5 Kb upstream to 
the first coding exon of the c-myc gene (Katzir et al., 1985). Additional studies 
reported the presence of the specific rearranged LINE/c-zwyc in tumours from 
different countries (Katzir et al., 1987; Amariglio et al., 1991). More recently it was 
reported that in two tumours from Japan, the inserted LINE-1 was 64 bp shorter than 
the LINE-1 previously described (Choi et al., 1999) and that that the total length of 
the inserted LINE-1 is not constant (Liao et al., 2003). The inserted LINE element is 
homologous to the canine LINE-1 ORF2, and contains a 416 bp region homologous 
to the complementary strand of the LINE-1 ORF 2, followed by a 5-bp deletion and 
962-bp sequences homologous to the 3' region of the LINE-1 ORF 2 (Choi et al.,
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1999) (Fig 1.3). The involvement of the truncated LINE-1 element on deregulation 
of c-myc transcription in the CTVT is not clear, although c-myc expression is high 
in the tumour (Katzir et al., 1987).
CTVT LINE-1/c-myc |
Rearranged ORF 2 .
Flanking region Exon 1 c-my
ORF 1
ORF 2-
LINE-1
Figure 1.3. Diagram of LINE-l/c-myc rearrangem ent in CTVT.
Gray rectangles represent the lObp flanking direct repeats, white 
rectangle indicates 5bp deletion.
1.5.8 Immune Response to CTVT
In 1906 Sticker performed a detailed immunological study on CTVT and 
demonstrated that spontaneous regression of the tumour is followed by immunity 
against subsequent transplantation (Sticker, 1906). Although natural cases of CTVT 
have been reported only in dogs, the tumour has been experimentally transplanted 
into immunocompetent wolves, coyotes, foxes, and jackals and into 
immunosuppressed mice. Both natural and experimentally transplanted tumour 
exhibits two stages; in the first stage the tumour grows progressively increasing its 
size from a minute nodule to a pedunculated mass reaching up to a 15 cm of
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diameter (Yang, 1988; Perez et al., 1998). This stage is usually followed by a 
regression stage, where the tumour decreases in size and assumes a friable 
consistency (Yang and Jones, 1973; Perez et al., 1998). Immunological studies have 
shown that the passive transfer o f post-regressive sera inhibited the development of 
tumours transplanted into naive dogs (Powers, 1968). Moreover, puppies bom from 
dams where the tumour had regressed limit the growth of the injected tumour (Yang 
and Jones, 1973). Naturally occurring CTVT in old or immunosuppressed dogs 
results in progressive growth and metastatic spread (Cohen, 1973). These results 
indicate that CTVT is potentially highly malignant but that the immune defence in 
immunocompetent animals limits the growth and spread of the tumour.
Early in vitro experiments demonstrated that the tumour antigens are recognized by 
canine lymphocytes and that sera from dogs bearing the tumour in the progressive 
stage suppresses lymphocyte activity (Bennett et al., 1975; Hess et al., 1975). The 
immunosuppressive activity of progressive tumours has been also supported by 
plasmapheresis experiments (Zander et al., 1980). Several studies have reported the 
presence of tumour specific antibodies in sera of dogs bearing tumour in progressive 
and regressive stages, and that tumour-specific antibodies could be detected 40 days 
after tumour transplantation (Dozza and Torlone, 1960a; Cohen, 1972). In spite of 
extensive efforts to identify the tumour antigens that drive the antibody response 
their nature remains unknown.
Immunological and histochemical studies have shown that during the progressive 
stage tumour cells do not express the Dog Leukocyte Antigens (DLA) class I and II, 
whereas these antigens are expressed during the regression stage (Cohen, 1974; 
Yang et al., 1987; Perez et al., 1998). It has been also reported that progressive 
tumour cells do not express p2-microglobulin (Cohen et al., 1984). Transplantation 
experiments suggested that the clinical course of the tumour is influenced by the 
diversity between tumour and host MHC (DLA) antigens (Epstein and Bennett, 
1974).
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Histological studies demonstrated that tumours in the regressive stage are much 
more infiltrated by lymphocytes and macrophages compared to tumours in 
progressive growth (Perez et al., 1998; Barber and Yang, 1999; Hsiao et al., 2002). 
A recent study reported that during progressive growth, the CTVT cells secret 
tumour growth factor beta (TGF-pl) and that during regression, tumour-infiltrating 
lymphocytes secrete an elevated amount of interleukin 6, so antagonizing the 
suppressive affect of the TGFpi (Hsiao et al., 2004).
1.5.9 Diagnosis
Although the CTVT has distinct clinical and anatomo-pathological features, 
cytological and histological examination is generally the most effective diagnostic 
method (Mozos et al., 1996; Marchal et al., 1997). Given the morphological 
similarities between CTVT and cutaneous histiocytoma, the diagnosis of extra­
genital CTVT with conventional stained tissue sections may be difficult. In such 
cases epidemiological and clinical records may help the diagnosis. Although 
cytogenetic analysis may be a reliable diagnostic method (Makino, 1963; Murray et 
al., 1969; Osipov and Golubeva, 1976), it is not commonly used, but more recently 
the LINE-l/c-myc insertion has been used (Liao et al., 2003).
1.5.10 Therapy
Although generally CTVT regresses spontaneously in healthy individuals, several 
therapeutic approaches have been used to treat the tumour. Surgical excision of the 
tumor is practicable in the localized forms without severe infiltration, however 
tumour recurrence after surgical removal without chemotherapy has been reported 
(Karlson and Mann, 1952; Prier and Johnson, 1964; Das and Das, 2000). Several 
reports have shown that the CTVT is sensitive to radiotherapy (Osipov and
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Golubeva, 1976; Ajello, 1980). The application of 1000 rad in 2 or 3 treatments is 
generally sufficient to induce the complete regression (Thrall, 1982). Although 
radiotherapy is highly effective, it requires chemical sedation of the animal and 
expensive equipment. Chemotherapeutic agents have been used to treat the tumour 
(Osipov and Golubeva, 1976; Ajello, 1980; Epstein and Sarpel, 1980; Das and Das,
2000). Vincristine sulphate or vinblastine seem to be most effective and with less 
collateral side effects than other chemotherapeutic agents. Generally six intravenous 
injections of Vincristine (0.025mg/Kg body weight) at weekly intervals are 
sufficient to induce complete regression (Brown et al., 1982; Singh et al., 1996).
1.6 The Canine Major Histocompatibility System
The canine Major Histocompatibility System (MHC) is also known as Dog 
Leucocyte Antigen (DLA). It contains clusters o f genes encoding proteins that are 
involved in the establishment and regulation o f the immune response. The DLA 
region has been mapped to chromosome 12q telomeric by fluorescence in situ 
hybridization (FISH) (Dutra et al., 1996). This region shows a high level of 
conserved synteny among the MHC of human, mouse and cat species (Debenham et 
al., 2005).
From immunological and structural studies the MHC genes have been subdivided in 
three classes: Class I, Class II and Class III. While Class I and Class II genes are 
involved in antigen presentation the Class III region contains genes coding for 
proteins involved in the coagulation process and in the immune regulation . Some of 
the Class I and Class II genes show a high degree polymorphism (Wagner et al., 
1999).
Based on the transcription level and polymorphism the Class I genes are divided in 
to classical (more polymorphic and high transcription) and non-classical (almost
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monomorphic and low transcription) genes (Burnett et al., 1997). The DLA class I 
region contains several non-classical genes and pseudogenes, but only one classical 
gene, DLA-88, is polymorphic among unrelated dogs (Burnett et al., 1997) 
(Graumann et al., 1998). Although the majority of the DLA genes are located on 
chromosome 12, the non-classical gene DLA-79 has been mapped on chromosome 
18, but its function is unknown (Burnett and Geraghty, 1995).
The DLA class II region like the MHC Class II region in other species is divided 
into sub-regions BTNL2-DOB, DOB-DOA, DOA-COL11A2, COL11A2-DAXX 
(Debenham et al., 2005). From the immunological point of view the most important 
region is the BTNL2 region. This sub-region contains the DR and DQ loci. The dog 
has two functional DR genes (DLA-DRA1 and DLA-DRB1) and two functional DQ 
genes (DLA-DQA1 and DLA-DQB1) (Kennedy et al., 2000; Debenham et al., 
2005).
Class I MHC proteins consist of a large protein with a transmembrane region (alpha 
chain) and an associated small extracellular protein (02- microglobulin) which is not 
encoded by MHC genes (Wagner et al., 2001). The alpha chain is folded to form 
three extracellular domains (1 ,2 , 3). While the alpha-3 domain is constant and is 
associated with the 02 microglobulin, the alpha 1 and 2 domains are polymorphic 
and together form the groove that binds peptide antigens to present them to 
cytotoxic cells (Roitt et al., 1988). The Class II proteins are heterodimers, composed 
of two transmembrane chains, alpha and beta. Both chains consist of one constant 
(C) domain and one variable (V) domain. The two variable domains interact to 
form the peptide-binding groove (Roitt et al., 1988). The role of the MHC Class I 
and Class II proteins in binding and presenting the antigens for immune recognition 
explains the extensive polymorphism present in these MHC genes.
Several studies have shown that the genetic variability of the MHC genes is under 
the influence of balancing selection, which maintains the variability and
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heterozygosity level beyond neutral expectations (Hedrick, 1998; Richman, 2000; 
Hedrick et al., 2002; Garrigan and Hedrick, 2003). Transplantation and immune- 
genetic studies have shown large variability in several species of the Canidae family 
(Wagner et al., 2002). Recently it has been shown that the level of variation of the 
DLA class II haplotypes in dogs is higher between breeds but is minimal within a 
breed (Kennedy et al., 2002). Although the level of homozygosity varies between 
DLA class II genes, the level of homozygosity tends to be higher in rare breeds than 
the common breeds, perhaps because they derive from a smaller number of founder 
animals (Kennedy et al., 2002). Given the high degree of genetic polymorphism in 
canine DLA-88 (Class I) and in DLA-DRA, DLA-DRB, DLA-DQA and DLA-DQB 
(Class II) genes, DLA markers are useful for the genetic analysis of CTVT.
1.7 Microsatellites
Eukaryotic genomes are full of repeated DNA sequences. These tandemly repeated 
sequences are classified by the length of the core unit and the length of the 
contiguous repeat units, into three main divisions: (a) Satellites, which are often 
associated with centromeres, where a single unit is repeated to form an array up to 5 
MB long; (b) Minisatellites, also known as variable number of tandem repeats 
(VNTRs) in which a unit of 10-100 bp is repeated to give an array of 0.5-3 kb size; 
(c) Microsatellites also known as short tandem repeats (STRs) are sequences 
containing a core unit of 2-8 bp, tandemly repeated and are distributed throughout 
the genome (Armour et al., 2001).
The discovery that repeated DNA sequences show variations in the number of 
tandem repeats known as variable number of tandem repeats (VNTRs) (Jeffreys et 
al., 1985a), which differ from individual to individual, led to the development of the 
DNA fingerprint technique (Jeffreys et al., 1985b). Given the wide distribution of 
microsatellites throughout the genome and that the number o f the repeats can be
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highly variable among individuals, microsatellites are widely used in evolutionary 
and genetic studies and in forensic science. Although several types of mutations 
may affect the microsatellites, the elevated mutation rate is mainly caused by 
changes in the number of repeats, a situation referred as microsatellite instability 
(MSI) (Eisen, 2001). The mechanism of the mutation process is still debated, and 
two models have been proposed. One model suggests that microsatellite instability 
is due to the recombination by unequal crossing over (UCO) between homologous 
chromosomes or by gene conversion (Smith, 1976). The alternative model proposes 
that MSI is caused by slip-strand mispairing (SSM) errors occurring in the DNA 
replication process. Several studies support the SSM model as the major mechanism 
involved in the microsatellite instability (Sia et al., 1997). It has been shown that 
the nature of the microsatellite itself plays an important role on the SSM 
mechanism. The mutation rate has been found to increase when the core unit and the 
number of repeated units increase (Wierdl et al., 1997; Bachtrog et al., 2000). The 
nature of microsatellites not only influences the mutational mechanism but also 
repair activity. Several studies suggest that long microsatellites form a loop when 
they are misaligned and that the mismatch repair machinery repairs the short size 
loops better than the long ones (Kroutil et al., 1996). The mutation mechanism and 
the repair process can be influenced by several factors that include the local DNA 
sequences (CG content), genome position (chromosome position), methylation state 
and level of transcription (Eisen, 2001).
In order to optimize the information provided by microsatellites for genetic and 
phylogenetic applications, two principal evolutionary dynamic models have been 
postulated: The infinite allele model (IAM) and the step wise mutation model 
(SMM). According to the IAM model, microsatellites may mutate by gaining or 
losing any number of tandem repeats (Kimura and Crow, 1964). In contrast, the 
SSM model postulates that the mutation involves the loss or gain of a single repeat 
unit (Kimura and Otha, 1978). Although the gain or loss of the repeat may have the 
same probability, genetic analysis shown that gain occurs more frequently than loss 
(Amos and Rubinstzein, 1996; Primmer et al., 1996). The propensity o f
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microsatellites to gain repeats would theoretically promote an infinite expansion of 
the microsatellites. This is in contrast with the fact that genomes rarely have long 
repeats compared to short repeats. This suggests that there must be a size constraints 
which restrict the repeat expansion (Amos, 2001). It has been estimated that the 
mutation rate (changes in repeat number) of microsatellites is higher than the 
mutation rate of point mutations (Ellegren, 2000). Estimates from pedigree analysis 
in humans suggest a rate around 10'3 mutations per locus per generation (Weber and 
Wong, 1993), and 10'3 to 10'4 in mice (Dallas, 1992) and 10'2 to 10"4 in dogs (from 
Elaine Ostrander, personal communications).
Given their high variability and their wide genome distribution, microsatellites are 
widely used for gene mapping, forensic analysis, conservation biology, and 
phylogenetic studies in several species. Thank to the efforts in developing the dog 
genome map, to date 1,589 canine microsatellite markers have been characterized 
(Ostrander and Wayne, 2005). The canine microsatellite markers have become the 
tool of choice in several applications. In conservation genetics microsatellites have 
been used to analyze the divergence between populations, hybridization and 
introgression between canine species, social structure and inbreeding (Gottelli et al., 
1994; Vila et al., 1999b; Lucchini et al., 2002; Vila et al., 2003).
Since the domestication of dogs from wolves, dogs have been selected for a specific 
body size, conformation, pelage, temperament and behaviour, thus undergoing a 
high diversification into different breeds. More than 400 breeds have been 
recognized throughout the world, displaying a very high phenotypic diversity. To 
maintain the physical and behavioral features to a specific breed, domestic dogs 
have undergone inbreeding and isolation, so contributing to the propagation and 
high prevalence of the breed specific genetic traits (Wayne, 2001). To exploit this 
breed related genetic information, microsatellites are a crucial tool to map genes 
important in diverse physiological and pathological situations.
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According to the American Kennel Club (AKC) there are seven major groups of 
dogs breeds, classified as follows: Herding, Sporting, Hound, Working, Terrier, 
Toy and non-Sporting. Recently canine microsatellites have been used to determine 
the genetic relationship between 85 breeds with a world-wide distribution (Parker et 
al., 2004). Results indicate that 99% of 414 individual dogs analyzed can be 
assigned to an original breed. The 85 breeds can be separated by clustering methods 
in to 4 clusters, each containing breeds with similar behaviour, morphology and 
geographical origin. Phylogenetic analysis separates these breeds into two clusters 
according to an ancient or modem origin.
From the foregoing discussion, there is a strong case for using microsatellite DNA 
to analyze CTVT. First, microsatellites can be used to determine whether the 
tumour differs from the host; second, if that is the case, microsatellites can be used 
to indicate the breed of origin of CTVT.
1.8 Mitochondrial DNA
Mitochondrial DNA (mt-DNA) is a circular molecule of 16,500 base pairs and it is 
located within the mitochondrion. There are about 100 mitochondria per cell and 
about 10 copies of mt-DNA per mitochondria. The number of mt-DNA copies 
within the cell is variable and depends on the cell type. In mature sperm there are 
about 50-80 mitochondria, while the mature oocyte, a large cell, contains more than 
100,000 mitochondria (Chinnery et al., 2000).
During fertilization the mitochondria present in the sperm do not penetrate into the 
oocyte, and thus the embryo contains only the maternal mitochondria. This type of 
inheritance is called non-Mendelian or cytoplasmic inheritance (Alberts et al., 
2002i). Given that the paternal mitochondria are not inherited, recombination 
between maternal and paternal mt-DNA does not take place, and therefore the only
57
source of variation is due to mutation (Chinnery et al., 2000). Although mt-DNA 
has generally been assumed to be maternally inherited, recent studies have 
suggested that a small fraction of mt-DNA may sometimes be paternally inherited 
(Roze et al., 2005).
The majority o f the mt-DNA contains genes that encode ribosomal RNAs, tRNAs 
and several subunits of the respiratory chain. However, there is a small non-coding 
region called the Control Region (CR) or Displacement-loop (D-loop) which is 
involved in the regulation of the replication and transcription (Alberts et al., 2002i).
In contrast to the nuclear genome, mitochondrial DNA molecules lack histones, and 
therefore mt-DNA is more susceptible mutation than nuclear DNA. It has been 
estimated that the mt-DNA mutation rates is 100-200 fold higher than nuclear DNA 
(Taylor and Turnbull, 2005).
The presence of reactive oxygen species (ROS) produced by the oxidative 
phosphorylation process and the attachment o f the D-loop region to the mt- 
membrane, makes the D-loop region highly mutable (Mambo et al., 2003). A further 
factor that contributes to the high mt-DNA mutation rate is the absence of an 
efficient DNA repair system, due to the fact that the mitochondrial DNA polymerase 
exhibits a low proofreading activity (Alberts et al., 2002i). Given the high mutability 
of the D-loop region, the presence of different mt-DNA haplotypes (heteroplasmy) 
has been reported within the individual or cell or single mitochondria (Shin et al., 
2004a; Shin et al., 2004b).
Recent studies have shown that the accumulation of somatic mutations in the human 
mt-DNA control region in normal individuals is age-dependent (Michikawa et al., 
1999; Elson et al., 2001; Trifunovic et al., 2004). However it has been suggested 
that expansion of preexisting mutants rather than de novo mutation in old age may 
be responsible for some aging-specific mutants (Shin et al., 2004b). The
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accumulation of somatic mutation in mt-DNA has been also described in several 
human and animal tumours (Van Tuyle et al., 1996; Bianchi et al., 2001; Chen et al.,
2004).
Several studies have described the presence of clonally expanded somatic mt-DNA 
mutations in normal and malignant tissues (Fliss et al., 2000; Shin et al., 2004b). 
Although the mechanism driving the mutated mt-DNA copies to homoplasmy is still 
unknown, these observations suggest a replicative advantage for mutated mt-DNA 
molecules within the mitochondria, and consequently a growth advantage for a cell 
containing certain mt-DNA mutations (Fliss et al., 2000; Bianchi et al., 2001). In 
addition, it is possible that some mt-DNA mutation may have a tumorigenic 
property (Petros et al., 2005). However, it has been argued that the observed 
homoplasmy might possibly have arisen entirely by genetic drift in tumor progenitor 
cells, without any physiological or pathological advantage (Coller et al., 2001).
The domestic dog (Canis familiaris) mitochondrial DNA has been sequenced (Kim 
et al., 1998), and the analysis of the mt-DNA control region variability has been 
used in forensic and phylogenetic studies (Wayne, 1993; Savolainen et al., 1997). 
Given the high degree of variation present in the control region and the high copy 
number within the cell, mt-DNA is a useful material for genetic investigation. It has 
been found that mt-DNA exhibits intra- and inter- breed variation (Okumura et al., 
1996; Tsuda et al., 1997; Savolainen and Lundeberg, 1999). Therefore the mt-DNA 
may not be used to assign individual dogs to the original breed. A recent survey 
showed that the exclusion capacity of the mt-DNA is around 0.929 (Angleby and 
Savolainen, 2005).
The analysis of the mt-DNA control region in several species belonging to the 
Canidae family has shown that domestic dogs originate from at least four female 
wolf lines, identified as four different clades (Vila et al., 1997; Savolainen et al.,
2002). The analysis of the mt-DNA control region in archeological dog specimens
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from the Americas dated before European colonization has shown that the native 
America dog breeds come from the Old World dogs, thus refuting the New World 
domestication hypothesis (Leonard et al., 2002). A recent phylogenetic analysis of 
the mt-DNA control region of 654 dogs distributed worldwide has shown that the 
greatest genetic variation is present in East Asian dog populations, which suggests 
an East Asiatic domestication event, and that present day dogs diverged from the 
wolf lineage approximately 15,000 years ago (Savolainen et al., 2002).
The utility of mt-DNA for phylogenetic analysis among dogs means that this non­
nuclear genetic marker can also be exploited to determine the evolution of CTVT.
1.9 Aim of Thesis Project
At the time that I began my thesis studies in 2001, there was strong circumstantial 
evidence, from karyotype analysis and from the common LINE-l/c-/w>>c insertion 
that CTVT may represent a sexually transmissible cancer cell rather than a tumour 
caused by a sexually transmitted oncogenic virus. However, proof of this concept 
was still lacking, and no investigation had previously obtained and analyzed normal 
and tumour tissues from a series of dogs that had naturally acquired CTVT. I 
therefore set about collecting such matched tumour and normal samples, as well as 
archival paraffin-embedded tumour biopsies from five continents. I sought to 
determine whether the tumour was distinct from its host, and whether it represents 
one or more distinct clones by using a variety of polymorphic genetic markers in the 
canine genome. Having shown that CTVT indeed represents a single clone of cells, 
I have sought to determine the breed o f origin of the tumour, and to estimate its 
approximate age.
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CHAPTER 2
Material and Methods
2.1 Specimens
Matched tumour and blood samples were obtained from 15 unrelated stray dogs of 
different locations, breeds, age and sex as specified in Table 2. Upon clinical 
examination ten dogs showed primary external genital lesions (penis and vagina) 
characteristic o f CTVT, and all dogs were in good general condition, whereas one 
dog showing multiple neoplastic lesions localized in the penis, skin and eyes, and 
was in poor general health. None of the dogs had received chemotherapeutic or 
immune stimulating drugs before specimen collection. Tumour tissues were 
obtained by surgical excision of primary and metastatic neoplasms. From 2 to 5 ml 
of peripheral blood were also collected. Tumour and normal (blood) tissues from 
Sicily were brought to the UK with permission of DEFRA and were tested for the 
absence of rabies by RT-PCR at the Veterinary Laboratory Agency (Weybridge) 
prior to use. DNA was extracted from tumours and blood samples of Indian 
(Kolkata) and Kenyan (Nairobi) specimens on site.
Thirty paraffin embedded tumour samples were collected from different 
geographical locations as specified in Table 2.
Table 2.1 Dogs providing fresh tumour and blood samples
Sample Date Breed Sex Age (yrs) Tumour location Country
A 2001 Mixed Male 2 penis Italy (Catania)
B 2001 Mixed Male 1 penis Italy (Catania)
C 2001 mixed Male 10 penis
eye
skin
lymph nodes
Italy (catania)
D 2001 Mixed Male 2 penis Italy (Catania)
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E 2001 Mixed female 5 vagina Italy (Catania)
F 2003 Mixed Male 3 penis India (Kolkata)
G 2003 Mixed Male 2 penis India (Kolkata
H 2003 Mixed female 2 vagina India (Kolkata
I 2003 Mixed female 3 vagina India (Kolkata
L 2003 Mixed Male ndT penis Kenya (Nairobi)
M 2003 Mixed Male nd penis Kenya (Nairobi)
N 2005 Mixed female vagina Italy (Messina)
0 2005 Mixed famle vagina Italy (Messina)
P 2005 Mixed female vagina Italy (Messina)
Q 2005 Mixed female vagina Italy (Messina)
e f
Fig 2.1 Canine Transmissible Venereal Tumour macroscopic 
appearance, a, b: CTVT in female dogs E and N; c-e: CTVT 
genital and extragenital (penis, skin and eye) in male dog C;f: 
CTVT on the glans penis of dog D.
62
Table 2.2 Paraffin embedded samples used for micro-dissection of tumours.
Sample Date Breed Sex Age (yrs) Tumour
location
Country
nd* Nd nd nd nd Turkey
3 nd Nd nd nd nd Turkey
4 nd Nd nd nd nd Turkey
5 nd Nd nd nd nd Turkey
6 nd Nd nd nd nd Turkey
8 nd Nd nd nd nd Turkey
9 nd Nd nd nd nd Turkey
11 nd Nd nd nd nd T urkey
12 nd Nd nd nd nd Turkey
14 1985 Mixed female vagina Spain
17 1985 Mixed female 2 vagina Spain
18 1986 Mixed female 2 vagina Spain
19 1986 Mixed female vagina Spain
20 1999 Mixed male 1 penis USA (Georgia)
21 1999 Beagle male 2 penis USA (Georgia)
25 1999 Husky female 4 vulva Brazil
27 1997 Husky male 1 penis Brazil
29 1999 Mixed male 4 penis/skin Brazil
30 1995 Mixed female nd cervix Brazil
32 1995 maremmano male 2 penis Italy (Sardinia)
33 1995 Mixed male nd penis Italy (Sardinia)
92 1992 Mixed female nd vagina Italy (Messina)
83 1983 Mixed female nd vagina Italy (Messina)
76 1976 Mixed female nd vagina Italy (Messina)
tnd , not determined
2.2 Histological examination and tissue microdissection
Paraffin blocks were placed at -20°C for 1 hour before cutting, then 3 consecutive 5- 
micron sections were cut from the paraffin embedded tissue and transferred to a 
clean floating bath heated at 42°C. The sections were then transferred to positively 
charges slides. After incubation for 30 minutes at 60 °C, sections were 
deparaffinised, submerged in to a glass tray containing xylene for 5 minutes, and 
transferred in a new tray containing clean xylene for further 5 minutes. After
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deparaffin i sat ion the sections were treated for 5 minutes with ethanol at 100%, 95% 
and 80% respectively and then washed with deionised water for 5 minutes. Middle 
sections were stained using standard haematoxylin-eosin staining for histological 
examination and the others were stained with methyl green for microdissection.
2.2.1 Haematoxylin and eosin staining
Middle slides were dipped in a slide holder containing hematoxylin for 3 minutes, 
and the slides were transferred in a tray containing tap water and rinsed with 
running tap water at low pressure for 5 minutes. Slides were then submerged into a 
tray containing eosin for 20 seconds, and dehydrated by immersing them in ethanol 
at 95 %, and 100 % for 3 minutes respectively. Finally they were treated with xylene 
for 5 minutes and the sections were covered with a coverslip slide using Permount 
medium.
Haematoxylin is an alkaline salt that combines specifically with the negative 
charged phosphate group of nucleic acids, therefore colouring the nucleus blue. 
Eosin in contrast combines with positively charge cytoplasmic proteins, colouring 
the cytoplasm and collagen fibres pink.
2.2.2 Methyl green staining
Given that haematoxylin-eosin staining can interfere with PCR amplification, 
methyl green staining was used for microdissection. Two slides for each sample 
were submerged in a slide holder containing a 0.1% methyl green solution for 3 
minutes, then transferred to a new tray containing distilled water for 5 minutes, and 
this step was repeated twice using each time clean water. Before microdissection the 
slides were air dried for 1 hour. Given that CTVT cells were simple to separate from 
host tissue, manual micro-dissection under stereomicroscopic observation was used.
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The tip of a 25 gauge needle was dipped in a lx  PCR buffer solution, and the 
selected area containing more then 70-80 % tumour cells were scraped, then the 
microdissected cells were transferred to a 0.5 ml sterile microcentrifuge tube 
containing 50 pi extraction buffer: lx GeneAmP PCR buffer II (without MgC12) 
gold buffer, 0.5% tween 20, 0.4 mg/ml of proteinase K (QIAGEN). The micro­
dissected samples were then incubated at 55 °C for 2 days (proteinase K was added 
after 24 hours). After 48 hours samples were heated at 99 °C for 15 minutes to 
inactivate the proteinase K.
2.3 Genomic DNA extraction
2.3.1 Blood and Tumour DNA extraction
DNA from tumour and blood samples was extracted using a QIAamp DNA kit 
(QIAGEN). Given that the QIA amp columns can bind up to a 100 pg of DNA, 
blood samples were divided in aliquot of 300 pi, whereas tumour biopsies were cut 
to a 1-cm3 size and subsequently into small pieces for each column. The cells were 
lysed by adding 300 pi of buffer AL for blood samples and 300 pi of buffer ATL for 
tumour samples, which contain lysis buffer and 40 pi o f proteinase K 20mg/ml 
(included in the kit). Samples were then incubated overnight at 55 °C. The next day, 
given that the QIA amp columns bind both RNA and DNA, 40 pi of RNAse A 
20mg/ml (included in the kit) were added and the samples were incubated at room 
temperature for 3 minutes. After the addition of 200 pi o f buffer AL, the samples 
were incubated at 70 °C for 10 minutes. To precipitate the DNA, 350 pi o f 100% 
ethanol was added and mixed. Then the mixture was applied to the QIA amp 
columns and centrifuged at 8000 rpm for 1 minute. To wash the columns, 500 pi of 
buffer AW was applied and centrifuged for 1 minute at 8000 rpm, and the washing 
step was repeated again with a centrifugation period of 3 minutes, to remove all 
residues from the column. To elute the genomic DNA from the columns, 200 pi of 
preheated buffer AE was added and after incubation at room temperature for 2 
minutes, and the columns were centrifuged at 8000 rpm for 2 minutes. The 
concentration of the DNA was determined using Nanodrop.
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2.3.2 Isolation of total RNA
Total RNA was isolated from tumour and blood samples using Trizol Reagent 
(GIBCO BRL), which contains a mono-phasic solution of phenol and guanidine 
isothiocyanate. Tumour tissues were homogenised in 2 ml of Trizol Reagent with a 
homogeniser. The sample was then incubated for 10 minutes at room temperature to 
allow complete dissociation of nucleoprotein complexes. Tumour lysates were 
subdivided in aliquots of 1 ml. Then 0.2 ml of chloroform was added to each tube 
and mixed vigorously by hand for 1 minute and incubated at room temperature for 3 
minutes. Samples were centrifuged at 12,000 g for 15 minutes at 4°C. After 
centrifugation the RNA present in the upper aqueous phase was transferred to a 
fresh tube and precipitated by adding 0.5 ml of isopropyl alcohol. After a further 
incubation at room temperature for 10 minutes the samples were centrifuged at
12,000 g for 10 minutes. After removal of the supernatant the pellet was washed 
with 1 ml of 75% ethanol and centrifuged at 7,500 g for 3 minutes. The pellet was 
air dried and then resuspended in 20pl o f RNAse-free water.
2.3.3 Purification of mRNA from total RNA
mRNA was isolated from total RNA using the Oligotex kit (QIAGEN). This 
procedure allows the isolation of poly-A mRNA by its hybridisation to T 
oligonucleotides covalently linked to polystyrene-latex spherical particles. 500 pg of 
total RNA were resuspended in 500 pi of RNAse-free water and transferred to a 
microcentrifuge tube containing 500 pi of pre-heated (70°C) OBB buffer and 
incubated at 70 °C for 3 minutes to allow the disruption the RNA secondary 
structure. The tube was then incubated at room temperature for 10 minutes to allow 
hybridisation of the mRNA poly A tail with the oligo dT of the Oligotex particles. 
The particles were pelleted by centrifugation at 14,000 rpm for 2 minutes, and the 
supernatant was removed. The pellet was resuspended in 400 pi of buffer OW2 by 
vortexing and transferred to a column, and then centrifuged at 14,000 rpm for 1 
minute. The Oligotex/mRNA particles were washed once with 400 pi of buffer 
OW2 and centrifuged for 1 minute at 14,000 rpm. The mRNA was eluted from the
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Oligotex particle by adding 70 pi of pre-heated (70°C) buffer OEB and centrifuged 
for 1 minute at 14,000 rpm. The quality and concentration of the mRNA was 
determined using a Bioanalyzer.
2.4 Genomic amplification
In order to analyse the genetic relationship between tumours and hosts and between 
tumours, several independent genetic markers were used. Genomic amplification 
was carried out using 50-100 ng DNA in 50 pi volume containing: IX buffer (10 
mM Tris-HCl (pH 9), 100 mMNaCl, 01% triton X) , 1.5-2.5 mM MgCl2, 200 pM 
dNTPs, 5 units of Taq DNA polymerase, 10-20 pmol o f forward and reverse primers, 
water (nuclease free) up to 50 pi. For microdissected samples forward primers were 
labelled with Cy5 and PCR products were run by non-denaturing polyacrylamide 
gel electrophoresis.To clone the PCR product, after 35 cycles of amplifications, 30- 
50 pi of PCR reaction were run in 1.5-2 % agarose gel and processed as described in 
the following sections.
Table 2.3 PCR primers
Primer name Primer sequence Product Size (bp)
LINE-1A GGTGGGGCAGGGAGACAACATTTTA 390
ATCCTAGAGAAGAACACAGGCAACAC
LINE-IB GGTGAGGCTTTCCCATCCTT 150
CTTCTTGCAAGATACATCCA
DLA-88exon 1-2-3 AGTCCAGCGGCGACGGCCAGTGTCCCCGGA 1,100
AGCCCTCCCTAGTGGAGGCGAGATCGGGGA
D RB1 exon 2 CCGTCCCCACAGCACATTTC 350
TGTGTCACACACCTCAGCACCA
DQB1 TCACTGGCCCGGCTGTCTCC 350
GGTGCGCTCACCTCGCCGCT
DQA1 CTCAGCTGACCATGTTGC 300
GGACAGATTCAGTGAAGAGA
DLA-88 exon 2 TCTCACCCGTCGGCTCCGCAG 350
GATGGGGGTCGTGCCCTGGCC
DLA-88 exon 3 ATTGGCGGCCTGTCGGG 350
AGGCGAGATCGGGGAGGC
CTVT DLA-88cc CCTTCAAGGAGACCGCACGAGGG 420
CTCCAGGTAGTTCCTTTCGTGC
CTVT DLA-880 CCATCAAGGAGACCGCACAGGTG 420
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CTCCAGGTAGTTCCTTTCGTGC
CTV TD RBl CGGTTTCTGGCGAGAAGCA 150
TCCACCGCGGCCCGCTCCTG
CTVT DQB1 GGCTTCTGGCGAGAGACATC 150
CGCCTCTGCTCCAAGAGCT
CTVTDQA1 GAATTTGATGGCGATGAGTT 150
TC AGGATGTTCA AGTTTTGTTTT AT
SRY CTCGCGATCAAAGGCGCAAGAT 80
TTCGGCTTCTGTAAGCATTTTC
650 GTCCTGGGTTCGGGTTAGTGTTAG 650
GTCCTGGGTTGAAGCCCTACATTG
HI 5422/Ll 6106 CTCTTGCTCCACCATCAGC 122*
AAACTATATGTCCTGAAACC
H15422/H15710 CTCTTGCTCCACCATCAGC 290t
GCATGGTGATTAAGCCCTTAT
* for fresh tissues, t  for paraffin embedded tumour.
Table 2.4 PCR conditions
Gene Initial
denaturation
Denaturation Annealing Extension Final
extention
LINE-1A 94 °C (5min) 94 °C (30sec) 60 °C (30sec) 72 °C 
(30sec)
72 °C(5m in)
LINE-IB 94 °C (5min) 94 °C (30sec) 50 °C (30sec) 72 °C 
(30sec)
72 °C (5min)
DLA-88exon 1- 
2-3
95 °C (15min) 94 °C (lm in) 65 °C (2min) 72 °C 
(3min)
72 °C (5min)
DRB1 exon 2 94 °C(5min) 94 °C (45sec) 61 °C (lm in) 72 °C 
(lm in)
72 °C (5min)
DQB1 94 °C (5min) 94 °C(5m in) 66 °C (45sec) 72 °C 
(lm in)
72 °C (5min)
DQA1 94 °C (5min) 94 °C (5min) 48 °C (lm in) 72 °C 
(lm in)
72 °C(5min)
CTVT DLA-88cc 95 °C(15min) 94 °C (lm in) 65 °C (2min) 72 °C 
(45sec)
72 °C (5min)
CTVT DLA-88(3 95 6C (15min) 94 °C (lm in) 64 °C (lm in) 72 °C 
(45sec)
72 °C (5min)
CTVT DRB1 94 °C (5min) 94 °C (lm in) 60 °C (45sec) 72 °C 
(45sec)
72 °C (5min)
CTVTDQB1 94 °C (5min) 94 °C (lm in) 58 UC (45sec) 72 °C 
(45sec)
72 °C(5min)
CTVTDQA1 94 °C (5min) 94 °C (lm in) 50 °C (45sec) 72 °C 
(45sec)
72 °C (5min)
SRY 94 °C (5min) 94 °C (lm in) 62 °C (lm in) 72 °C 
(30sec)
72 °C (5min)
650 94 bC(5m in) 94 tiC (lm in) 65 GC (lm in) 72 °C 
(lm in)
72 °C(5min)
Mt-DN A /16106 94 °C (2min) 94 °C (15sec) 50 °C (30sec) 72 ^C 
(lm in)
72 °C(5min)
MtDNA/15710 94 °C (2min) 94 °C(15sec) 50 °C (30sec) 72 °C 
(30sec)
72 °C(5min)
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2.5 Microsatellite genotyping
To analyse the genetic distance between tumours and hosts, nine microsatellite 
markers were chosen for their high polymorphism and their reliability for canine 
parentage testing. The markers are distributed on different chromosomes, except 
AHT125 and FH2010, however these two markers are distant enough to allow for 
independent recombination. Forward primers were labelled with different dyes 
(Table 2). To optimise the amplifications, a gradient PCR with different primer 
concentrations was performed. All PCR amplifications were carried out in 10 pi 
containing: 25ng of DNA, 2 mM MgCL, 100 pM each dNTP, 15 mM Tris-HCl 
(pH 8.3) 75 mM KC1, 0.5 units of AmpliTaq DNA polymerase (PE Applied 
Biosystems), and 0.3 -0.6 pM of primers (see Table 1) using a DNA Tetrad Engine 
(MJ Research). Cycling conditions consisted of: 5 min at 94 °C, followed of 30 
cycles of 94 °C at 45 sec, annealing temperature (specific for each marker see table 
1) for 45 sec, 1 min at 72 °C, followed of 5 min at 72 °C. Dye-labelled amplicons 
were pooled (3pl each) for multiplex analysis and diluted in 50 pi of deionised water 
and then 10 pi were mixed with lpl o f internal size standard GeneScan 350 
TAMRA and lx Loading dye ( 95 % formamide, 25 mM EDTA containing 50 
mg/ml of dextran blue). The mixture was denatured at 95 °C for 3 min. PRC 
products were run for 2 hours on an ABI 377 sequencer gel electrophoresis 
apparatus (PE Applied Biosystems). Genotypes were analysed using GeneScan 
software (PE Applied Biosystems). To determine the specific tumour genotype the 
normal contaminating alleles were excluded.
Table 2.5 List of Microsatellite primers *
Marker Ch Repeat Dye Primer sequence forward and reverse Prim
(pM)
AT
AHT 125 24 CA HEX CCACGATCCTCATGTCACCT 0.4 60 °C
ATCAAAGTCATGAAATTCCGTG
CPH2 32 CA FAM TTCTGTTGTTATCGGCACCA 0.3 60 °C
TTCTTGAGAACAGTGTCCTTCG
CPH5 17 CA HEX TCCATAACAAGACCCCAAAC 0.6 58 °C
GGAGGTAGGGGTCAAAAGTT
CPH6 23 CA FAM CATTGGCTGTTTGACTCTAGG 0.5 60 bC
ACTGATGTGGGTGTCTCTGC
CPH9 29 CA TET CAGAGACTGCCACTTTAAACACAC 0.3 62 °C
AAAGTTCTCAAATACCATTGTGTTAA
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FH2001 23 GATA TET TCCTCCTCTTCTTTCCATTGG 0.3 54
TGAACAGAGTTAAGGATAGACACG
FH2004 11 GAAA TET CTAAGTGGGGAGCCTCCTCT 0.3 60
ACTGTGACCTACTGAGGTTGCA
FH2010 24 ATGA FAM AAATGGAACAGTTGAGCATGC 0.3 62
CCCCTTACAGCTTCATTTTCC
FH2054 12 GATA HEX GCCTTATTCATTGCAGTTAGGG 0.4 56
ATGCTGAGTTTTGAACTTTCCC
* The microsatellites used in this study. The primer sequences are from the dog genome project web 
site i w w u l l K i V A ' i u  m ' i c i k  d i ' i: ueiu'me Jog.html).
In order to determine the genetic origin o f the tumour and to estimate its age, 
tumours were analysed using 96 dinucleotide markers used previously to determine 
the genetic relationship among 85 different dog breeds. List of primers sequences is 
shown in Table 2.6. Amplifications were performed using M13 tailed forward 
primers containing 19 bases o f M13 sequence on the 5’ end of the specific 
microsatellite primers, and the PCRs were labelled using tagged M l3 primers. In 
order to run in the same capillary 4 different amplicons, M l3 primers were tagged 
with either 6FAM, VIC, NED, PET dyes. PCRs were carried out in 5 pi of volume 
containing: 0.3 pM of forward (M13tailed) and reverse primers , 1 X PCR buffer, 
0.1 mM dNTPs, 1.5 mM MgCL 0.15 units o f Taq DNA Polymerase (Bioline, USA), 
2 ng of genomic DNA, and 0.25 pmol o f M l3 labelled primer. Reactions for 
microdissected samples were carried out in 10 pi volume. PCRs were performed in 
96 well plates on the MJ research PTC 200 thermal cycler using the following 
conditions: 94 °C x 5 minutes, 35 cycles 94 °C x 20 seconds, 58 °C or 50°C x 20 
seconds, 74 °C x 20 seconds, and a final extension of 74 °C x 5 minutes.
Following amplification, the four differently labelled reactions were mixed. 10 pi of 
the pooled PCRs was mixed with 1 volume of deionised formamide and 15 pmol of 
GeneScan-500LIZ size standard (ABI, Foster, CA). Samples were run on an ABI 
3730 capillary electrophoresis instrument. The alleles were analysed using 
GeneMapper 3.0 (ABI, Foster, CA). To align the previously reported genotypes 
(414 dogs of 85 different breeds listed in table 2.7) with the tumour genotype, a 
common positive control was included in each plate.
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Table 2.6 microsatellite primers (Parker et al, 2004).
Marker
Number
Marker
Name
Chromosome M 13 lagged forward and reverse primers; Annealing
Temperture
Published
PIC*
1 REN285G14 1 CACGACGTTGTAAAACGACAACATGGTGACGAGAAGGCT 55 NA
CC ATTCGCC AC AAGT AGGTT
2 CO 1 673 1 CACGACGTTGTAAAACGACCCACCACTTACATAAACATGGC 58 0 36
TTCCAGACTGCTGCCTCC
3 REN 112102 1 CACGACGTTGTAAAACGACATAGCCCATGAAATCCA 58 0 76
CCCCAAATACATCCCTACAT
4 REN172C02 1 CACGACGTTGTAAAACGACCCCTTAGGAGGAGGCAAGAC 55 0 4 8
CGTGCTTTGTTATGGCTTGA
5 FH2793 1 CACGACGTTGTAAAACGACCTATGTGCACGCTGAGAGAG 58 0 7 6
TACCCATAAAGTTGGGCTTG
6 REN143K.19 1 CACGACGTTGTAAAACGACGTCAGAGCCCCAGAGACAAG 55 0 5
CTTTCTTCCGCCACTACCTG
7 FH2890 2 CACGACGTTGTAAAACGACCCAGATTAACCAGGATGAGG 55 0.59
AAT GGC A AGG AT GCT ACT C C
8 C02 466 2 CACGACGTTGTAAAACGACTCTGGATTGTGGTCACAACC 58 0.55
ACTGGACACTTCTTTTCAGACG
9 C02.894 2 CACGACGTTGTAAAACGACTCAGCATCTAGAAAATTAGGT 58 0.72
ACTC ATTTT CT CTT ATTCT GC AG
11 FH2895 3 CACGACGTTGTAAAACGACTGCGATACACTTAGAAAACAGG 58 0 7
AAAAACCCACAACAAAGTGC
12 REN157C08 3 CACGACGTTGTAAAACGACGCAAATGGCAAGATTTCGTT 55 0.72
CAAGGGTTAGCACCTGGGTA
13 C03 445 3 CACGACGTTGTAAAACGACTCTTTGGTAAAGTCTCCATGGG 58 0 6
GGGTGTGAAAACAGCCAACT
14 FH2732 4 CACGACGTTGTAAAACGACGAAAGGGTGTGGATAAAGAGC 58 0 84
TGGCATATTCAACAAATTGC
15 FH2776 4 CACGACGTTGTAAAACGACGGAACAGATGAGAAGCATGG 58 0.49
CTGGGTGGTTCAGTAGTTGG
16 REN 160J02 4 CACGACGTTGTAAAACGACACCGTGCACAAGTCAGTCAG 58 0.82
AAGCTGAGCCATTCTTTTCC
17 REN262N08 4 CACGACGTTGTAAAACGACAGGATTTTGTGGTGATTGGG 55 NA
TTGC AGCCT ATT GT GG ACTTT
18 REN92G21 5 CACGACGTTGTAAAACGACTACTCGTTCTGTGCCATTTCT 58 0.66
CACACCAGCTCGTCCTCATAA
19 REN285I23 5 CACGACGTTGTAAAACGACCAGCTGTCCGGGGATATAAA 55 0 5 8
GGCTGTGGTTTGTCCTTGTT
20 C05.414 5 CACG ACGTTGT AA AACG ACGCCCCT ATTTTTITTTTTCCC 58 0 4 7
TTGGGTTTC AC ACT C AGC AG
21 FH2752 6 CACGACGTTGTAAAACGACTTTAGGCATTTGAGGAGGAG 58 0 38
GGCACAGAATCCAACTTGAG
22 REN210114 6 CACGACGTTGTAAAACGACCTGCTCTCTCCCCCAAC'rTA 55 0 6 6
CAGGGCCATTGGTCTAGAAA
23 REN37H09 6 CACGACGTTGTAAAACGACATTCCCTTGTA TTGCTCA 58 0 6 7
CCCC AAAAAATCCAACCA
24 REN97M11 7 CACGACGTTGTAAAACGACTGAGGCTCCGTGGGTATGTG 55 NA
AGGCCAAGGGAATGATGCTC
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25 REN286L19 7 CACGACGTTGTAAAACGACCAGTAATGTTTTGTGGCCTCTG 58 0.66
GGGAGTGGGGGAAATAAATG
26 FH2860 7 CACGACGTTGTAAAACGACTGCCCTCAAACAATTTGC 55 0.62
ATCATCCTAGCACTCAGAAGG
27 REN204K13 8 CACGACGTTGTAAAACGACTCGGGATGTTTCTCTTCCAC 55 0 4 8
CTGCTTAAATTCTCCCAGCG
28 C08 373 8 CACGACGTTGTAAAACGACTATTTAAAAAATCCCAGGCACA 58 0 6 8
AGCATCAATTAGATGTCAGCG
29 C08 618 8 CACGACGTTGTAAAACGACCAACCCAGGGTGGAAGC 55 0.82
TAGCAAGAAAATGTGCCCA
30 C09.173 9 CACGACGTTGTAAAACGACATCCAGGTCTGGAATACCCC 58 0 7 8
TCCTTT G AATT AGC ACTT GGC
31 C 09474 9 CACG ACGTTGTAAAACGACTT AAGCCTT ATTTTGT GTTGGG 55 0 78
TCCAGGAAGTGTCTGCAGG
32 FH2885 9 CACGACGTTGTAAAACGACCTTTTAGGGTGCCTTCAACC 55 0.74
TGG ATT ATT A AGGGG A ATTT AGC
33 CIO 781 10 CACGACGTTGTAAAACGACACCTCCAAGATGGCTCTTGA 55 0 6 2
ACGTCGAGCTCCTGGCAT
34 REN73F08 10 CACGACGTTGTAAAACGACATTCCCCAGCGATACCA 55 0.54
AACAGCATTTCAGACAGAGG
35 REN154G10 10 CACGACGTTGTAAAACGACTGGACGCTAAGCCTGACTTT 55 0.71
AAACGGAGTTCCATCTCTGG
36 REN164B05 11 CACGACGTTGTAAAACGACTGGGATGTGTGTCATGTGTG 55 0.5
CCT AT GCAGGGT AGGC AC AT
37 FH2874 11 CACGACGTTGTAAAACGACAACTTCTGGCTTTCATACCG 55 NA
TCTTCAAAGAAAACCAACAGG
38 Cl 1 873 11 C ACGACGTTGTAAAACGACCTGGCAGATTACAGGTAGC 58 0 81
GTT CT C C AAAGCACTCAT
40 REN213F01 12 CACGACGTTGTAAAACGACCATTCTGGGCAGGTTTCATT 55 0 82
GGGGACAAATTTCCACTCCT
41 REN208M20 12 C ACG ACGTT GT A A A ACG ACT GC ATC ATTT GTGGGT GTTT 58 0 6 4
AT GGAGCATGGGTGAGAAAT
42 REN94K11 12 CACGACGTTGTAAAACGACATACCACTGTCCCTCCTCTTA 55 0 56
ATCCT GGT AT C AAATCTATCA
44 REN286P03 13 CACGACGTTGTAAAACGACGCACATTCACAAAGTGGTGC 58 0 78
GCAATGGAAAGAGGATGGAA
45 C l3 758 13 CACGACGTTGTAAAACGACAAGCATCCAGAATCCCTGG 55 0 75
GTTGATTGGGAGATAATCCACA
46 C14 866 14 CACG ACGTTGTA AAACGACTGTCATAATAGTTGGAATGAC 55 0 7 4
TTAGAGCTTACTCATGATATCTG
47 FH3072 14 CACG ACGTTGTA A AACGACCCTGGATTAACAGTTGTCTGG 55 0 6 3
CCTGGATTATAAGCATGAGAGC
48 FH3802 15 CACGACGTTGTAAAACGACTTTTCACCAGCTCTGAGATAGC 55 0 44
TTTCTG AGCC ACTTTTCC AT AG
49 REN06C11 15 CACGACGTrGTAAAACGACTGCAGGGCAGAGGCTGGAGG 58 0 79
GGGGGTGTCGGTGGAGTTCT
50 REN 144M10 15 CACGACGTTGTAAAACGACTCTCATGCAAATCTTCG'rTCA 58 0.66
GCCACCTCATTCCAAAAAGA
51 REN85N14 16 CACGACGTTGTAAAACGACAAGGCAGGAGGAGGAGCAC 58 0 78
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T AT GGAGATGGAGGGCACAC
52 FH3096 16 CACGACGTTGTAAAACGACTCAGCTCAGGGAGTGATCC 55 0.79
ATGAGGAGGTGCAACTATCC
53 Cl 7.402 17 CACGACGTTGTAAAACGACAAATGGGTAATTCATCCAGTGC 58 0.75
C AGGCTTT GTTG AGGT GT C A
54 REN50B03 17 CACGACGTTGTAAAACGACATGTGGGGTAAAATAAAGG 58 0.74
AACACTGACATGCATCCAC
55 REN112G10 17 CACGACGTTGTAAAACGACGAGGGATGGCTGTCAAGA 55 0 7
TGGTGGATAAATAGATAAGGA
56 REN186N13 18 CACGACGTTGTAAAACGACAGGCTCTCCGAGGGTAAGAC 58 0 6 6
ATTGCTTGGATAAGAGGGGG
57 FH2795 18 CACGACGTTGTAAAACGACGGCTGGACTTTTGTCATTTG 58 071
TGTGAGTAGGGTAGGGCAAG
58 C l8 460 18 CACGACGTTGTAAAACGACCTTCCCATTATAGCCCTGTCC 58 0 5 3
GGTGTCAGGAAAATGAGACCA
59 FH2783 19 CACGACGTTGTAAAACGACTCCCTCCTGACACTGCTTTA 55 NA
AGGCCTGCTGTTTCTCTTCT
60 REN91I14 19 CACGACGTTGTAAAACGACCCCTTTTGCACTACTGTTGAG 58 0.72
TCCCTTTTTGTGGCTGAA
61 REN274F18 19 CACGACGTTGTAAAACGACTTCTCGTGACCCCTAAAGGA 58 0.66
GGCATAAATTGTCTTTGCCC
62 FH2887 20 CACGACGTTGTAAAACGACAAACAAGACAGTAGGAAGAGAGG 55 0 7 7
CAAGATTCAAAACAAGCAACC
63 FH3109 20 CACGACGTTGTAAAACGACTGGGAGCTTCATACAAATGC 58 0.62
CCATGGAGAGTGGTTATTGC
64 REN293N22 20 CACGACGTTGTAAAACGACAATTACTCGGCCTCTCTGGG 58 0 4 8
AATGACATTGAGCCTGGGAA
65 FH2914 21 CACGACGTTGTAAAACGACGTGATCCACTTGCTTGTATCC 55 0.61
ATAGCCTTGGGAATTTTTGC
66 FH3069 21 CACGACGTTGTAAAACGACCATGCCTGACTCAACTGATG 55 0 53
TATGGACCTTCGTTCAGAGG
67 REN49F22 22 CACGACGTTGTAAAACGACGGGGCTCTGTTATTAGGTG 55 0.66
TCAT AAGGCAAAGAAAACC
68 REN107H05 22 CACGACGTTGTAAAACGACTGACTTACTCTAGCCACTTTT 55 0 86
TTGT CCCTT GT AT AACT GAT G
69 REN78116 22 CACGACGTTGTAAAACGACTTACATTTAGGGGCTCCAGT 55 0.63
TTAGACAAAATAGGCTTCAA
70 FH3078 23 CACGACGTTGTAAAACGACGCCTTCTTTGGAAAAACACC 55 0.67
TTCAGGGAATTCTTTCTTGG
71 C23 277 23 CACG ACGTTGTA AAACGACACACATTTGTGTGCTTGTCTTG 55 0.54
TTGTATGGAGGTGGGGAGAG
72 REN181K04 23 CACG ACGTTGTA AA ACG ACACAAGCCGACTCTAGCG AAA 58 0 6 4
AGATGGGGCCTAACCAAAGT
73 REN 106106 24 CACGACGTTGTAAAACGACGGTCCCATCCTCAAAATCCTC 55 0 5 8
CCCTTCTGGCCTCCTACACA
74 FH3083 24 CACG ACGTTGTAAA ACG ACATTTGCCAGGTACCATTCC 55 061
CAGGTTATTCTGGGCTATGG
75 REN54EI9 25 CACGACGTTGTAAAACGACGCAGACGAGCACACCGAA 55 0 5 4
TATTCCACATCATTCACC
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77 REN87021 26 CACGACGTTGTAAAACGACTGGCTGTGGCTAAGGCTTTGT 55 0.62
CCCCTTCCAGCTTCGGTGTAG
78 C26 733 26 CACGACGTTGTAAAACGACCCCTCTACTTATGTCTCGGCC 55 0.61
GAGAGGAGAAACAACCAACACC
79 C27.442 27 CACGACGTTGTAAAACGACCCAAGAACAGCCTAAGCTGG 55 0 74
ACACATACACGCCCAATTCA
80 C 27436 27 CACGACGTTGTAAAACGACCAGCTGGATTGGGGACTC 55 051
C AT CTT GCTCT CTC AAC
81 REN72K.15 27 CACGACGTTGTAAAACGACCCGATGCCTGTCCTTTGA 55 0.66
ACCTGGCCTCTTCTGTTGTCT
82 FH2759 28 CACGACGTTGTAAAACGACAGTACTTGAGGCTTGGAGTCAG 55 0 71
C AAGCT GAGAGCCATGTAGG
83 FH2785 28 CACGACGTTGTA AAACGACATGGCAGGTCAAGAGTATGG 55 0 4 6
GATAGATCCAAGCCAACACC
84 REN239K24 29 CACGACGTTGTAAAACGACTTCATTGGCTGGTGACTTTG 55 0.78
CCCCAGGACCATTTGTTAGA
85 FH3082 29 CACGACGTTGTAAAACGACAGTAAAGGGTTCTCAAGTGTGC 55 0.54
CATTTGTCATTGTGGAAAACC
86 REN51C16 30 CACGACGTTGTAAAACGACCAGTTCATCCTTCCCCCTCTC 55 0.8
GTGCTAGTCTGGCTGTGCTCA
87 FH3053 30 c a c g a c g t t g t a a a a c g a c g a t t a a a a g g g c a a g c a a c c 55 0.74
TCATCTCCAGCTTTTCATGG
88 REN43H24 31 CACGACGTTGTAAAACGACCAGTGAGCAAAGCAAATGAA 55 0.66
ATGTGAACCCCGCCCAATA
89 FH2712 31 CACGACGTTGTAAAACGACAAGGTAGTCCCACGATCCTC 55 0.67
GAGCCCTGTTCTCAGGTTG
90 FH2875 32 CACGACGTTGTAAAACGACTGATACCCATTAAGTCCATCC 55 0 6
CAATACCCTGATACCAAAACC
91 FH2790 33 CACG ACGTTGTA AAACGACCCAATATTGTTAAGAAGTTCA AGC 55 0.58
AGGCCTTCTCTGTCCTCTTG
92 REN291M20 33 CACGACGTTGTAAAACGACCCTCTAGATCCATCCATATTGTCA 58 0 7 6
TGTCCACCCACAGATGAATG
93 REN160M18 34 CACGACGTTGTAAAACGACAATGGTGGTGATATTCACAGAGA 58 0 7 6
GGATGCTTGGGAATCTTGAA
94 FH3060 34 CACGACGTTGTAAAACGACAGGCAGAGCTAAACCTGAGC 55 0 4
TACAGGCACTCCTTCCTACG
95 REN314H10 34 CACGACGTTGTAAAACGACGAAATTGTTCCATTTCTGTGACAT 55 0 54
AGGTTTGGGCTCCTCATTCT
96 RENO 1GO 1 35 CACGACGTTGTAAAACGACTACATCTCCACATCTACTGA 55 0 54
GAGACTTAACACAGTATTTG
97 REN112C08 35 CACGACGTTGTAAAACGACATGGCCCACCGATACACA 55 0.42
TCGGGGACATACTTGAACC
98 REN 106107 36 CACGACGTTGTAAAACGACITCCCCAAGCCACACC 55 0 78
AACCACTATCCAACTTTAT
99 FH2708 37 CACGACGTTGTAAAACGACCAGCAATTGGACAAGAAAAAG 55 0 6 3
GAAAGAGGATGAAGGGTGTG
100 REN86G15 38 CACGACGTTGTAAAACGACCAGCGAATTTGGGCACTAA 55 0.76
CAACTAAGGCAGAGAATACCA
* PIC = Polymorphism information content
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Table 2.7 List of breeds used to analyse the genetic origin of the CTVT
Afghan Hound Irish Setter
Airedale Terrier Irish Terrier
Akita Irish Wolfhound
Alaskan Malamute Italian Greyhound
American Cocker Spaniel Keeshond
American Water Spaniel Kerry Blue Terrier
American Hairless Rat Terrier Komondor
Australian Shepherd Kuvasz
Australian Terrier Labrador Retriever
Basenji Lhasa Apso
Basset Hound Manchester Terrier Toy
Beagle Mastiff
Bedlington Terrier Miniature Bull Terrier
Belgian Sheepdog Miniature Schnauzer
Belgian Tervuren Newfoundland
Bernese Mountain dog Norwegian Elkhound
Bichon Frise Old English Sheepdog
Bloodhound Pekingese
Border Collie Pharaoh Hound
Borzoi Pointer
Boxer Pomeranian
Bulldog Portuguese Water Dog
Bullmastiff Presa Canario
Cairn Terrier Pug Dog
Cavalier King Charles Spaniel Rhodesian Ridgeback
Chesapeake Bay Retriever Rottweiler
Chihuahua Saint Bernard
Chow Chow Saluki
Clumber Spaniel Samoyed
Collie Schipperke
Dachshund Shar Pei
Doberman Pinscher Shetland Sheepdog
English Cocker Spaniel Shiba Inu
Flat-coated Retriever Shih Tzu
French Bulldog Siberian Husky
German Shepherd Soft-coated Wheaten Terrier
German Shorthaired Pointer Standard Poodle
Giant Schnauzer Standard Schnauzer
Golden Retriever Tibetan Terrier
Great Dane Welsh Springer Spaniel
Greater Swiss Mountain dog West Highland White Terrier
Greyhound Whippet
Ibiza Hound
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2.6 Gene quantification by real time PCR
The polymerase chain reaction is a technique that allows the amplification of 
specific DNA sequences. The reaction is characterised by an initial logarithmic 
increase of the target sequence per cycle, followed by a plateau where there is no 
increment. The final amplified product is visualised by ethidium bromide after gel 
electrophoresis. The peculiarity of real time PCR is that the amplification process is 
monitored at every cycle in real time by measuring fluorescence signals that are 
proportional to the amount of the PCR product generated (Wilhelm and Pingoud, 
2003). The fluorescence signals can be generated by sequence specific fluorescence 
probes (TaqMan), or by fluorescence dyes that bind double stranded DNA. The 
most used fluorescence dye is SYBR green 1 (Ponchel et al., 2003). It is an 
asymmetric cyanine dye with a DNA binding affinity 100 times higher then that of 
ethidium bromide. The fluorescence emitted by the bound dye is 1000 fold higher 
than that of the free dye. SYBR green is able to detect a single target molecule 
(Ponchel et al., 2003).
In order to determine the gene dosage of the DLA genes, real time PCR based on 
SYBR-Green I fluorescence was used. PCRs were carried out using the SYBR- 
Green PCR Core Reagents kit (Applied Biosystems). In order to avoid the 
amplification of non-specific products and reduce the formation of primer dimers, 
primer concentrations for each target and reference gene was optimised using PCR 
reactions containing 0.3, 0.5 and 1 pM of primers. To check for specific 
amplification, PCR products were analysed by agarose gel electrophoresis. After 
optimisation quantitative PCR reactions were carried out in 50pl volume containing 
IX PCR buffer, 200pM dNTPs, 2pM MgCl2. 0.25pl of AmpliTaq Gold DNA 
polymerase (5U/pl), 50ng and lOOng of genomic DNA for fresh and microdissected 
samples respectively. Given the presence of normal cells within the tumour tissue, 
to determine the tumour specific gene dosage, tissues with a high percentage of 
tumour cells must be used. The percentage of the tumour cell within the tumour 
tissue was determined by histological analysis, and all tumour samples analysed
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contained more than 80% tumour cells. To normalize the SYBR green fluorescence 
variation due to pipetting variation and fluorescence fluctuation, an internal 
fluorescence dye (ROX) that does not interfere with the PCR reactions was included 
in the PCR buffer.
All quantitative PCRs were performed in the ABI Prism® 7000 Sequence Detection 
System (SDS). This system consists of a thermal cycler and a laser directed via 
optical cable fibres to each of the 96 sample wells. A device collects the emission of 
the fluorescence signal from each sample and the data are analysed automatically by 
SDS software to calculate the Ct value, melting curve and gene copy number. The 
threshold cycle (Ct) parameter is the cycle number at which the fluorescence passes 
a fixed threshold above the baseline. The threshold is calculated as ten times the 
standard deviation of the average baseline fluorescence signal measured between 
cycles 3-15. Therefore the fluorescence signal that is detected above the threshold 
representing the background is analysed to calculate the Ct value. The data are 
displayed as an amplification plot, in which the fluorescence signals are plotted 
against the number of cycles (see Fig 2.2a). Following the amplification, a melting 
curve is performed, in which the temperature is increased very slowly from 60 °C to 
95 °C. At low temperature SYBR green binds to the double stranded PCR product, 
generating an high fluorescence signal, whereas at high temperature the denaturation 
of the PCR product increases the proportion of the free SYBR green, therefore 
decreasing the fluorescence signal (see Fig. 2.2b).
Target DNA can be quantified using either absolute or relative quantification. 
Absolute quantification determines the copy number of the target DNA, whereas 
relative quantification determines the ratio between the target and a reference gene 
present in the same sample. In this study I used the absolute quantification method. 
To determine DNA copy number an external standard curve was constructed. To 
generate the standard curve, target and reference genes were amplified and cloned
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into the pGEM T vector. The copy number of standard DNA molecules was 
calculated using the following formula:
molecules/pl = (g/pl DNA /plasmid length x 660) x 6.022 x 10 23
PCR reactions containing dilution series from 102-109 copies of each plasmid were 
performed using the same conditions described above for each target and reference 
gene. The resulting Ct values were plotted in a linear line as a function of the log 10 
concentration of input plasmid amount. The slope of the line was used to determine 
PCR efficiency and the unknown copy number in the samples. To determine the 
correlation between input data a linear regression analysis was automatically 
calculated (Fig 2.2c). For each target and reference gene, tumour and normal copy 
number was determined against a standard curve run in parallel with the samples. 
All samples were run in triplicate. Amplification of the correct sequence was 
confirmed by dissociation curve analysis. To determine the DLA gene dosage, two 
internal reference genes were used. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and P-actin are housekeeping genes that are expressed normally in all 
cells and are unlikely to be mutated or deleted in tumours; therefore they are 
routinely used to normalise the amount and quality of genomic DNA and RNA.
The gene dosage (N) was determined using the formula (Bieche et al., 1998):
Copy number of target gene
N =  -----------------------------------
Copy number of reference gene
To exclude the possibility that the gene dosage of reference genes were altered in 
tumour tissue, the ratio between GAPDH and P-actin was also calculated. Given that 
target-reference ratio is variable between different normal samples, to determine the 
cut-off values in the tumour samples, 4 normal samples were also tested.
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Table 2.8 primers for q-PCR
Gene Forward Reverse Size
bp
GAPDH GGCGGGGCCAAGAGGGTCA TCTTGAGGGAGTTGTCAT 120
P-Actin CTCCATCATGAAGTGTGACGTTG CGATGATCTTGATCTTCATTGTGC 150
DQA1 CTCAGCTGACCATGTTGC CACAGGCAGCCGCCAGAC 150
D Q A lt TAAGGTTCTTTTCTCCCTCTGT TGCTAGGGAGGAAGGGGAAAG 389
DQB1 TCACTGGCCCGGCTGTCTCC CTCCCCCACGTCGCTGTC 150
DRB1 CCGTCCCCACAGCACATTTC TGTGTCACACACCTCAGCACCA 350
DLA-88 TCTCACCCGTCGGCTCCGCAG GATGGGGGTCGTGCCCTGGCC 350
DRA CATCCAAACCCCAGTGCTCC ACCCCTGTGGAACTGGGAGAG 212
Pglfr Rn v? Qygl?
coc
Cycle Number
Fig 2.2a. Amplification plot of a dilution series 
containing 10~-109 template copies
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Fig2.2b. Dissociation curve analysis of amplification products with melting point 
of 81 °C Fig 2.2c. Standard curve obtained with a tenfold dilution of a positive 
control template. The resulting Ct values for each point are plotted as a function of 
the log 10 concentration of input template.
2.7 Reverse Transcription-PCR
Single strand cDNA was synthesised from RNA by using Superscript II RNase H- 
Reverse Transcriptase kit (Invitrogen). All material and reagents used during reverse 
transcription were RNase free and the bench and gloves and pipettes were treated 
with the RNase decontamination solution RNaseZap (Ambion). Before reverse 
transcription the mRNA was treated with RQ-RNase free-DNase (Promega) to 
eliminate DNA contamination; the reaction was carried out in lOpl volume 
containing: lx DNase buffer, 1 unit of DNAse, and 500 ng of mRNA. The reaction 
was incubated for 10 minutes at 37 °C, and then DNAse was inactivated by heating 
at 65 °C for 15 minutes. 50 ng of mRNA was transferred in a 0.5 microcentrifuge 
tube containing: 2 pmol of the specific reverse primers, 1 pi of 10 mM dNTP mix, 
and sterile water up to 12 pi. The reaction was incubated at 65 °C for 5 minutes to 
disrupt the mRNA secondary structure and to allow primers to bind the 
complementary target sequence, and then quickly chilled on ice. 4 pi of 5x First
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Strand Buffer, 2 pi of 0.1 M DDT, lp l of recombinant ribonuclease inhibitor (40 
units/pl) RNAseOut were added. The mixture was incubated at 42 °C for 2 minutes, 
and 1 pi (200 units) of reverse transcriptase was added and incubated at 42 °C for 50 
minutes. The enzymes were inactivated at 70 °C for 15 minutes. 2 pi (10%) of the 
first strand cDNA reaction was then amplified using the PCR condition described in 
section Table 2.3 and 2.4, and host specific (dog C, see Table 2.1 and Fig 2.1c-d) 
DRB1 and DLA-88 allele primers and PCR conditions described in Table 2.8 and 
2.9.
Table 2.8 DLA-DRB1 and DLA-88 host (dogC) allele specific PCR primers
Gene Forward Reverse Size
bp
C-DLA- 
88(29)
CGCCAAGGAGACCGCACAGGTGT CCTCAGGTGCCCTGCATCACCT 420
C-DLA- 
88 (42)
CCATCAAGGAGACCGCACAGAGG CCTCAGGTGCCCTGCATCACCT 420
C-DLA-
DRB1
CGGTTCGTGGAAAGATACA CAATCACCCCGTAGTTGTG 169
Table 2.9 PCR conditions for host (dog C) host allele specific DLA-DRB1 and 
DLA-88 amplifications
PCR steps C DLA 88 (29) C DLA 88 (42) C DLA DRB1
Initial Denaturation 95 (3min) 95 (3min) 95 (3min)
Denaturation 94 (lmin) 94 (lm in) 94 (lmin)
Annealing 65 (2min) 64 (lm in) 61 (lmin)
Extension 72 (45sec) 72 (45sec) 72 (45sec)
2.8 Representational difference analysis
In an attempt to identify unique DNA in CTVT possibly representing part of the 
genome of an oncogenic virus or microbe, representational difference analysis 
(RDA) was performed as outlined in Fig 2.4
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Fig 23  Outline of RDA Process
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2.8.1 Genomic DNA digestion
3 jig of genomic DNA extracted from a metastatic tumour removed from dog C (see 
Table 2.1) internal metastasis (Tester) and 3 fig of genomic DNAs extracted from 
five unrelated normal canine blood samples (Driver) were digested separately in a 
volume of 100 pi containing: 30 U of BamH I (Promega) (10 units per pg of DNA), 
lx Buffer E, 2mg BSA. The digestion reactions were incubated at 37 °C for 16 
hours. Digested DNA was checked by 1% agarose gel electrophoresis.
2.8.2 Digested DNA extraction
Digested DNA was purified by adding 1 volume of (25/24/1) 
phenol/chloroform/isoamyl alcohol to the digestion reactions, mixed and centrifuged 
for 3min at 13000 rpm. The aqueous layer was removed and the purified DNA was 
precipitated by 2 volumes of ethanol and 0.1 volume of 3 M sodium acetate. The 
tubes were incubated at -20 °C for 15 min. and then centrifuged at 13,000 rpm for 10 
min. Precipitated DNA was washed with 1ml of 70 % ethanol and centrifuged at
13,000 rpm for 2 min. The final pellet was air dried and resuspended in TE buffer 
(10 mM Tris-HCl, ImM EDTA, pH 8.0) and solubilised by heating to 65 for 5 min.
2.8.3 Ligation of oligonucleotide adaptors
Ligation was performed in 60 pi containing: 2pg of digested DNA, 1000 pmol of 
R24 and R12 adaptors, IX ligase buffer (New England Biolabs). To anneal the 
adaptors the ligation reaction was heated to 55 °C for 3 minutes, and then cooled for 
1 hour at 4 °C. The reaction was placed on ice for 3 min, then 2pl (800 U) of T4 
DNA Ligase (New England Biolabs) was added and the contents mixed carefully. 
The ligation reaction was incubated at 16 °C for 18 hours.
Table 2.10 list of RDA BamHI adaptors.
Oligonucleotide 24-mer 12 m er
BamH I R 5 ’-AGC ACTCTCC AGCCTCTCACCG AG 5’-GATCCTCGGTGA
BamH I J 5 ’-ACCG ACGTCG ACTATCC ATGA ACG 5’-GATCCGTTCATG
BamH I N 5 ’-AGGC A ACTGTGCTATCCG AGGG AG 5’- GATCCTCCCTCG
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2.8.1 Genomic DNA digestion
3 fig of genomic DNA extracted from a metastatic tumour removed from dog C (see 
Table 2.1) internal metastasis (Tester) and 3 pg of genomic DNAs extracted from 
five unrelated normal canine blood samples (Driver) were digested separately in a 
volume of 100 pi containing: 30 U of BamH I (Promega) (10 units per pg of DNA), 
lx Buffer E, 2mg BSA. The digestion reactions were incubated at 37 °C for 16 
hours. Digested DNA was checked by 1% agarose gel electrophoresis.
2.8.2 Digested DNA extraction
Digested DNA was purified by adding 1 volume of (25/24/1) 
phenol/chloroform/isoamyl alcohol to the digestion reactions, mixed and centrifuged 
for 3min at 13000 rpm. The aqueous layer was removed and the purified DNA was 
precipitated by 2 volumes of ethanol and 0.1 volume of 3 M sodium acetate. The 
tubes were incubated at -20 °C for 15 min. and then centrifuged at 13,000 rpm for 10 
min. Precipitated DNA was washed with 1ml of 70 % ethanol and centrifuged at
13,000 rpm for 2 min. The final pellet was air dried and resuspended in TE buffer 
(10 mM Tris-HCl, ImM EDTA, pH 8.0) and solubilised by heating to 65 for 5 min.
2.8.3 Ligation of oligonucleotide adaptors
Ligation was performed in 60 pi containing: 2pg of digested DNA, 1000 pmol of 
R24 and R12 adaptors, IX ligase buffer (New England Biolabs). To anneal the 
adaptors the ligation reaction was heated to 55 °C for 3 minutes, and then cooled for 
1 hour at 4 °C. The reaction was placed on ice for 3 min, then 2pl (800 U) of T4 
DNA Ligase (New England Biolabs) was added and the contents mixed carefully. 
The ligation reaction was incubated at 16 °C for 18 hours.
Table 2.10 list of RDA BamHI adaptors.
Oligonucleotide 24-mer 12 m er
BamH I R 5 ’-AGC ACTCTCC AGCCTCTCACCG AG 5’-GATCCTCGGTGA
BamH I J 5 ’-ACCGACGTCG ACTATCC ATGA ACG 5’-GATCCGTTCATG
BamH 1 N 5 ’-AGGC AACTGTGCTATCCG AGGG AG 5’- GATCCTCCCTCG
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2.8.4 Production of amplicons
PCR amplification of ligated DNA was performed in 400 pi volume containing: 
80ul of: 5X PCR buffer, 32 pi of 4 mM dNTPs, 500 pmol of R24 adaptor and 100 ng 
of the R ligated DNA. 100 pi of mineral oil was layered on the top of the reaction 
mix. Initially PCR reaction was heated to 72 °C for 3 min to dissociate the R12 
adaptors from the template, then 20 U of Taq polymerase (AmpliTaq Perkin-Elmer 
Cetus) was added under the oil layer and the reaction was mixed by pipetting up and 
down several times. The samples were incubated for 5 min at 72 °C to allow the 
fragments 3’ ends to extend thus forming the complementary strand for the R24 
oligonucleotides. In order to determine the optimal number of amplification cycles 
that yield a distinct and more intense band of 750 bp (due to the presence of high 
copy of a repetitive element) a preliminary amplification was performed; at cycles 
25, 27, 30, 35, the amplification reaction was placed on ice and 10 pi was removed 
and run on a 1% agarose gel and visualised by UV illuminator. Given that the 750 
bp band was more distinct and intense at the 30th cycle, six tubes of tester (tumour) 
and thirteen of driver (normal) were amplified separately (to avoid DNA 
contamination between tester and driver samples while adding the Taq DNA 
polymerase) using the following conditions: 30 cycles of (95 °C 1 minute and 72 °C 
for 3 minutes) followed by a final extension at 72 °C for 10 minutes. After 
amplification the PCR profile was checked by agarose (1.5 %) gel electrophoresis. 
Once the mineral oil was removed from the PCR reactions, the tester and driver 
amplicons were purified and precipitated as described above. The extracted PCR 
products were resuspended in TE and the DNA concentration was determined by 
measuring absorbance at 260 nm in a UV spectrophotometer.
2.8.5 Amplicon digestion
In order to cleave the R adaptors both tester and driver amplicons were digested 
with the restriction endonuclease BamH I in 200 pi volume containing: BamH 1(10 
U /ug DNA), IX buffer E, and lOpg of driver and tester amplicons for 2 hours at 37 
C. Considering that a total of 150 pg of driver amplicons were produced, 15
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independent digestions were required for each driver sample. In order to determine 
the success of the technique, 50 pg o f tester amplicon was used as driver amplicon. 
The digested drivers amplicons were extracted as above. The R adaptors were 
removed from only the digested tester amplicons by Centricon-100 ultrafiltration 
(Amicon, Beverly, MA); 200 pi of tester digestion reaction was diluted in 2 ml of 
TE. The diluted tester was applied to the columns and centrifuged at 750 g for 30 
min. The retained tester was diluted in TE to 100 ng/pl. The success of the digestion 
was checked by running 10 pi of ligated and digested reaction in a 2% agarose gel.
2.8.6 Ligation of new adaptors on tester amplicons
2pg of digested tester amplicons were ligated with new adaptors J24: 
ACCGACGTCGACTATCCATGAACG, and J12: GATCCGTTCATG, using the 
same ligation conditions used for the R24 and R12 adaptors. The success of the 
ligation was checked by agarose gel electrophoresis, where a 50 bp difference 
between digested and ligated fragment should be observed. The J ligated tester was 
diluted to 10 ng/pl with TE.
2.8.7 DNA hybridisation
All five driver amplicons were pooled and mixed by pipetting up and down several 
times. Forty micrograms of pooled digested driver amplicons and 0.4 pg of J ligated 
tester were combined. Forty micrograms of the tumour driver amplicon was also 
combined with 0.4 pg of J ligated tester. The driver-tester mixture was purified by 
Phenol/chloroform/isoamyl alcohol, and then precipitated by addition of 30pl of 10 
M ammonium acetate (Sigma) and 2.5 volumes of ethanol, the amplicon mixture 
was placed on dry ice for 10 min followed by 2 min at 37 °C. The mixture was 
precipitated by centrifugation at 13,000 rpm for 15 min, and resuspended in 4 pi of 
3 X EE buffer (30 mM EPPS, 3 mM EDTA pH 8.1), (the EPPS contained in the EE 
buffer was used because it does not acidify when heated to 98 °C), then incubated
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for 5 min at 37 °C, and 30 pi of mineral oil was added. The amplicon mixture was 
denatured at 98 °C for 4 min in a heat block, and 1 pi o f 5 M NaCl was added 
directly without removing the tube from the heat block, and mixed carefully to 
avoid the formation of bubbles. The mixture was then incubated for 24 hours at 67 
°C.
2.8.8 Selective amplification
Once the mineral oil was removed, the hybridisation mixture was diluted in 400 pi 
of TE buffer. The hybridisation reaction was amplified in 400 pi volume containing: 
IX PCR buffer, 0.4mM dNTPs, and 40 pi of hybridised mixture. The PCR reaction 
was incubated at 72 °C for 3 min, and then 20 U of Taq Polymerase was added for 5 
min at 72 °C. To amplify the self-re-annealed tester DNA, 500 pmol of J24 primers 
were added. The first amplification consisted of 10 cycles at 95 °C 1 min and 70 °C 
3 min) followed by 72 °C 5 min. The amplified products were extracted as above 
and resuspended in 40 pi of water, then treated with mung bean nuclease (New 
England Biolabs) to remove single strand DNA molecules. The reaction consisted 
of: 1 X mung bean nuclease buffer, 20 U of mung bean nuclease, 20 pi of amplified 
hybridisation products. The reaction was incubated at 30 °C for 30 min, the nuclease 
was inactivated by adding 160 pi o f Tris-HCl pH 8.9 and incubated at 98 °C for 5 
min. The mung bean nuclease treated product was purified by Centricon-100 filter 
as described above and diluted in 120 pi of water. 40 pi of the nuclease treated 
products were amplified using the J24 primers. Once the PCR reaction was overlaid 
with mineral oil and denatured at 95 °C for 1 minute, 20 U of Taq DNA polymerase 
was then added. The amplification conditions consisted of 20 cycles at 94 °C for 1 
minute, followed by 70 °C for 3 minutes, with a final extension of 10 minutes at 72 
°C. The PCR products were run on 1.5 % agarose gel to check the profile and yield.
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2.8.9 Changing the adaptors for subsequent hybridisation/amplification step
The difference product (DP) from the first selective amplification was re-digested 
with BamH I to remove the J adaptors than ligated with new adaptors N24 and N12, 
following the same conditions as described above. The second and third rounds of 
hybridisation were repeated hybridising 50 ng and 100 pg of DPI and DP2 
respectively with 40 pg of drivers amplicon following the same conditions as 
described. Selective amplifications were repeated as described in the first selective 
amplification using the N24 and J24 oligonucleotides respectively.
After three round of hybridisation and selective amplification, the difference 
products were visualized by 1.5 % agarose gel electrophoresis.
2.8.10 Fourth hybridisation/amplification round
Given that the tester and drivers were genetically unrelated, in order to reduce the 
selective amplification of a fragment that represents a normal genetic polymorphism 
a fourth hybridisation was performed using pooled amplicons prepared as before 
from 10 unrelated mixed breed dogs. The hybridisation mixture containing 5 pg of 
DP3 and 40 pg of pooled drivers amplicon was hybridised and selectively amplified 
using the N24 primers. The amplified products were run along with a 100 bp ladder 
on 2% 1:1 NUSieve/agarose gel (FMC, Rockland, ME and Gibco/BRL) gel in 0.5 X 
TBE buffer and visualized by ethidium bromide staining.
2.8.11 Isolation and enrichment of difference products from NUSieve/agarose 
gel
Each visible band was excised from the gel with a different clean scalpel. In order to 
clone fragments that may not be sufficiently abundant to be seen, in addition to 
excising the visible bands, gel fragments in a range of 200-1500 bp, so that each 
fragment includes a 200-300 bp range, were excised. The excised gel fragments 
were resuspended in 200 pi for the more intense bands and 400 pi for the larger gel 
pieces, in Tris-HCL pH 8.9, and then melted for 7 min at 98 °C. Fourty pi volume of
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diluted product extracted from larger gel pieces was re-amplified using the N24 
primers using the same conditions as above with 15 amplification cycles. The purity 
of the re-amplified products was checked on 2% 1:1 NUSieve/agarose gel. The 
visible bands produced by re-amplification were excised as before and diluted in 
200 pi ofTE.
2.8.12 Cloning and screening of difference products
Purified PCR products from the fourth round were ligated into the pGEM-t Vector 
and transformed in super competent bacteria TOP 10 as described in section 2.12- 
2.13. Seven colonies from each cloned band were amplified by PCR using the N24 
primers and purified using QIAGEN PCR Purification kit according to manual. In 
order to avoid cloning background material, purified products were digested with 
restriction endonuclease Mnll (New England Biolabs), which cuts frequently 
therefore provides a restriction fingerprint. The digested products were run on a 2% 
NUSieve gel. The fragment used as probe for southern blot analysis was selected by 
the criterion that if three or more of the seven colonies share a common restriction 
fingerprint, it was more likely to represent the difference product rather than 
background material.
2.9 Probe labelling
Selected inserts were labelled with alpha dATP 32 P by random primer labelling 
(HexaLabel DNA labelling Kit, Fermentas). The labelling reaction was carried out 
into a 1.5 ml microcentrifuge tube by adding the following components: 100 ng of 
DNA, 1 X reaction buffer mixed with hexanucleotides, and deionised water to 40 pi. 
The microcentrifuge tube was then vortexed and spun down for 5 seconds. The 
reaction was incubated in a boiling water bath for 10 minutes and cooled down on 
ice. Three pi Mix A (containing a mixture of dNTPs except dATP) and 500 pCi of 
a  32 P dATP (ICN) were added to the labelling reaction. In order to label the DNA
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fragment with a32P dATP, 5 units of Klenow fragment (exonuclease negative) was 
added. The reaction was then incubated at 37 °C for 15 minutes. Four pi (ImM) of 
dNTPs (including dATP) was added to the reaction and incubated for 5 minutes at 
37 °C. The labelling reaction was stopped by adding 1 pi of 0.5 M EDTA (pH 8). 
The unincorporated dNTPs were removed by applying the labelling reaction in to 
pre-spin Sephadex G 50 columns and centrifuged at 3000 rpm for 2 minutes.
2.10 Southern blots
0.5 pg of driver and tester amplicons from the first amplification were subjected to 
electrophoresis on 2% NUSieve agarose (FMC Byproducts) for 2 hours at 60 volts. 
The DNA was visualised by staining the gel with ethidium bromide (0.5 pg/ml). In 
order to denature the DNA amplicons, the gel was transferred to a Pyrex baking dish 
containing 0.4 M of sodium hydroxide and 1.5 M of sodium chloride, for 10 minutes 
on a rotary shaker. The gel was then neutralised with a solution containing 1.0 M of 
Tris-HCl pH 8.0, 1.5 M of sodium chloride and then with deionised water. To 
transfer the DNA amplicons a positively charged nylon membrane Hybond-Xl was 
used (Amersham Pharmacia, Biotech). The membrane was cut 2 mm larger than the 
gel in both directions and then washed in deionised water and briefly in 0.4 M of 
NaOH. The DNA was transferred overnight by capillary transfer to a membrane 
using 0.4 M of sodium hydroxide as transfer buffer.
2.10.1 Hybridisation
After transfer the membrane was removed from the gel and placed in a tray 
containing 2X SSC (Sodium c hloride Sodium Citrate) (20X SSC: 3M Sodium 
chloride, 0.2 Sodium citrate; pH 7.0) and 0.5 % sodium dodecilsulphate (SDS) for 
15 minutes. The DNA was cross-linked to the membrane using the UV-linker 
Stratalinker (Stratagene). The membrane was transfered to a Pyrex hybridisation 
tube containing 10 ml of Hyb solution (Amersham) and 10 pg/ml of salmon sperm 
DNA, and incubated in a roller hybridisation oven at 65°C for 30 minutes. After the
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pre-hybridisation, a mixture containing 50 pi of labelled probe and 1ml of Hyb 
Solution was heated in a boiling water bath for 7 minutes and immediately 
transferred to the hybridisation tube. Hybridisation was performed at 50 °C for 24 
hours.
2.10.2 Washing and detection.
After the removal o f the hybridisation solution, a solution containing 150 ml o f 2X 
SSC, and 0.1 % of sodium dodecilsulphate (SDS) was added to the tube and 
incubated for 15 minutes in the roller hybridisation oven. This procedure was 
repeated twice more but using IX SSC the first time and 0.1 X SSC the second time. 
After the membrane was dried it was exposed to the Phospho Imager cassette for 24 
hours and analysed using the Storm 860 scanner (Molecular Dynamics).
2.11 Non- denaturing polyacrylamide gel electrophoresis
Cy5 labelled PCR products were run using 5% polyacrylamide gel containing: lx 
TBE (90 mM Tris-borate, 2 mM EDTA pH 8.3) 5% Long Ranger (Cambrex) 
(containing polyacrylamide) and distilled water up to 50 ml. To polymerise 25 pi of 
N, N, N ’, N ’ Tetramethylethylenediamine (TEMED), and 250 pi of 10% 
ammonium persulfate were added and mixed for 2 minutes. After polymerisation 
the gel was run in IX TBE buffer at 50 V for 1-2 hours. PCR products were 
detected using the Storm 860 phosphoimager (Molecular Dynamics)
2.12 Ligation of PCR product into cloning vector
Gel purified PCR products were ligated in to pGEM-T vector (Promega). This linear 
vector possesses overhanging thymidines at both 3’ ends, therefore enabling the 
ligation of PCR products that have been adenosylinated at the 3’ends by Taq DNA 
polymerase. The ligation reactions were carried out in a total volume of 10 pi 
containing: 5 pi o f 2X rapid ligation buffer, lpl of T4 DNA ligase (3 units), 1 pi of 
Vector (50 ng), and 150 ng of PCR product; in all cloning procedures an 
insert:vector ratio o f 3:1 was used, the volume was adjusted to 10 pi with deionised
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water. All components were mixed and centrifuged for 3 seconds at 13,000 rpm. 
The reaction was incubated overnight at 4 °C.
2.13 Transformation of chemically competent bacterial cells
Transformation was carried out using chemically competent One Shot TOP 10 cells 
(Invitrogen), which are compatible with blue/white screening and ampicillin 
selection. Competent cells (50 pi) contained in a 1.5 ml vial were thawed on ice and 
2 pi of the ligation reaction was added directly into the competent cell solution and 
mixed by gently tapping. The cells were then incubated for 30 minutes on ice. Cells 
were heat shocked at 42 °C for 30 seconds and then placed on ice for 2 minutes. 250 
pi o f pre-warmed SOC medium was added to the transformed cells and incubated at 
37 °C for 1 hour in a shaking incubator at 225 rpm. 100 pi of transformed culture 
were spread in on LB agar plates containing lOOpg/ml ampicillin, 0.5 mM of 
ispropyl-P-D-thiogalactopyranoside (IPTG) (Promega) and 80 pg/ml of 5-bromo-4- 
chloro-3-indolyl p-D-galactopyranoside (X Gal) (Promega). The LB plates were 
then incubated overnight at 37 °C.
2.14 Screening transformants for insertion
The pGEM-T vector contains the cloning site within the p-galactosidase gene, 
which encodes for an enzyme that converts the colourless X Gal substrate into a 
blue dye. Thus successful ligation interrupts the P-Gal coding sequences and 
colonies with the insert are white, and colonies without an insert are blue. Positive 
white colonies were subsequently analysed by PCR.
2.15 Isolation and purification of plasmid DNA
Selected white colonies were inoculated into 3ml of LB medium containing 100 
pg/ml ampicillin, and then incubated overnight at 37 °C in a shaking incubator at 
250 rpm. The next day the culture was centrifuged at 10,000 rpm for 1 minute, and 
after the removal of the supernatant the plasmid DNA was extracted using the QIA
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miniprep kit (QIAGEN); the pellet was resuspended in 250 pi of Buffer PI, the 
bacterial cells were lysed by adding 250 pi of Buffer P2 (alkaline buffer) and after 
inverting the microcentrifuge tube 5-6 times, and the mixture was incubated for 5 
minutes. The lysate was neutralised by adding 350 pi of buffer N3 and inverting the 
tube 5-6 times. To separate plasmid DNA from genomic DNA and proteins, the 
lysate was centrifuged at 13,000 rpm for 10 minutes. The supernatant was 
transferred to a QIAGEN mini column, which contains an anion exchange resin able 
to bind DNA. The plasmid DNA was isolated by aspirating the supernatant through 
the column using a vacuum system. The DNA bound to the column was then 
washed by adding 750 pi of buffer AW and centrifuged 2 times at 13,000 rpm for 1 
minute to remove residual buffers and to dry the column. Plasmid DNA was eluted 
by adding 50 pi of deionised water in the centre of the silica gel membrane and 
centrifuged at 13,000 rpm for 1 minute. The DNA concentration was determined 
using Nanodrop.
2.16 Automated DNA sequencing
The insert cloned in to pGEM-t Vector was sequenced by adding 150 ng of purified 
plasmid in a sequencing reaction containing: 3.2 pmol of vector or insert specific 
primers and 8 pi o f Dye Terminator Cycle Sequencing mix (Beckman Coulter) and 
sterile deionised water up to a total volume of 20 pi. The reaction components were 
mixed thoroughly and then centrifuged at 13,000 for 2 seconds. Amplification was 
performed on an MJ research PTC 200 thermal cycler with a heated lid using the 
following conditions: an initial denaturation at 92 °C for 2 minutes, followed by 30 
cycles consisting of 20 seconds at 96°C, 20 seconds at 50 °C and 4 minutes at 60°C. 
To precipitate the amplified product, the sequencing reaction was transferred to a 
sterile 0.5 ml microcentrifuge tube containing 4 pi of stop solution freshly prepared 
by mixing equal volumes of 3M sodium acetate pH 5.2 and 100 mM 
ethylenediaminetetraacetic acid (EDTA) and 1 pi of 20 mg/ml of glycogen. After 
mixing thoroughly, 60 pi of cold (-20 °C) 95% ethanol was added and mixed by 
pipetting up and down several times. The tube was immediately centrifuged at
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14,000 rpm at 4 °C for 30 minutes. After centrifugation the supernatant was 
carefully removed and the pellet was washed twice with 200 pi cold (-20 °C) 75% 
ethanol, each time the tube was centrifuged at 14,000 rpm at 4 °C for 3 minutes. 
After removal of all supernatant, the pellet was vacuum dried at room temperature 
for 40 minutes and then resuspended in 40 pi sample loading solution (Beckman 
Coulter) containing deionised formamide. The resuspended product was then 
transferred into 96 well plates and overlaid with a drop of mineral oil. The 
sequencing product was run in a Beckman CEQ 2000 DNA analysis machine.
2.17 Genetic and phylogenetic analysis
In order to analyse the genetic variation, DNA sequences were aligned by using 
BioEdit Sequence Alignment Editor 5.0.9 (Hall, 1999). To analyse the genetic 
relationship between tumour and normal sequences, DLA and mtDNA sequences 
available from GenBank were also analysed. A Blast analysis was also performed to 
see if tumour and normal sequences found in this study had been already described. 
Phylogenetic analyses were made using PAUP version 4.0 beta version (Swofford, 
2001). The mtDNA neighbor joining tree was constructed according to the LogDet 
model. The LogDet method assumes that all sites of a specific sequence can vary at 
the same rates, and allows the base frequency or base composition to vary over the 
tree (Tamura and Kumar, 2002). Unlike other methods that assume complex but 
specific models of nucleotide substitution, the LogDet model was chosen in order to 
correct for potential multiple substitutions (otherwise the evolutionary distances 
would be under-estimated) and could be used without collapsing the topology of the 
tree.
The substitution model to construct the trees was chosen using Model Test 3.06 
(http: in hit', b\ u.ctl u 1 ac u 11 \ kvac C randall lab modcltcst Ji tlm). Model T est
(Posada and Crandall, 1998) compares different models of nucleotide substitution, 
calculating the likelihood ratio test (LTR) scores and Akaike Information Criterion 
(AIC) values for each of the 50 models. The output file containing the best-fit model
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selected by the program is then used by the PAUP program to compute the 
phylogenetic tree (neighbor joining, maximum parsimony, maximum likelihood). 
For MP or ML methods the best tree is computed by a heuristic search, whereas for 
NJ and MP methods bootstrap analysis can be performed. For the DRB1 a ML 
phylogenetic tree was built using a K81uf model (GTR+G+I) (selected by AIC in 
Model Test), and the best tree was chosen from 333,025 simulated trees (with a 
running time of 16 hours). The genetic relationship between tumour, host sequence 
and sequence present in the mtDNA Clade A, was also analysed by using a median 
joining networks calculated by Network 4.0 (hup: \s u \n.tluxus-enuinecrinu.com) 
(Bandelt et al., 1999). The Median Joining method consists of two algorithms. The 
first finds the minimum spanning trees for a set of sequences, without creating any 
connection between them and without inferring additional node; the second 
algorithm elaborates maximum parsimony trees by creating a median vector 
between sequences. Median vectors can be interpreted as consensus sequences, 
which represent unsampled sequences or extinct ancestral sequences. A default 
setting of c =0 and with identical weight between nucleotide was chosen to elaborate 
the MJ network.
2.18 Microsatellite statistical analysis
This analysis was undertaken in collaboration with Jonathan Pritchard at the 
University of Chicago. In order to analyse the genetic relationship between tumour 
and its host, and between tumours, a Bayesian clustering model implemented in the 
program Structure was used (Pritchard et al., 2000). The Structure algorithm 
constructs genetic clusters using microsatellite frequency data to infer population 
structure and to assign probabilistically individuals to populations. This method 
does not assume any particular mutational process, but assumes that markers within 
populations are in Hardy-Weinberg equilibrium. The program adopts a Bayesian 
inference model to estimate several prior parameters such as: allele frequencies in 
all population, population of origin of the individual and the proportion of the 
individual genome that originated from a specific population. The essence of the 
Bayesian method is to infer the posterior probability using the joint distribution
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between prior parameters, distribution and likelihood distribution according to the 
following formula:
p(<D) p(X |0)
p(<D|X)= ----------------------
P(X)
where p(0|X) represents the posterior distribution of the parameters given the data 
p(O) is the prior distribution o f the parameters , p(X |0) is the likelihood that specify 
the probability of the data given any particular parameters values and p(X) prior 
represents the distribution of the data (Shoemaker et al., 1999; Beaumont and 
Rannala, 2004). The join distribution was estimated using a Markov Chain Monte 
Carlo method.
In this study 11 tumours and 11 host genotypes consisting of 5 dinucleotide and 4 
tetranucleotide markers were run. First I performed 10 independent runs with
100.000 iterations following a burn-in period of 10,000 iterations, assuming prior K 
values (number of clusters) from 1 to 5 and without prior information regarding the 
origin of the tumour. An ancestry model with admixture (where the individuals may 
have mixed ancestry) and uncorrelated allele frequency (where the allele 
frequencies in each population are independent) was first performed. Second sets of 
runs were performed using an unmixed model (where each individual comes purely 
from one specific population) and correlated frequency (allele frequencies in 
different population are similar).
In order to determine the origin of CTVT, a tumour consensus genotype based on 73 
dinucleotide markers was compared with normal genotype obtained from 414 pure­
bred dogs representing 85 breeds (five unrelated dogs for each breed) and from 8 
unrelated wolves (from China, Oman, Iran, Italy, Sweden, Mexico, Canada, and 
United States). 20 independent runs using 100,000 iterations and a burn in period of
20.000 iterations with admixed and uncorrelated models and with K=4 were 
performed without prior origin (breed) information. Following the determination of
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the cluster in which the tumour was assigned, all individuals within the cluster were 
used to assign the tumour to a specific population. Two data sets were used: in the 
first data set dogs and wolves were analysed together with the tumour genotype, 
whereas in the second data set only the tumours and dogs genotype were analysed. 
The runs consisted of 100,000 + 20,000 iterations with admixed, uncorrelated or 
correlated models. For dogs and wolves, prior origin information was used but no 
prior origin information was used for the tumours. Microsatellite genetic distances 
were estimated by two methods: chord distance (Cavalli-Sforza and Edwards, 
1967), and proportional shared allele (Dps) distance (Bowcock et al., 1994) using 
MICROSAT(http: hp gl. stun ford.ed u projects mic rosat.hilm) (Goldstein et al., 
1995). NJ phylogenetic trees were constructed with the programs Neighbor and 
Consense in the PHYLIP3.5.(http://evolution.genetics.washington.edu/phvlip.html) 
(Felsenstein, 1989).
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CHAPTER 3
Search for an aetiological agent by RDA
3.1 Introduction
Cancer can be viewed as a genetic disease, where the heritable genetic alterations 
are somatically transmitted (Nowell, 1976). The genetic alteration that initiates the 
transformation can be caused by chemical and physical agents or by infectious 
agents. Among infectious agents viruses have been implicated as causative agents in 
several tumours in animal and humans (Gross, 1983; Wyke and Weiss, 1984).
The reproducibility of CTVT either naturally by coitus or experimentally by 
inoculation of tumour cells, led scientists to investigate whether an infectious agent 
induced the tumour (Gross, 1983). The search for an oncogenic virus was attempted 
either by inoculation of tumour cell free extract or by electron microscopy. 
Although some investigators (Ajello, 1960; Dozza and Torlone, 1960b) reported the 
successful transmission of the tumour by lyophilised cell extract inoculations, 
numerous attempts to reproduce the disease failed to transmit it by tumour cell free 
extracts. However, the presence o f crystalline virus-like particle structures has been 
observed in experimentally reproduced tumours (Ajello and Gimbo, 1965; Lombard 
and Cabanie, 1967; Kennedy et al., 1977).
Despite of numerous efforts so far, all results have failed to identify an infectious 
agent able to induce and transmit the tumour. However it has been suggested that an 
infectious agent(s) may have originally induced CTVT, but that viral involvement is 
no longer be required for the progression and transmission of the tumour (Kennedy 
et al., 1977). It is also possible that a defective virus might play a synergistic role 
with the tumour cell during the pathogenesis of the tumour.
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Wigler and Lisitsyn (Lisitsyn et al., 1993), developed a powerful and versatile gene 
discovery method called Representational Difference Analysis (RDA) which allow 
the analysis of the differences between any two sets of DNA, such as normal versus 
tumor DNA, or uninfected cells versus cells infected with an unknown virus. 
Recently RDA has been used to search for foreign sequences belonging to an 
infectious agent in AIDS-associated Kaposi’s Sarcoma, Multiple Sclerosis and GB 
hepatitis (Chang et al., 1994; Challoner et al., 1995; Simons et al., 1995). RDA 
analysis led to the identification o f a new Human Herpesvirus (HHV8) as the 
causative agent o f the Kaposi’s sarcoma. Interestingly, before the identification of 
the HHV8, epidemiological studies suggested that like CTVT, Kaposi’s sarcoma 
might be caused by cellular transmission (Hayes et al., 1983). Therefore conversely, 
the finding that Kaposi’s sarcoma is virus-induced suggests that an unknown virus 
may also be the causative agent of CTVT.
In addition, RDA has been used in tumours to detect genetic lesions including 
rearrangement, amplifications and deletions (Lisitsyn et al., 1995). It is also been 
used to obtain polymorphic DNA markers for genetic analysis in several species 
including dogs (Lisitsyn et al., 1994; Everts et al., 2000). Although the abnormal 
karyotype of CTVT was described a long time ago, so far no detailed genetic studies 
have been undertaken. Therefore given that RDA allows the detection of genetic 
differences between normal and tumour cells, in this study I have utilised the RDA 
method to seek to identify DNA of a pathogen or to detect host genetic 
abnormalities associated with CTVT. (See Fig 2.3 in Chapter 2 for the schematic 
protocol of the representational difference analysis).
3.2 Results.
In order to avoid DNA contamination o f external pathogens or microbes, RDA was 
performed with tissue from an internal metastatic tumour as tester DNA and a pool 
o f normal DNA from different unrelated dogs as drivers. The driver amplicons were
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produced independently and mixed before hybridisation at the fourth step. To test 
the success of the first round of subtraction, individual driver amplicons were tested 
with the tester amplicon. Fig 3.1 shows the Difference Products (DP) of the first 
round, where several bands of different sizes from 500 to 1300 bp are present when 
drivers and tester were hybridised, while hybridising the tester amplicons to each 
other do not produce any visible band. After three rounds of hybridisation several 
bands were still present in all driver samples (Fig 3.2).
Given that the tumour is genetically not related with the host, to subtract the normal 
polymorphic sequences and the sequence repeats present in the different products 
after the third round (Fig 3.2), a second pool of driver amplicons from ten unrelated 
dogs was used in the fourth round. Fig 3.3 shows the difference products from the 
first to the fourth round. After four rounds of RDA a total of 9 bands was obtained. 
In order to differentiate the DNA fragments having the same size but different 
sequences, the PCR products were digested with M nll. From these bands, after 
Mnll fingerprint selection 10 DP were isolated. All 10 DP products were labelled 
and analysed by Southern blot. Of 10 selected probes, 8 showed hybridisation only 
with the tester amplicon (Fig 3.4) whereas clones 40 and 13 hybridised with all 
driver amplicons.
After sequencing the DP products, clone 37 was found to be identical to clone 39. 
In order to search for sequence homology, all DP sequences were analysed by Basic 
Local Alignment Search Tool (BLAST). None of the sequences showed any 
similarity with pathogen sequences. Although the sequences do not match canine 
gene sequences, they show more than 90% similarity to canine genome non-coding 
sequences located in different chromosomes.
To see if the DP were close to genes, sequences were run against the recently 
published dog genome using Ensembl software. Fig 3.5 shows the physical 
assignment of the DPs in different chromosomes.
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Although no pathogens or cancer-related genetic alterations have been found, the 
success of the RDA technique was demonstrated by the detection of polymorphic 
markers associated with CTVT.
M A1 A2 R1 B2 Cl C2 D1 02 E l E2 T1 T2
750 bo 
250 bo
Fig 3.1. First round of hybridization/amplification . For each 
amplicons 2 tubes were yielded; lanes from A1 to E2, represent 
different products 1 (DPI) obtained hybridizing each driver 
amplicon against tester amplicon; Lanes T1-T2, represent the DPI 
hybridizing tester samples each other. Lane 1 (M) contains the 50 bp 
DNA ladder.
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M A B C D E M PI P2 P3 P4
500bp
500bp
IBS* I
lit
Fig 3.2 Third round 
Difference Products. Lane 
A-E represent the selective 
amplified product obtained 
using drivers A-E 
respectively. Lane 1 (M) 
contains 100 bp DNA ladder
Fig 3.3 RDA Difference 
Products. Lanes PI to P4, 
contain the first, second, 
third, fourth round DP 
products respectively. Lane 
1 (M) contains 100 bp DNA 
ladder
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40
13
A  27
17
18
39
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28
Fig 3.4 Southern blotting of the RDA amplicons derived from BamHI -  
representation DNAs from normal and tumour samples, hybridized with probes 
representing the differential products. Lane T, indicates tester amplicons; 
Lanes A, B, C, D and E indicate drivers amplicons.
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Fig 3.5 Blast search results for each DP sequence against the canine genome using 
Ensembl.
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3.3 Discussion
Among different DNA molecular approaches to detect unknown pathogens, 
representational difference analysis (RDA) does not rely upon any sequence 
information regarding the eventual pathogen, and therefore represents the optimal 
choice to discover new pathogens.
RDA may be successfully applied to the analysis of tumour genetic lesions in two 
different ways. Firstly, tumour DNA is used as driver to detect genetic deletion, 
whereas secondly, tumour DNA is used as tester to isolate genetic amplifications as 
well as genetic rearrangement. In order to reduce the genome complexity and to 
increase the analytical power of the RDA, the genomes are simplified by making 
representations that consist of small DNA restriction fragments amplified by PCR.
In this study CTVT was used as tester samples and normal DNA represented by 
different unrelated DNA samples were used as drivers. The tester and driver 
samples were obtained by cutting the DNA with BamH I restriction enzyme.
Although the application for RDA requires precise matching of the polymorphisms 
between tester and driver genomes, given the impossibility here to analyse the 
original host, the genetic polymorphisms present in the CTVT was subtracted using 
several unrelated DNA samples as driver. Similarity searches of the isolated BamH 
I fragments against the GenBank database do not show any matches with known 
pathogens. In contrast, these fragments were identical to non-coding sequences 
present in the canine genome. Therefore the RDA detected fragments represente 
normal genetic differences between unrelated individuals.
Although CTVT possesses a highly rearranged karyotype, the lack of detection of 
any genetic lesion by Southern blot analysis using the selected amplified BamH I 
fragments as probes indicates that the rearranged chromosomes may be due to
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chromosome fusion rather than chromosome rearrangements. However it should be 
pointed out that the unsuccessful detection of genetic lesions or foreign pathogens 
sequences in CTVT may be due to the fact that the RDA search was limited by the 
use of only one enzyme BamH I to isolate the genetic differences. Furthermore the 
search for a pathogen was limited to DNA pathogens, thus missing RNA or single­
stranded DNA viruses.
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C H A PT E R  4 
Clonal identity of tumour
4.1 Introduction
Cancer develops through an evolutionary process, where the neoplastic cell carrying 
the most advantageous mutated genome is selected and undergoes clonal expansion 
(Nowell, 1976; Greaves, 2002). The involvement of the selection process implies 
genetic diversity between tumour cells. The genetic diversity in cancer is generated 
through a process called genetic instability. Thus during tumour progression, genetic 
instability increases genetic divergence within the tumour, whereas natural selection 
minimizes tumour genetic diversity (Nowak et al., 2005). Cytogenetic and X 
inactivation analysis suggested that tumours are monoclonal in origin (Fialkow, 
1979). Recently genotyping analyses using microsatellite markers have confirmed 
the monoclonal origin of several tumours (Fujii et al., 2000; Van Tilborg et al., 
2000). Recent results have suggested that during clonal expansion tumour cells form 
a patch (genetic island), where tumour cells are genetically homogeneous (Garcia et 
al., 2000; Braakhuis et al., 2003). During tumour progression as the lesion becomes 
larger, clonal divergence gives rise to various sub-clones that form their own 
patches. Tumours are considered dynamic ecosystems, in which the genotype and 
habitat size of the tumour cell populations change through time (Tomlinson, 1997; 
Gonzalez-Garcia et al., 2002). While early or founder mutations are expected to be 
shared by all tumour cells, later mutations might be restricted to sub-clones and 
therefore to a specific topographical areas. Given these observations, the assessment 
of tumour clonality is constrained to the time of the analysis. Thus several genetic 
markers and multiple sampling are needed to determine tumour clonality (Garcia et 
al., 2000).
In the 1960s it was postulated from cytogenetic studies that CTVT might have 
originated from a single tumour cell clone (Takayama and Makino, 1961).
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Additional genetic studies have shown the presence of a Long Interspersed Element 
(LINE-1) insertion upstream of c-myc gene, in tumours from several countries thus 
supporting the monoclonal origin o f CTVT (Katzir et al., 1987; Amariglio et al., 
1991). However these studies did not analyse paired normal and tumour tissue 
obtained from the same animal bearing natural occurring tumours. Although this 
LINE-1 insertion might represent a somatic rearrangement acquired during tumour 
progression, it might alternatively represent an inherited genetic marker present in a 
particular breed or in a family (Brooks et al., 2003).
This chapter describes the genetic analysis o f naturally occurring tumours and their 
hosts collected from 1976 to 2005 in 5 different continents. The genetic analysis 
was based on several genetic polymorphic markers, including four major 
histocompatibility (MHC) genes, microsatellites, and mitochondrial (mt) DNA. The 
Line-l/c-mvr rearrangement was also used as marker to test the presence of this 
insertion in naturally occurring tumours. These genetic markers were used to 
determine the genetic distance between tumours and their hosts and the genetic 
divergence between tumours from different geographical origins.
4.2 Results
4.2.1 Line -l /c-myc  rearrangement tumour-host DLA haplotype
Using specific primers flanking the 3' insertion site to amplify the Line-l/c-cmyc 
rearrangement, we found that all tumours but none of the matched normal samples 
possessed this LINE-1 insertion (Fig 4.1 a-b). This finding indicated that the 
tumours did not require a host germline LINE-1 insertion, and that the LINE-1 
insertion site can be used as diagnostic marker of the tumour. A further 21 paraffin 
embedded tumours were found to carry the insertion (Fig 4.1b) consistent with 
previous studies (Katzir et al., 1987; Liao et al., 2003).
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Fig 4.1 LINE-l/c-myc PCR amplification. A: PCR amplification from fresh 
tumours. For each dog (A to Q) fresh normal and tumour host samples are 
indicated with N or T. b: PCR amplification of microdissected tumour cells 
from paraffin-embedded specimens. * = Catania, t  = Messina, { = Sardinia
4.2.2 CTVT-host DLA haplotype
In order to determine the genetic diversity between tumour and host and the genetic 
divergence between tumours of the same or different geographic areas, the most 
polymorphic genes o f the canine MHC (also known as Dog Leukocyte Antigens 
DLA) one class I (DLA-88) and three class II (DRB, DQB1, DQA1) were analysed 
(Fig 4.2 a-j). Given that the greatest genetic variation is present in exons 2 and 3 of 
the DLA-88 and in exon 2 of the DLA class II genes, these regions were amplified 
using flanking intronic primers.
Given that tumour tissue contains normal stromal cells, the tumour specific DLA 
haplotype was determined to eliminate the alleles found in the paired host.
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In each dog examined the CTVT DLA haplotype was different from the host, 
whereas all tumours from 3 different countries shared the same DLA haplotype (Fig 
4.2a-j). In all tumours the DLA Class II DQA1 and DQB1 genes appear to be 
homozygous. In DRB1, there was only one non-synonymous substitution between 
the two DRB1 alleles (Fig 4.2 i-j). Two DLA-88 alleles (named alpha and beta) 
were found in all tumours (Fig 4.3 a-d). The tumour DLA-88 alpha allele differed 
from the beta allele by 8 nucleotides (5 in exon 2, and 3 in exon 3).
I therefore designed specific CTVT primers in the hypervariable region of the DLA 
genes, and observed specific bands in all tumours but not in the hosts (Fig 4.3 a). 
The use o f a common DLA-88 intron sequence as a positive control showed that all 
samples contained sufficient DNA for amplification. These data demonstrate that 
the tumours from Italy, India, and Kenya share the same haplotype in all four DLA 
genes
The DLA typing analysis was extended to microdissected tumour tissue derived 
from paraffin embedded specimens obtained from Brazil, USA, Turkey, Spain and 
Italy. Given that the DNA extracted from fixed samples is degraded and that the 
length of the PCR product obtained using the tumour specific DLA-88 primers was 
too long (450 bp), only the class II genes amplicons (150 bp) were analysed in 
microdissected tumour samples. The tumour specific DLA DRB1, DQB1 and 
DQA1 alleles were shared by all tumours analysed (Fig 4.3 b).
In order to see if the tumour specific alleles have been previously described, a 
comparison between the CTVT DLA sequences and the sequences present in 
GenBank was performed. The DLA-88 and DRB1 alleles found in the tumours have 
not been identified so far in any canine species; however, the CTVT DQB1 and 
DQA1 alleles have been described, DQB1 03501 in North American and European 
wolves and in dogs (mongrels and Shih Tzu), and DQA1 04202 only in Huskies.
The possible breed of origin is analyzed further in Chapter 7.
I l l
Although the tumour is heterozygous for the DLA-88 locus, the DLA typing 
analysis suggested that the DLA class II genes are either homozygous or 
hemizygous. In order to determine the DLA genetic status, quantitative PCR 
analysis was performed (Fig 4.4). While the DLA-88, DRA, DRB1 loci were 
diploid in all tumour samples analysed, the DQB1 locus was hemizygous in 5/11 
fresh tumours and the DQA1 was hemizygous in 12/19 of the tumour analysed, thus 
indicating the frequent loss o f the class II alleles.
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Fig 4.2c-d. DLA-88 exon 2 and exon 3 aminoacid alignment
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Fig 4.2g-h. DLA-DQB1 exon 2 nucleotide and aniinoacid alignment
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Fig 4.2i-j. DLA-DRB1 exon 2 nucleotide and aminoacid alignment
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Fig 4.3 a-b. LINE-l/c-myc and CTVT specific DLA haplotype PCR 
amplification, a: For each dog (A to M) fresh normal and tumour host 
samples are indicated with N or T. b: PCR amplification o f DNA from 
microdissected tumour cells o f paraffin-embedded specimens.
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Fig 4.4. DLA gene dosage by SYBR-Green I Real-Time PCR. a. gene dosage 
detected in fresh tumour biopsies, b, DQA1 dosage comparison in fresh and fixed 
tumour biopsies. Orange bars represent the normal samples.
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4.2.3 Microsatellites
In order to analyse the genetic divergence between tumours and hosts, and to 
examine the genetic divergence between tumours, 22 polymorphic microsatellites 
markers were used. Eighteen of these were dinucleotides and 4 were tetranucleotide 
repeats (Appendix).
A Bayesian clustering analysis was performed using the Structure program 
(Pritchard et al, 2000). Several simulations were run assuming prior K values from 2 
to 10, using an uncorrelated model with a mixed ancestry model. All runs were 
performed using 100,000 iterations following a burn-in period o f 10,000. 
Comparison o f the likelihood o f the data using K from 2 to 10 showed a highest 
value o f K = 6 for the uncorrelated model (Table 4.1). Throughout the simulation, 
the hosts were allotted to different clusters. In contrast all tumour samples were 
grouped in the same cluster with membership values (Q) from 0.977 to 0.988. This 
finding suggests that that all tumours have a common origin, whereas hosts were 
assigned at different clusters indicating a mixed origin. Fig 4.5 and Table 4.2)
A second genetic analysis was performed using the program Microsat (Goldstein et 
al.. 1995). Neighbour Joining (NJ) phylogenetic trees were constructed using two 
different measures o f genetic distances: chord distance and proportional shared 
alleles (DPS). These genetic distance methods do not assume any specific 
mutational model, thus the genetic distance matrices were based on the allele 
frequency. A bootstrap analysis was performed to support the chord distance tree, 
and a majority-rule consensus tree was constructed using the Consensus software, 
contained in the PHYLIP 3.572 program (Felsenstein, 1989).
In all phylogenetic trees the matched tumours and hosts are genetically separated, 
with all tumours clustered together. This separation was supported in all 1000 
bootstrap replicates. The chord and DPS trees show that the tumours have a recent
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common ancestor compared to the host dogs (Fig 4.6 a-c). Despite a low bootstrap 
support, phylogenetic analysis showed that while all tumours were genetically 
related, they were also grouped according to their geographical origin, with the 
Italian and African tumours more closely related than the Indian tumours, with the 
exception of the Indian tumour sample H, which was closer to Italian and African 
tumours. This geographical separation was also evident for the hosts, where African 
and Italian dogs were more closely related than Indian dogs, again with the 
exception of the dog H that was closer to the Italian and African dogs.
I ■
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Fig 4.5. Structure analysis. Summary Plot of the estimated membership coefficients 
(Q) of individuals, in each cluster, assuming a model with admixture and 
uncorrelated frequencies, with K=6 (highest K value see table 4.1), without prior 
population information. The plotted result represent the run with highest posterior 
probability out of 5 independent runs with the same parameters. Each individual (N= 
normal; T= tumour) is represented by a single column, which is partitioned in to K 
colored segments representing the individual estimated membership fraction in each 
of the inferred K. clusters.
K Estimated Ln Prob of Data
2 -1250.3
3 -1197.9
4 -1173.8
5 -1168.0
6 -1143.8
7 -1178.8
8 -1169.8
9 -1208.8
10 -1253.6
Table 4.1. Estimates of posterior 
probabilities of the populations with K 
values from 2 to 10. Red arrow indicates 
the the highest posterior probability.
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1 AT (4) 0.001 0.001 0.001 0.001 0.994 0.001
2 AN (0) 0.024 0.884 0.070 0.012 0.002 0.009
3 BT (0) 0.002 0.001 0.001 0.001 0.993 0.001
4 BN (0) 0.010 0.433 0.024 0.035 0.002 0.496
; 5 CT (4) 0.002 0.002 0.002 0.016 0.968 0.010
6 CN (0) 0.036 0.677 0.016 0.032 0.002 0.237
7 DT (9) 0.001 0.002 0.001 0.001 0.993 0.001
8 DN (0) 0.008 0.007 0.008 0.007 0.002 0.968
! 9 ET (0) 0.001 0.001 0.001 0.001 0.994 0.001
10 EN (4) 0.190 0.739 0.049 0.012 0.001 0.010
11 FT (0) 0.001 0.001 0.001 0.001 0.993 0.001
12 FN (9) 0.224 0.016 0.033 0.710 0.001 0.016
13 GT (0) 0.001 0.001 0.001 0.001 0.994 0.001
14 GN (0) 0.008 0.120 0.020 0.846 0.002 0.004
15 HT (0) 0.002 0.003 0.002 0.002 0.989 0.002
16 HN (0) 0.631 0.034 0.299 0.016 0.002 0.018
17 IT (0) 0.001 0.001 0.001 0.001 0.994 0.001
' 18 IN (4) 0.022 0.007 0.006 0.651 0.001 0.313
19 LT (0) 0.005 0.002 0.002 0.001 0.989 0.002
20 LN (4) 0.027 0.086 0.855 0.004 0.002 0.025
: 21 MT (4) 0.002 0.001 0.001 0.001 0.993 0.001
I 22 MN (9) 0.064 0.014 0.705 0.015 0.002 0.200
Table 4.2. Estimated membership of each individual (tumour and 
host) in the 6 inferred clusters. Columns 1 and 2 are the ID for 
each individual, column 3 indicated the percentage of missing 
data (allele), and columns 4-9 are the estimated membership in 
each inferred cluster or population
CN
MT
LT
CM
HT
CT
CT-
DT
BT
Fig 4.6a Unrooted neighbor joining trees showing the genetic relationship 
between tumour and host genotypes based on chord distance using a matrix 
representing the mean of 1000 bootstrap replicates.
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Fig 4.6b. Unrooted neighbor joining tree showing the genetic relationship between 
tumour and host genotypes based on proportional shared allele (Dps) distance, using 
a matrix representing the mean of 1000 bootstrap replicates. The red outlined circle 
indicates tumours cluster
Fig 4.6c. Unrooted Consensus NJ tree of tumours and hosts based on chord distance 
and 1000 bootstrap replicates. Bootstrap values are indicated at the corresponding 
node as percentage. Only bootstrap values over 50% are indicated. Branch lengths 
are proportional to bootstrap values. The red outline indicate tumour cluster.
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The genotyping analysis was then extended to microdissected tumour cells derived 
from paraffin-embedded specimens from Brazil, USA, Turkey, Spain and Italy 
(Table 2.2). Bayesian clustering analysis was performed using 13 dinucleotide 
markers. Tumour and host genotypes were run using increasing values o f K (2-10) 
to test the tumour genetic divergence between different continents. (Fig 4.7)
While the hosts were subdivided proportionally to the K values, all tumours were 
assigned to a single cluster throughout the simulations, confirming that all tumours 
have a common ancestry. The clustering solution was maximal with K= 6, like the 
previous analysis based on 21 markers. This suggests that the hypothetical 
population containing tumour and host “individuals” may contain six genetically 
distinct groups, and where all tumour “individuals” are clustered in the same group 
(Table 4.3) Subsequently a phylogenetic tree (Fig 4.8) was computed for both fresh 
and paraffin embedded microdissected tumour using chord genetic distance. All 
tumours were still grouped in a single cluster, confirming their monophyletic origin.
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Fig 4.7 Clustering assignment based on ten independent runs of Structure using values of 
K from 2 to 10. Each Plot represents the estimated membership coefficients (Q) for each 
individual, in each cluster, assuming a model with admixture and uncorrelated 
frequencies, without prior population information. Each individual (N= normal; T= 
tumour) is represented by a single column, which is partitioned in to K colored segments 
representing the individual estimated membership fraction in each of the inferred K 
cluster. Bold red K value indicates the inferred K with highest posterior probability
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4985199419
1 AT (0) 0.002 0.002 0.002 0.992 0.002 0.002
2 AN (0) 0.076 0.125 0.019 0.002 0.146 0.631
3 BT (0) 0.002 0.002 0.002 0.992 0.001 0.002
4 BN (0) 0.233 0.059 0.003 0.002 0.191 0.512
5 CT (7) 0.002 0.003 0.002 0.989 0.002 0.002
6 CN (0) 0.034 0.056 0.007 0.002 0.074 0.827
7 DT 0 5 ) 0.002 0.002 0.002 0.990 0.002 0.002
8 DN (0) 0.532 0.013 0.006 0.002 0.432 0.015
9 ET (0) 0.001 0.002 0.002 0.992 0.001 0.002
10 EN (0) 0.051 0.218 0.015 0.001 0.085 0.629
11 FT (0) 0.002 0.002 0.002 0.991 0.002 0.002
12 FN (15) 0.092 0.187 0.561 0.002 0.137 0.021
13 GT (0) 0.002 0.002 0.002 0.990 0.002 0.002
14 GN (0) 0.009 0.010 0.959 0.005 0.009 0.008
15 HT (0) 0.002 0.003 0.003 0.988 0.002 0.002
16 HN (0) 0.201 0.418 0.031 0.002 0.212 0.136
17 IT (0) 0.001 0.001 0.002 0.992 0.002 0.002
18 IN (7) 0.091 0.016 0.819 0.002 0.067 0.005
19 LT (0) 0.004 0.004 0.003 0.982 0.004 0.002
20 LN (7) 0.208 0.357 0.007 0.002 0.316 0.111
21 MT (0) 0.002 0.002 0.002 0.990 0.002 0.002
22 MN (15) 0.319 0.382 0.049 0.002 0.225 0.022
23 NT (0) 0.002 0.002 0.002 0.992 0.001 0.002
24 NN (7) 0.082 0.043 0.003 0.002 0.121 0.749
25 OT (0) 0.002 0.003 0.002 0.989 0.002 0.002
26 ON (7) 0.235 0.092 0.008 0.002 0.227 0.436
27 PT (0) 0.002 0.003 0.002 0.987 0.003 0.003
28 PN (30) 0.005 0.114 0.008 0.002 0.005 0.866
29 2T (0) 0.002 0.002 0.001 0.992 0.001 0.001
30 3T (7) 0.002 0.002 0.002 0.991 0.002 0.002
31 4T (7) 0.002 0.002 0.002 0.991 0.002 0.002
32 5T (7) 0.002 0.002 0.002 0.991 0.002 0.002
33 6T (0) 0.002 0.002 0.001 0.992 0.002 0.001
34 8T (0) 0.003 0.003 0.002 0.988 0.003 0.002
35 1 IT (7) 0.002 0.001 0.002 0.992 0.002 0.002
36 77T (7) 0.002 0.001 0.002 0.992 0.001 0.002
37 301T 0 5 ) 0.003 0.003 0.002 0.988 0.002 0.002
38 85T (0) 0.006 0.004 0.002 0.982 0.003 0.002
39 83T 0 5 ) 0.018 0.007 0.007 0.950 0.014 0.004
40 92 T (23) 0.002 0.002 0.002 0.990 0.002 0.002
41 76T (0) 0.002 0.002 0.001 0.992 0.002 0.001
Table 4.3. E stimated membership of each individual (tumour and 
host) in the 6 inferred clusters with K= 6. Columns 1 and 2 are the ID 
for each individual, column 3 indicated the percentage of missing 
data (allele), and columns 4-9 are the estimated membership in each 
inferred cluster or population.
Fig 4.8. Unrooted neighbor joining tree showing the genetic relationship between 
tumours (in oval) and hosts genotypes based on a chord distance. The red outlined 
oval indicates tumours cluster.
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4.2.4 Mitochondrial DNA
A 550 bp segment o f the mt-DNA control region containing the hypervariable 
region 1 was amplified and sequenced in matched tumour and normal tissues (Fig 
4.9). In addition a shorter 257 bp fragment within the hypervariable region were 
also sequenced in 21 microdissected tumour cells from paraffin embedded 
specimens (Fig 4.10). In all samples sequenced there were differences between the 
host haplotype and the tumour haplotype. Intra-tumour variation was detected, 
particularly in tumours G, H and L. To compare the genetic relationship between 
tumours and hosts and between different tumours, a minimum-spanning network 
was built using Network 4.0 software. All tumours were genetically distant from 
their hosts, and tumour divided in two clusters (Fig 4.11 a-b). Kenyan and Italian 
tumour haplotypes and also one Indian tumour sample (HT) were grouped in one 
cluster, while the remaining three Indian samples were grouped in the second 
cluster. This was the same Indian tumour that grouped with Kenyan and Italian 
tumours in microsatellite analysis.
To compare the tumour mt-DNA haplotypes with published haplotypes, we used a 
maximum likelihood method implemented in PAUP. As previously described, 
phylogenetic analysis of the mtDNA control region of wolves, dogs and coyotes 
identifies 5 phylogenetic groups or clades (Fig 4.12). Although the host haplotypes 
were distributed across clades A, B, and C, all tumour haplotypes were grouped in 
clade A. To date the majority o f the wolf haplotypes are present in the clades B and 
C, and the only 3 wolf haplotypes present in clade A are clearly distant from the 
tumour haplotypes. This observation suggests that the tumour may have originated 
from a dog. However further analysis given in Chapter 7 indicates that a wolf origin 
of CTVT should not be precluded. Given the possibility that an ancestral tumour 
haplotype may be the origin o f the 2 tumour mt-DNA haplotypes, I used the 
haplotypes present in all tumours, to reconstruct a hypothetical ancestral mt-DNA 
haplotype. The hypothetical ancestral tumour mt-DNA haplotype was included in 
the minimum spanning network representation (Fig 4.1 lb, 4.13a).
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To resolve in more detail the genetic relationship between mt-DNA haplotypes 
present in clade A, a minimum spanning network was used (Fig 4.13a). The Kenyan 
haplotype M IT is shared with the A18 and A20 dog haplotypes. The Italian tumour 
haplotypes were equidistant from haplotypes A18/A20 and the dog haplotype A 13. 
The Indian tumour haplotype HT and the Kenyan LT appear to be close to the MT 
haplotype or to the Italian tumour haplotypes identified with ATI. The Indian 
tumour haplotypes IT, GT, FT and their variants seem to derive from the haplotype 
GT4, which is distinct from the dog haplotype A22 by one mutation. The 
reconstructed theoretical ancestral tumour haplotype is linked with the haplotype 
A 13, a haplotype that has so far been found only in the Siberian dog breed, West 
Laika.
Although some sequence variation in the mt-DNA control region can arise from 
somatic mutation in human tumours [Vega, 2004 #1897], the greater genetic 
variation between normal and CTVT mt-DNA haplotypes, and the striking genetic 
similarity between tumours, confirms that CTVT in different dogs has a common 
ancestry. A shorter 257 bp fragment in 21 microdissected tumour cells from paraffin 
embedded specimens was analysed in addition to the 11 fresh specimens Fig. 4.13b 
shows that the tumour mt-DNA haplotypes remained grouped into two clusters. 
Interestingly, all tumours in mt-DNA cluster 2, except for tumour 9, were those that 
were hemizygous for DLA DQA1, indicating that the ancestral clone split into two 
distinguishable sub-clades during its evolution as a transmissible tumour.
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Fig 4.11. Minimum-spanning networks representing the genetic relationship between 
mt-DNA haplotypes found in tumors and their hosts. Fig a-b represent networks 
without and with inferred tumour ancestral haplotype respectively. Each branch 
represents a 1 bp change or indel, dots represent hypothetical intermediates. Tumor 
haplotypes are indicated in squares, circles represent the host haplotypes, red circle 
represents the tumor ancestral haplotype. The red lines represent the link in the 
presence of the tumor ancestral haplotype. Haplotypes found in India, Kenya, and Italy 
are indicated with green, blue, pale blue respectively. Tumor haplotype ATI contains 
the haplotypes found in tumors B, C, D, and E. Tumor haplotype variants present in 
the same tumor are indicated with numbers
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Fig 4.12. ML Phylogenetic tree of mt-DNA control region. Tumour and host 
sequences are indicated with T and N respectively with different colours indicating 
their origin: blue (Italy), blue pale (India), green (Kenya). A, B, C, D F, represent the 
5 inferred clades
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Fig 4.13. a. Phylogenetic relationship of the mt-DNA haplotypes found in tumours 
and their hosts with the published mt haplotypes. Each branch represents a 1 bp 
change ignoring indel, black dots represent hypothetical intermediates, and red dots 
represent median vectors. The squares and circles represent the tumour and host 
haplotype, yellow circles indicate the published haplotypes. The red circle represents 
the inferred hypothetical tumour ancestral sequence. Squares and circles are 
proportional to the number of tumours sharing the same haplotype. b, Phylogenetic 
network based on a 236 bp sequences of mtDNA haplotypes found in tumours from 
fresh and microdissected tumour samples. The red and blue outlined squares indicate 
tu m o u rs  sa m n le s  w ith  h o m n 7 v a o u s  an d  h em i7 v an iK  D O A  1 n a tte m
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4.3 Discussion
The clonal evolution model of cancer implies that tumour cells trace their origin to 
an ancestral tumour cell. Therefore the genetic relationship between tumour cells 
can be represented as a phylogenetic tree, where the external branches represent the 
existing tumour cells, whereas the internal branches and nodes represent inferred 
intermediate ancestral tumour cells, and the root of the tree represents the common 
ancestral tumour cell (Tsao et al., 2000). In contrast to evolutionary inference in 
normal multicellular organisms, where genetic differences are due to germ line 
mutations, in cancer the genetic diversity between tumour cells is due to somatic 
mutations. The genetic differences are directly proportional to mutation rates and 
time (Tsao et al., 2000). Thus assuming an identical mutation rate between 
individuals, the genetic diversity increases throughout time. Generally tumours 
evolve within the lifetime of the host, and the mutations rate is too low to allow the 
accumulation of many mutations and consequently phylogenetic inference is 
extremely difficult (Shibata, 2001).
The transmissible venereal tumour CTVT has long been thought to be caused by 
tumour cell transplantation rather than caused by an oncogenic virus (Gross, 1983; 
Cohen, 1985). The notion that the tumour was transmissible came from three lines 
o f observations. First, CTVT is experimentally transmitted only by transplanting 
living tumour cells and not by cell filtrates (Cohen, 1974). Second, tumours 
collected from different geographical locations have similar or identical karyotype 
(Takayama and Makino, 1961). Third, a long interspersed nuclear element (LINE-1) 
insertion near to the c-myc gene was found in all tumours analyzed (Katzir et al., 
1987). However a detailed molecular genetic analysis o f naturally transmitted 
tumours has not been previously performed to resolve the genetic relationship 
between tumour and its host and neither has the genetic diversity been examined 
between tumours collected worldwide. In order to analyse the genetic relationship 
between tumours and host and to determine the genetic divergence between
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tumours, matched tumour tissues and host blood samples from naturally affected 
dogs were analysed for the first time, collected from 16 unrelated dogs in Italy, 
India, Kenya. In addition, 21 tumour paraffin embedded specimens collected from 
Brazil, USA, Turkey, Spain and Italy were analysed. Consistent with previous 
reports obtained from experimentally transplanted tumours, all naturally occurring 
tumours but none o f the matched normal tissues posses the LINE-l/c-w^c 
rearrangement. The 21 naturally occurring tumours obtained from Brazil, USA, 
Turkey, Italy and Spain also shared this insertion.
Although this LINE-1 insertion might represent a somatic rearrangement, and the 
presence o f this marker in all tumours would therefore indicate a monoclonal origin 
(Katzir et al., 1987), the possibility that this LINE-1 insertion might represent an 
inherited genetic marker present in a particular breed or family is still open. 
Recently a LINE-1 insertion in intron 5 of the canine factor IX gene, in German 
Wirehaired Pointers affected by haemophilia B, was found to be inherited for at 
least five generation (Brooks et al., 2003). In humans a non-deleterious LINE-1 
insertion inherited in a family for at least three generation has been described 
(Conley et al., 2005). Given these considerations, to provide compelling evidence 
for the monoclonal origin of CTVT, I considered a genetic analysis based on 
multiple genetic markers to be essential. In this study I have tested the CTVT clonal 
origin by analysing different polymorphic DNA markers including four DLA genes, 
21 microsatellite loci and mt-DNA control regions. I found that tumours are 
genetically distinct from their hosts and that all worldwide CTVTs arose from a 
common ancestral neoplastic clone.
According to the clonal evolution theory of cancer, tumour cells evolve through 
selection and clonal expansion (Nowell, 1976; Greaves, 2002). Experimental and 
theoretical studies have suggested that in order to evolve, tumour cells must acquire 
an increased mutation rate (Loeb and Loeb, 2000). Several studies have shown that 
tumours with defects in the mismatch repair system have an elevated mutation rate.
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As a consequence o f genetic instability, tumour cells are expected to diverge during 
tumour progression. Thus to analyse the clonal evolution of tumours it is necessary 
to use several genetic markers with different mutation rates (Garcia et al., 2000). In 
phylogenetic analysis genetic markers with low mutation rates are used to infer 
ancestral divergence and markers with high mutation rates are used to infer recent 
divergence (Ridley, 2004a).
In this study I found that CTVT samples from 5 continents share the same 
sequences in four polymorphic DLA genes, but that using more highly polymorphic 
markers such as mt-DNA and microsatellites, tumours showed a partial clonal 
divergence. During its evolution the original clone has diverged in two subclades 
according to mt-DNA clusters and loss o f alleles in DLA DQA1.
Although tumour mt-DNA divergence might suggest two separate origins, the DLA 
and c-myc results support a monoclonal origin. This divergence may be also 
explained, if one assumes that in the original tumour more mt-DNA haplotypes 
were present (heteroplasmy). Heteroplasmy of mt-DNA has been described in 
physiological conditions related to aging and in cancer (Michikawa et al., 1999; 
Bianchi et al., 2001). It is also a well known phenomenon in neurological diseases 
caused by mt-DNA deletion/mutations (Fassati et al., 1994). It is also conceivable 
that this tumour on rare occasions might acquire host mt-DNA; the tumour has 
phagocytic phenotype and could take up cytoplasmic fragments from neighbouring 
host cells. However, it would be an even rarer event for mt-DNA introduced in this 
way to become the dominant population or achieve homoplasmy. The lack of 
intermediate tumour haplotypes between the 2 tumour clusters may be due to 
mitochondrial genetic drift during cell division and also to a bottleneck effect during 
transplantation between dogs, because only a small number of tumour cells will be 
implanted in the next host. Given the impossibility to obtain the normal counterpart 
o f the paraffin embedded tumour samples, the mt-DNA heteroplasmy in these 
samples might be also due to the presence of normal mt-DNA haplotypes.
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The fact that tumours across five continents maintain the sequence of 4 polymorphic 
MHC genes unmutated seems to suggest that the MHC genes are under selection. 
One the most peculiar features of CTVT is its natural transplantability. This ability 
has been suggested to be due to the fact that the tumour cells do not express the 
DLA class I and II antigens during the progressive stage of tumour growth (Yang et 
al., 1987). According to somatic evolution, tumour cells evolve towards the 
selfishness that ultimately results in a more malignant phenotype with a severe 
effect on the host's fitness (Greaves, 2002; Michor et al., 2004). During progression 
tumour cells frequently evade immunosurveillance by down-regulating the MHC 
antigen expression (Dunn et al., 2004a). In contrast to parasite evolution, the host 
conditions are extremely important, and virulence has to be modulated to limit 
damage to the host particularly if host fitness is necessary to maximize the 
transmission to a new host (Frank, 1996). Although CTVT does not express MHC 
class I and II antigens during the progression stage, it does express MHC antigens 
during the regression stage (Yang et al., 1987), thus acting as a relatively benign 
parasite in the immune competent host.
Recently it has been shown that mt-DNA mutation rates in tumours reflect the 
neutral evolution of mt-DNA in the normal human population (Vega et al., 2004). 
In this study I found that the mutations present in the mitochondrial control region 
of the tumours are common to mutational hotspots described in normal dog 
populations. These results indicate that the mt-DNA divergence between the 2 
subclades might be due to genetic drift rather than selection.
Generally tumours evolve within the lifetime of the host, and the mutation rate is 
too low to allow the accumulation of many mutations and consequently 
phylogenetic inference is difficult. Due to their high mutation rates, microsatellites 
markers are extremely useful in phylogenetic studies. Several studies have shown
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that tumours with defects in the mismatch repair system have an elevated mutation 
rate, especially in microsatellites (Atkin, 2001).
It generally thought that tumour genetic instability increases throughout progression, 
so that tumour cells evolve toward a genetically instable phenotype (Loeb and Loeb, 
2000; Nowak et al., 2005). Genotyping results based on 21 microsatellite loci 
indicate that CTVT is genetically stable and suggest that the moderate genetic 
diversity present between tumours from different geographical locations is the result 
o f normal mutation rates. Although CTVT is highly aneuploid, the karyotype is 
remarkably constant among tumours from USA, Africa and Japan (Cohen, 1985). 
Therefore its genomic rearrangement appears to have stabilised early in its 
emergence as a transmissible parasite. My results indicate that CTVT during its 
evolution has stabilised its genome in order to maintain the parasite features. It is 
generally accepted that cancer evolves to increase its independence from the host 
and to became more selfish (Nunney, 1999). However CTVT cells with their 
stabilised genome may reflect kinship selection and reduced virulence, thus aiding 
host survival and onward tumour transmission. The decreased pathogenicity may be 
also favoured by the fact that during transmission only a small proportion of tumour 
cells implant in the new host, thus decreasing the genetic variability within the 
tumours and therefore the competition between tumour cells having different fitness 
advantages. The results obtained in this study seem to contrast to the common view 
that cancer evolution progressively leads to an increasingly genetically instable and 
selfish clone.
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Samples Origin Name 1 1 2 2 8 8 9 9 28 28 31 31 38 38 42 42 53 53 66 66 68 68 92 92
TUMOUR ITALY AT 158 158 171 171 169 , 169 164 174 134 134 132 132 152 158 123 123 178 178 179 179 140 140 145 145
HOST ITALY AN 158 158 177 185 165 174 168 170 130 130 134 134 168 165 143 140 159 161 179 179 141 166 158 160
TUMOUR ITALY BT 158 158 171 171 163 163 164 174 134 134 132 134 152 158 123 123 178 178 179 179 140 140 145 145
HOST ITALY BN 158 158 183 185 180 172 168 172 128 130 129 136 160 163 146 148 159 159 181 179 137 159 158 158
TUMOUR ITALY CT 158 158 171 171 163 169 164 174 134 134 132 134 152 158 123 123 142 178 0 0 140 140 145 145
HOST ITALY CN 158 158 183 160 174 172 166 172 130 136 134 138 165 165 140 142 171 189 179 179 160 160 158 160
TUMOUR ITALY DT 158 158 171 171 163 163 0 0 134 134 134 134 0 0 123 123 178 178 179 179 140 140 145 145
HOST ITALY DN 158 158 187 185 182 182 162 164 128 138 129 129 168 160 146 146 189 171 181 184 159 178 158 166
TUMOUR ITALY ET 158 158 171 171 163 163 164 174 134 134 132 134 152 158 123 123 178 178 179 179 140 140 145 145
HOST ITALY EN 158 158 176 183 171 176 167 167 130 136 141 138 163 168 145 145 159 159 179 186 141 182 160 160
TUMOUR INDIA FT 158 158 171 171 169 169 164 174 134 134 130 134 152 158 123 123 178 178 179 179 140 140 145 145
HOST INDIA FN 158 158 177 189 165 168 0 0 130 130 143 145 0 0 121 126 191 193 179 179 196 192 138 158
TUMOUR INDIA GT 158 158 171 171 169 169 164 174 134 134 130 134 152 158 123 123 178 178 179 179 140 140 145 145
HOST INDIA GN 158 158 183 183 168 182 183 183 136 130 162 162 162 167 123 143 186 198 179 179 192 192 158 160
TUMOUR INDIA HT 158 158 171 171 163 169 164 174 134 134 132 134 152 154 123 123 178 178 179 179 140 140 145 154
HOST INDIA HN 158 158 165 183 172 165 168 168 136 130 147 130 171 156 121 129 185 185 179 181 182 139 148 160
TUMOUR INDIA IT 158 158 171 171 163 169 164 174 134 134 132 134 152 158 123 123 178 178 179 179 140 140 145 145
HOST INDIA IN 158 158 183 191 162 162 170 183 136 136 141 129 169 162 133 141 186 189 179 179 0 0 166 158
TUMOUR AFRICA LT 158 158 171 171 169 169 164 174 134 134 132 134 152 159 123 123 178 178 179 182 136 136 145 145
HOST AFRICA LN 158 158 177 177 170 172 0 0 128 130 136 138 175 171 141 134 193 189 179 179 141 141 160 160
TUMOUR AFRICA MT 158 158 171 171 163 163 164 174 134 134 132 134 152 158 123 123 178 178 174 174 140 140 145 145
HOST AFRICA MN 158 158 176 183 182 172 164 164 130 130 0 0 150 169 134 141 0 0 183 181 174 190 160 164
TUMOUR ITALY NT 158 158 171 171 163 169 164 174 134 134 132 134 152 158 123 123 178 178 179 179 140 140 145 145
HOST ITALY NN 158 158 183 187 0 0 168 179 132 138 138 138 177 165 140 140 159 159 173 181 182 160 165 158
TUMOUR ITALY OT 158 158 171 171 163 169 164 174 134 135 132 134 152 158 123 123 178 178 182 182 140 140 145 145
HOST ITALY ON 158 158 0 0 164 172 185 168 130 130 136 129 168 165 121 145 171 189 179 179 159 162 158 158
TUMOUR ITALY PT 158 158 171 171 169 169 164 164 130 134 132 134 152 154 123 123 178 178 182 182 140 140 145 159
HOST ITALY PN 158 158 160 183 180 180 0 0 0 0 145 138 0 0 145 145 159 159 179 179 137 137 0 0
TUMOUR TURKEY 2 158 158 171 171 163 163 164 174 134 134 127 127 152 158 123 123 178 178 178 178 140 140 145 145
TUMOUR TURKEY 3 158 158 171 171 163 169 164 174 130 134 127 134 152 158 123 123 178 178 178 178 0 0 145 145
TUMOUR TURKEY 4 158 158 171 171 163 169 164 174 130 134 132 132 152 158 123 123 178 178 0 0 140 140 133 145
TUMOUR TURKEY 5 158 158 171 171 163 163 0 0 130 134 132 132 152 158 123 123 178 178 178 178 140 140 145 145
TUMOUR TURKEY 6 158 158 171 171 169 169 164 174 134 134 132 132 152 152 123 123 178 178 181 181 138 140 133 145
TUMOUR TURKEY 8 158 158 173 173 163 169 164 174 134 134 132 132 152 152 123 123 178 178 178 178 140 140 133 145
TUMOUR TURKEY 11 158 158 171 171 163 169 164 174 134 134 132 134 152 152 123 123 178 178 0 0 140 140 145 145
TUMOUR SPAIN 77 158 158 171 171 169 169 164 174 134 134 132 134 152 152 123 123 178 178 0 0 140 140 145 145
TUMOUR USA 301 158 158 171 171 169 169 164 174 130 134 0 0 0 0 123 123 178 178 181 181 138 138 145 145
TUMOUR SPAIN 85 158 158 171 171 159 169 164 174 130 134 132 134 152 158 123 123 178 178 181 181 140 140 145 145
TUMOUR ITALY 83 158 158 171 171 0 0 164 174 130 130 129 134 152 158 123 123 160 160 178 178 0 0 145 145
TUMOUR ITALY 92 158 158 171 171 163 163 0 0 0 0 0 0 152 158 123 123 178 178 178 181 138 140 145 145
TUMOUR ITALY 76 158 158 171 171 163 163 164 174 134 134 132 134 152 158 123 123 160 178 178 181 138 140 145 145
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Samples
TUMOUR
Origin
ITALY
Name
AT
AN
BT
BN
93
120
122
120
93
120
122
120
H2
94
98
94
H2
94
107
94
H6
121
131
124
H6
121
125
H5
112
116
H5
112
116
112
125
96
102
96
125
96
91
98
H9
138
143
H9
140
143
2004
316
243
2004
316
316
2010
221
233
2 0 1 0
221
2054
0
2054
0
2001
0
2001
0
HOST ITALY 233 144 153 131 131
TUMOUR ITALY 124 112 138 140 317 3171 221 233 168 168 0 0
HOST ITALY 122 124 96 106 131 125 112 116 102 98 151 151 234 238 225 299 169 153 139 131
TUMOUR ITALY CT 120 120 94 94 121 121 114 114 96 98 138 140 316 316 221 233 169 165 0 0
HOST ITALY CN 122 124 98 107 121 119 116 116 104 102 142 155 234 290 228 236 172 156 148 131
TUMOUR ITALY DT 120 120 94 94 121 121 112 112 96 98 138 140 316 316 221 233 168 168 0 0
HOST ITALY DN 122 133 96 106 121 119 112 114 102 108 142 142 242 246 236 241 169 153 148 144
TUMOUR ITALY ET 120 120 94 94 121 121 112 112 96 98 138 140 316 316 221 221 168 165 0 0
HOST ITALY EN 122 22 98 96 123 113 110 116 88 93 151 155 238 238 228 233 0 0 148 131
TUMOUR INDIA FT 120 120 94 94 121 121 112 112 94 96 138 140 234 234 221 233 157 157 0 0
HOST INDIA FN 137 135 100 102 119 123 114 114 91 98 145 157 230 242 228 236 169 172 148 131
TUMOUR INDIA GT 120 120 94 94 121 121 112 112 94 96 138 140 234 234 221 233 157 157 0 0
HOST
TUMOUR
INDIA
INDIA
GN
HT
135
120
135
120
98
94
98
94
13*1
121
131
121
116
112
116
112
98
94
98
94
151
138
157
140
234
308
234
308
225
221
237
233
160
152
169
156
144
0
144
0
HOST INDIA HN 122 130 96 109 128 119 116 112 86 92 151 157 243 317 236 236 148 173 144 139
TUMOUR INDIA IT 120 120 94 94 121 121 112 112 94 96 138 140 254 254 221 233 157 157 0 0
HOST INDIA IN 135 133 96 102 130 130 114 114 102 104 142 145 234 238 225 236 169 172 153 135
TUMOUR
HOST
AFRICA
AFRICA
LT
LN
120
122
120
122
94
103
94
107
124
127
1 2 4 _
121
112
118
112
113
96
88
96
94
138
151
138
151
300
243
300
243
221
237
233
237
148
153
157
169
0
148
0
131
TUMOUR AFRICA MT 120 120 94 94 124 124 112 112 94 96 0 0 308 308 221 233 161 161 0 0
HOST AFRICA MN 122 123 96 106 128 119 118 116 98 104 140 142 243 243 237 237 144 176 153 140
TUMOUR ITALY NT 120 120 93 93 124 124
HOST ITALY NN 122 122 98 102 118 125
TUMOUR ITALY OT 120 120 94 94 121 121
HOST ITALY ON 130 122 96 98 116 119
TUMOUR ITALY PT 120 120 93 93 124 124
HOST ITALY PN 122 128 102 107 0 0
TUMOUR TURKEY 2 120 120 94 94 121 121
TUMOUR TURKEY 3 120 120 89 89 121 121
TUMOUR TURKEY 4 120 120 94 93 124 124
TUMOUR
TUMOUR
TURKEY
TURKEY
_____5
6
120
120
120
120
94
94
94
94
121
121
121
121
. . - -  - ---- ------- -------
TUMOUR TURKEY 8 120 120 94 94 121 121
TUMOUR TURKEY 11 120 120 94 94 121 121
TUMOUR SPAIN 77 120 120 89 89 121 121
TUMOUR USA 301 120
120
120
120
94
89
94
89
121
121
121 ------ --------------- ----------------- - ---------------- --------------------
TUMOUR SPAIN 85 121
TUMOUR ITALY 83 120 120 94 94 121 121
TUMOUR ITALY 92 120 120 94 94 121 121
TUMOUR ITALY 76 120 120 94 94 121 121
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Chapter 5
CTVT DLA Transcriptional analysis
5.1 Introduction
According to the immunosurveillance hypothesis o f cancer the immune system 
protects the host against the development o f tumours (Dunn et al., 2004a). The 
Major Histocompatibility Complex antigens play a key role in the recognition of 
tumour cells by the immune cells (Garrido and Algarra, 2001). Therefore defects in 
processing and presentation o f MHC antigens represent an advantage for tumour 
progression. Loss o f MHC antigen expression can occur at the genetic, 
transcriptional and post-transcriptional level (Algarra et al., 1999; Cabrera et al.,
2003). Several studies have shown that many human and animal tumours do not 
express or down regulate the expression o f MHC class I and II antigens (Algarra et 
al., 1999; Cabrera et al., 2003). Tumour cells obtain this result by deleting or 
mutating the MHC genes or several genes involved in the antigen presenting 
process, or by down regulating these genes by genetic and epigenetic mechanisms 
(Algarra et al., 1999; Nie et al., 2001; Cabrera et al., 2003). One of the mechanisms 
that reduces MHC class I expression involves P2 microglobulin expression (Garrido 
and Algarra, 2001). The loss or reduced expression of P2 microglobulin can be the 
result o f homozygous or heterozygous mutations.
Early studies have shown that CTVT can be transplanted into immunocompetent 
animals of other canine species such as coyotes, jackals and foxes (Ajello, 1980; 
Cohen et al., 1984; Cohen, 1985). It has been reported that CTVT does not express 
p2 microglobulin on the surface of the tumour cells (Cohen et al., 1984). From this 
study it was suggested that the lack of P2 microglobulin could account for CTVT 
allotransplantability. Other studies have shown that naturally and experimentally
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transplanted CTVT do not express DLA class I and II antigens during the 
progressive stage and that these antigens are expressed during the regression stage 
(Yang et al., 1987; Perez et al., 1998). A recent study shows that during progressive 
growth secretion o f tumour growth factor beta (TGF- p i) by CTVT is a potent 
inhibitor o f the local host immune response (Hsiao et al., 2004). Numerous studies 
suggest that in cancer heritable gene function alteration may be mediated by 
epigenetic as well as by genetic mechanisms. DNA hypermethylation and/or histone 
deacetylation contribute to the absent or down-regulated expression of different 
components o f the tumour recognition complex (Magner et al., 2000; Magner and 
Tomasi, 2000).
This chapter describes the transcriptional analysis o f tumour DLA class I (DLA-88) 
and class II (DLA- DRB1, DQB1) genes by reverse transcriptase PCR (RT-PCR) of 
a tumour biopsy collected from a dog bearing a progressively growing naturally 
occurring tumour.
5.2 Results
In order to investigate if the reported lack o f the MHC class I and II expression 
during the progression stage is due to transciptional or post transcription alterations, 
the mRNA expression level of Class I antigen (DLA-88) and Class II antigens 
(DRB1) was analysed. From DLA genotyping data tumour and host specific DLA- 
88 and DRB1 primers were designed in order to analyse specifically the differential 
expression of these mRNAs, between tumour and host in the same biopsy sample. 
Given that the MHC expression may be altered in an in vitro system (tissue culture 
of tumour cells), the RNA was extracted from a tumour biopsy (Dog C see Table 
2.1 and Fig 2.1 c-d).
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According to the tumour size and the clinical history of Dog C, the tumour was 
classified as a progressing tumour. Histopathological examination by haematoxylin 
and eosin stained tissue sections confirmed the clinical diagnosis and showed that 
the tumour cells represent over 90 % of the tumour tissue (Fig 5a).
Considering that the majority of tumour tissue is constituted of tumour cells, RT- 
PCR analysis shows (Fig 5b) that both the tumour DLA-88 alleles (a P) are down 
regulated with respect to the host stromal cells DLA-88 expression (allele 29 and 
42). In contrast to host DLA-88 alleles, tumour alleles exibits a different level of 
expression, with a more pronounced downregulation in allele p. Fig 5b also shows 
that although host DLA DRB1 alleles were expressed, the DRB1 mRNA in tumour 
cells was undetectable. These results suggest that the transient expression of the 
tumour MHC Class I and II antigens during the progressive and regressive stage is 
due mainly to transcriptional silencing of the DLA genes rather than genes involved 
in transport and processing.
5a
5b
M T T  N N  M T N
P a  29 42
DLA-88 DRB1
Fig 5a: Penile CTVT of dog C: Haematoxylin and eosin stained 4 pm 
section. Bar = 50 pm.
Fig 5b: Expression of DLA class I (DLA-88) and class II (DRB1) in 
the tumour o f dog C by RT-PCR using tumour cell specific primers (T) 
and primers for the alleles of the host stromal cells (N).
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5.3 Discussion
The immune system plays an important role in controlling the emergence or 
elimination of cancer cells . A wide range o f immune mechanisms are involved in 
protecting the host against tumour cells. However, tumour cells acquire different 
mechanisms to escape immunological surveillance (Dunn et al., 2004a). Therefore, 
the immune system not only protects the host against development of primary 
cancers but also during tumour progression sculpts tumour immunogenicity by 
selecting tumours having an escape phenotype (Khong and Restifo, 2002; Dunn et 
al., 2004b). One o f the most frequently described mechanisms of immune evasion is 
the partial or total lack of MHC antigen expression. The MHC deficiencies may be 
irreversible or reversible. The irreversible include mutations affecting the expression 
or function o f MHC antigens and or proteins involved in MHC assembly and 
transporting, such as beta 2 microglobulin and TAP proteins (Garrido and Algarra, 
2001). In contrast to the irreversible alteration the reversible MHC class I and class 
II deficiencies are caused by transcriptional silencing by involving all levels of the 
MHC class I-restricted antigen presentation machinery, and their expression can be 
restored by cytokines or by DNA demethylation/histone hyperacetylation (Magner 
and Tomasi, 2000; Moreau et al., 2003; Morimoto et al., 2004).
Early and more recent studies suggest that the transplantability of CTVT in immune 
competent dogs is due to the lack o f MHC antigen expression. 
Immunohistochemical analyses have shown that natural and experimentally induced 
CTVT exhibits an initial stage of rapid growth, characterised by lack of MHC class 
I and II expression, followed by a regressive stage, where the MHC antigens are 
detected on CTVT cells (Yang et al., 1987; Perez et al., 1998). In a preliminary 
study Cohen et al (1984) described the lack of beta 2 microglobulin on CTVT cells, 
so suggesting that the MHC class I deficiency observed in CTVT is due to beta 2 
microglobulin alterations (Cohen et al., 1984). However my transcriptional analysis 
indicates that reversible expression of the DLA class I and II antigens is due mainly 
to their transcriptional silencing.
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Epigenetic modifications such as DNA methylation and histone deacetylation play a 
major role in cancer through transcriptional silencing not only in tumour suppressor 
genes but also in genes involved in immune evasion (Esteller and Herman, 2002). 
Recent studies have highlighted the importance of epigenetic modifications by the 
observation o f the hyper methylation of the MHC promoter sequences in MHC 
deficient tumours in absence of mutations in MHC genes and beta 2 microglobulin. 
Methylation can also inhibit indirectly MHC transcription by silencing the MHC 
transactivator such as coactivator class II transactivator (CIITA) and or genes 
involved in assembly and transport (Nie et al., 2001; Morimoto et al., 2004). 
Although the reduced or absent levels o f MHC class I antigens helps tumour cells to 
evade the classical T cell dependent immune responses, it simultaneously activates 
the natural killer cells by the 'missing self signals (Miller, 2001).
Recent findings have suggested that tumour cells can exploit the mechanism 
adopted by the semi-allogeneic fetus in controlling the maternal immune response 
(Miller, 2001). Therefore the fetal trophoblast-matemal relationship has been 
suggested to be analogous to a tumor-host interaction (Rouas-Freiss et al., 2005). 
Like tumour cells the trophoblast does not induce transplantation immunity and 
resists natural killer (NK.) cells. It has been suggested that trophoblast does not 
induce transplantation immunity because it does not express classical polymorphic 
MHC genes, whereas it does express a non-polymorphic Class I molecules HLA-G 
(Hunt et al., 2005). This plays an important role in protecting the fetus from 
maternal immune attack by the interaction of inhibitor receptors expressed in 
maternal natural killer and T cells.
Canine MHC Class I include only one classical Class I gene (DLA-88), and several 
non classical genes such as DLA-79, DLA-64, DLA-12 (Bryan et al., 1997; Burnett 
et al., 1997; Graumann et al., 1998). However, to date no detailed studies have been 
undertaken to elucidate their function in pregnancy and in cancer. Given their
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reduced genetic polymorphism, the differential transcription analysis between 
tumour and host cannot be assessed using specific PCR primers. Thus a systematic 
analysis o f several tumours during different stages of growth and regression using 
laser capture microdissected tumour cells would be required to test the involvement 
of non classical MHC genes in evading the NK cell response.
One mechanism of cancer immune evasion is the local suppression of anti-tumour 
immunity. Several studies have suggested that tumour cells can directly secrete 
several cytokines or indirectly induce the stromal cells to secrete inhibiting factors 
in order to evade the immune responses or to induce an immuno-tolerance status. 
Recently Hsiao et al (2004) in experimentally transplanted CTVT have shown that 
CTVT cells secrete tumour growth factor beta (TGF-p 1), thus inhibiting the host 
immune response. Several studies have observed that in immunocompetent dogs 
CTVT is localised exclusively at the superficial mucosae and that intravenous 
inoculation o f tumour cells trigger an efficient immune response able to destroy 
tumour cells (Cohen, 1985). This suggests that CTVT cells are able to evade the 
local mucosal immune response. However the majority o f the immunogical studies 
regarding CTVT have analysed the systemic immune response in vivo and by in 
vitro assays.
In contrast to alpha and beta T cells, gamma/delta T cells are more abundant in 
epithelial and mucosal tissues (Hayday, 2000). Several findings have suggested that 
gamma/delta T cells are involved in modulation of the immune responses in 
tumours and in several infectious and parasitic diseases and tumour (Kapp et al.,
2004). Recently it has been reported that epithelial gamma/delta cells are capable of 
recognising the antigen expressed by damaged or stressed keratinocytes and 
producing keratinocyte growth factors (KGFs) and chemokines, therefore arguing 
for their active role in wound repair (Jameson et al., 2002). These observations 
suggest that the local immune response should be thoroughly analysed in order to 
elucidate the immune evasion mechanisms adopted by CTVT.
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Chapter 6
SRY Amplification
6.1 Introduction
The ability to discriminate whether a biological sample originated from a male or a 
female is essential in forensic science. Over the years using polymerase chain 
reaction methods, different DNA markers on the sex chromosomes have been 
shown to be useful in gender identifications (Butler, 2001). This ability has been 
also used to discriminate the sexual origin in different sex mismatched conditions 
like organ and haematopoietic transplantation and fetal-maternal chimerism 
(Aractingi et al., 1998; Wang et al., 2002).
One of the most frequently used DNA markers within the male Y chromosome is 
the sex-determining region (SRY). The canine Y chromosome is the smallest 
chromosome and the SRY region is located in the non-recombinant region (Olivier 
et al., 1999). In dogs several PCR based assays have been used to study naturally 
occurring inherited disorders of testicular differentiation (Meyers-Wallen et al.,
1995), and to monitor the chimerism in bone marrow transplantation (Fiegler et al., 
2002). In monkeys, it has been shown that PCR assays based on SRY amplification 
can detect less than four cells in the presence of 103 background cells (Sieverkropp 
et al., 2005).
The transmission of a cancer cell is a rare complication of human tissue and organ 
transplantation (Penn, 1997). Recently the SRY marker has been successfully used 
to demonstrate the donor cell origin o f Kaposi’s sarcoma cell in a female post­
transplant recipient (Barozzi et al., 2003). Given that CTVT is a sexually 
transmitted tumour, and given the success o f the sex DNA typing approach in
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resolving the origin o f donor cells in a sex mismatched recipient, this approach 
could be applied to CTVT although it has not previously been used to test the 
cellular transmission of CTVT. In this study, 9 CTVT samples collected from 
female hosts were analysed for the presence o f the Y chromosome DNA by PCR 
using Y chromosome specific primers.
6.2 Results
The presence of the Y chromosome DNA in the tumour cells was tested by PCR 
amplification of a 104 bp segment o f the Sex Region of the Y chromosome (SRY). 
Among the 9 tumour samples derived from female dogs the matched normal tissues 
were also examined from 3 animals (blood o f Dogs, E, H and I). In primary 
amplification no clear SRY bands were observed in the tumour samples (pictures 
not shown). In contrast, the SRY sequence was efficiently amplified from DNA 
taken from the blood of a healthy male dog. Therefore a second, nested 
amplification was tested to visualize the specific 104 bp band. O f the 9 tumour 
samples, 8 were positive, and one was negative (sample 30) (Fig 7.1 a and b). 
Where matched tumour and host DNA was analysed each of the 3 fresh tumour 
samples were positive, but the matched host blood samples were negative (Fig 
7.1a). To exclude the possibility of PCR contamination, a second region of the Y 
chromosome called the 650 region was also tested. Due to the length of this region 
(650 bp), only the DNA extracted from fresh samples could be analysed (Dogs E, H 
and I). A specific 650 bp band was amplified only in the tumour (a faint band is 
present in sample HT) and not in the matched host samples (Fig 7.2).
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Fig 7.1a and 7.1b: Detection of Y chromosomal 
DNA by SRY PCR in tumour tissues from 
female hosts. M, 50 bp DNA ladder, + positive 
control (peripheral blood mononuclear cell 
DNA from a male host). Lanes EN and ET are 
matched normal and tumour samples 
respectively from dog E; lanes HN and HT 
matched normal and tumour samples from dog 
H; lanes IN and IT matched normal and tumour 
samples from dog I; Lanes 14-30 paraffin 
embedded tumour samples.
Fig 7.2: Amplification of 650 bp fragment of Y 
chromosome in tumour samples from female 
hosts. M, 50 bp DNA ladder, + positive control 
(peripheral blood mononuclear cell DNA from 
a male host). Lanes EN and ET matched 
normal and tumour samples from dog E; lanes 
HN and HT matched normal and tumour 
samples from dog H; lanes IN and IT matched 
normal and tumour samples from dog I.
M + EN ET HN HT IN IT
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6.3 Discussion
To further test the cellular transmission of CTVT and to evaluate the possibility that 
the CTVT has originated from a male animal, the presence of the Y chromosome 
was analysed by PCR in tumour biopsies obtained from female hosts. The presence 
o f Y chromosomal DNA in the tumours and not in the normal blood of matched 
female hosts may indicate that CTVT arose from a male. However, despite using the 
same amount o f template in the primary PCR as for the positive male control, the 
tumour samples exhibited a much lower intensity of the PCR bands than in the 
control samples.
Although unlikely, these results might be explained by assuming that mutations in 
the flanking region of both the SRY and the 650 regions could decrease the PCR 
amplification efficiency. Alternatively the presence of the Y chromosome DNA in 
female hosts might occur if male fetal progenitor cells traffic to the mother during 
pregnancy and persist in the maternal circulation for many years (Jimenez et al.,
2005). However this hypothesis is ruled out by the absence of Y chromosomal DNA 
in the matched female blood samples.
Cytogenetic analyses of tumours in human and animals have reported that in 
tumours with a high degree of chromosome rearrangement, the Y chromosome is 
more frequently lost (Kujawski et al., 2004). Given that CTVT is highly aneuploid, 
the Y chromosome could have been lost from a male tumour at an early stage of the 
CTVT progression, before the stabilization of its abnormal karyotype. If only a 
small proportion o f tumour cells retained the Y chromosome that could explain the 
weak signal. I did not study whether the X chromosome was diploid or haploid.
An alternative explanation is that the detection of the Y chromosomal DNA in 
sexually transmitted CTVT tumours could come from passenger cells seeded during
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intercourse by the previous male host. This could be from sequestered sperm cells, 
although this seems unlikely in CTVT samples taken weeks after the presumed date 
o f sexual exposure, or it could be from male stromal cell in the tumours.
Generally tumour development is viewed as an autonomous process, in which, the 
accumulation o f somatic mutations have led cancer cells to overcome the 
microenvironmental control to gain independence from the host. However recent 
evidence has highlighted the importance o f the stromal cells in cancer initiation, 
progression and in invasion (Kiaris et al., 2004; Zigrino et al., 2005).
Tumour stroma contains a rich cellular population, which includes fibroblasts, 
smooth muscle cells, endothelial cells and inflammatory cells. Tumour cells 
interact with stromal cells and the microenvironment through the release o f soluble 
factors and by cell-cell and cell-matrix contact. It is thought that tumour cells alter 
stromal cell gene expression, by the production o f specific factors such as growth 
factors and cytokines, thus shaping the microenvironment surrounding the tumour. 
However recent analysis of stromal cells in breast tumours have identified specific 
mutations in tumour suppressor genes, suggesting that stromal cells can play an 
active role in tumorigenesis. Recent in vivo studies using mouse models and 
xenografts suggest that mutations in stromal fibroblasts can also initiate epithelial 
tumours (Bhowmick et al., 2004). It has been further suggested that chronic 
inflammation might lead to an alteration of stromal cell gene expression profiles 
which decrease their negative control over the cell proliferation, thus favouring the 
development of cancer (Coussens and Werb, 2002).
It can be argued that the presence of CTVT-associated stromal cells during 
transplantation could stimulate the host immune response therefore eliciting the 
tumour rejection. However, recently it has been shown that in addition to MHC 
down-regulation, the CTVT cells induce local immunosuppression to overcome
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immune rejection (Hsiao et al., 2004). Thus it can be argued that local immune 
suppression might also favour the proliferation o f normal passenger cells.
New blood vessel formation (angiogenesis) is a fundamental event in the process o f 
tumour growth and metastasis. New blood vessels can derive from the pre-existing 
vasculature or by direct acquirement of progenitor cells (Carmeliet, 2003).
Although tumour transplantation has been widely used since the time of Novinski 
(1876) as a tool to study and propagate tumour cells in vivo, the role of the stromal 
cells (passenger cells) in tumour growth is only just beginning to emerge. In a recent 
study Duda et al (2004) evaluated the fate of the tumour associated endothelial cells, 
demonstrating that endothelial cells proliferating in the new host remain 
functionally active for more than 4 weeks after transplantation, and govern the 
initial tumour neo-vasculature (Duda et al., 2004).
The important role of stromal cells has also been demonstrated in transplantation, 
where it is claimed that they are responsible for the prolongation of allograft 
survival (Ikehara, 2001) . Therefore the presence of passenger cells during natural 
transplantation of CTVT could favour the transplantation and proliferation process.
The presence o f Y chromosome DNA in tumour tissue derived from a female host 
needs further analysis, to determine whether the Y chromosome is present inside or 
outside the tumour cells themselves. For this reason CTVT chromosome spreads 
prepared using fresh tumour biopsies will be analysed by Fluorescence In situ 
Hybridisation (FISH) in collaboration with Professor Malcolm A. Ferguson-Smith 
and Dr David Sargan at the Cambridge Resource Centre for Comparative Genomics, 
Centre for Veterinary Science, University of Cambridge. If the Y chromosome is 
present outside the tumour cells, the morphology of the 'male' cells will be 
important to determine their origin. In contrast, if the Y chromosome is inside o f the 
CTVT cells, specific Y chromosome microsatellites markers can be analysed for
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phylogenetic studies as counterpart of the autosomal microsatellites and the mt- 
DNA analysis that it has been undertaken in this study.
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Chapter 7
Breed of origin and age of CTVT
7.1 Introduction
The place and origin o f the domestic dog has long been debated. Charles Darwin 
argued that the phenotypic variability observed in dogs is due to multiple and 
independent origins from two or more canine species. Konrad Lorenz suggested that 
dogs posses phenotypic traits of both wolves and jackals (Wayne and Ostrander, 
1999). However, molecular genetic studies based on mitochondrial control region 
sequences from wolves, jackals, coyotes and dogs have shown that wolves are the 
sole ancestors of the domestic dogs and that modem domestic dogs originated from 
at least four maternal wolf lines (Wayne et al., 1997; Savolainen et al., 2002). A 
recent phylogenetic study based on the examination of the mt-DNA control region 
from 654 dogs representing all major dog populations worldwide, showed that dog 
populations originated from a single genetic pool arguing for a East Asiatic 
domestication event about 15,000 years ago (Savolainen et al., 2002).
Although mitochondrial DNA analysis has been successfully used to elucidate the 
phylogenetic relationship between dogs and wolves, its evolution rate is too low to 
allow the inference of genetic relationships between dog breeds (Vila et al., 1999b; 
Savolainen et al., 2002). To date there are more than four hundred breeds with high 
phenotypic diversity. The majority of the dog breeds have had a recent origin from a 
diverse founding stock with subsequent interbreeding between breeds (Sutter and 
Ostrander, 2004). Mitochondrial DNA analysis indicated a low correlation between 
mt-DNA haplotype and breed; therefore the same haplotype can be found in 
different breeds, and different haplotypes are present within a breed (Savolainen et
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al., 2002). In order to clarify the genetic relationship between dogs several studies 
based on the Dog Leukocyte Antigens (DLA) analysis have shown a high variation 
between breeds and relatively low intra-breed variation of DLA class II haplotypes 
(Kennedy et al., 2002). Thanks to the important advance in theoretical population 
genetics, microsatellites have been used to infer population structure and 
demographic history in several species, including humans and dogs. A study based 
on 10 nuclear microsatellite DNA markers and involving 250 dogs belonging to five 
different breeds, showed that modem individual clustering methods allow the 
correct assignment o f individuals to their breed of origin (Koskinen, 2003). 
Recently Parker et al (2004), in an attempt to analyse the genetic relationship 
between breeds, analysed 414 dogs belonging to 85 dog breeds, using 96 
dinucleotide microsatellite markers; they showed that microsatellite markers 
combined with phylogenetic and clustering analysis can assign 99% of individual 
dogs to their original breed (Parker et al., 2004).
Tumours can be described as populations of tumour cells, originating from a single 
transformed cell, evolved through successions o f selection and clonal expansion 
(Greaves, 2002). Despite of numerous applications of microsatellite analysis in 
cancer, such as molecular markers to analyse the monoclonal origin, or the tumour 
response to chemotherapy or immuno-therapy or detect genetic abnormalities, they 
have only recently been used to infer genetic histories in mutator tumours (Tsao et 
al., 2000). Given that the mutation rates in most tumours are less than 10"6 per locus 
per division, the detection of somatic mutations in non-mutator type tumours is 
difficult (Shibata, 2001).
The inference o f the time of the most recent common ancestor (TMRCA) is based 
on the assumption of common mutation rates between populations (Stumpf and 
Goldstein, 2001). For tumours, this issue is difficult to resolve, because tumours 
with mutator phenotypes during progression may have different mutation rates 
between tumour populations.
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The results described in the Chapter 4 showed that CTVT arose from a common 
ancestral neoplastic cell o f a single host. Although CTVT cells are highly aneuploid, 
the tumour genotype is remarkably stable. Phylogenetic analysis has been widely 
used to understand past events in different human and animal populations, and it can 
similarly be used to understand the origin and evolution of CTVT.
This chapter describes inferences of the phylogenetic origin and an estimate of the 
age o f CTVT. First the DLA alleles specific to CTVT were examined to gain an 
indication o f the breed of origin. Second a more intensive analysis of tumour 
genotypes was carried out based on a set o f dinucleotide microsatellite markers used 
previously to determine genetic relationships among 85 different dog breeds. Third, 
mt-DNA tumour haplotypes were analysed using different phylogenetic methods.
7.2 Results
7.2.1 Breed of origin according to DLA haplotype
DRB1 polymorphisms have been extensively used in genetic and evolutionary 
studies in several canid species (Kennedy et al., 2002). In contrast, DLA-88 
polymorphisms are poorly characterised. Therefore a phylogenetic analysis was 
performed using host and tumour allele sequences found in this study and 
previously published DRB1 sequences including alleles of dogs, North American 
and European grey wolves and coyote.
The phylogenetic analysis was performed using the maximum likelihood method 
implemented in PAUP. The ML tree (Fig 7.1) shows that the CTVT DRB1 alleles 
are clustered with nine DRB1 sequences; however DRB1 04101 and DRB1 04201 
described in North American wolves and coyotes are closer in term of nucleotide
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substitutions. O f these nine DRB1 haplotypes, the 04701 allele has been found in 
association with the DQA1 00402 allele in Huskies.
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Fig 7.1. DLA DRB1 phylogenetic relationship between tumours and their hosts 
and published DRB1 alleles of dog, wolves, and coyotes. Human DRB1 alleles 
were used as outgroup. Alleles in Blue, Green and Pale Blue represent host alleles 
found in Italy, Kenya and India respectively. Tumour alleles are indicated in red.
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7.2.2 Breed of origin according to microsatellites
In order to determine the origin o f the CTVT in more detail, seventy-three 
microsatellite loci were genotyped in three matched tumour and normal samples one 
each from India, Italy and Kenya. A further analysis of twenty-four microdissected 
tumour samples o f diverse geographic origin was performed using a subset of 18 of 
the 73 markers. These microsatellites markers were chosen because they have been 
previously genotyped by Parker et al (2004) in a set of 8 wolves from different 
countries and 414 dogs representing 85 different breeds. Tumour genotypes were 
compared with the genotypes described by Parker, using a common positive control 
sample to ensure consistent conversion of peak sizes to alleles (binning) between 
runs.
A model-based clustering algorithm. Structure (Pritchard et al, 2000) was used to 
investigate the relationship between CTVT and the data obtained from dogs 
belonging to 85 breed and 8 wolves. The Structure method groups individuals in to 
a pre-specified number o f clusters, as explained in Chapter 4 for comparing tumours 
and hosts. In this case no prior information regarding the breed of origin was 
applied to the algorithm. As shown in (Fig 7.2), using 18 dinucleotide markers and 
assuming 2 clusters (K=2), the tumour samples were clustered with wolves and a set 
o f dog breeds that were previously grouped by Parker et al (2004) in an ancient 
breed cluster, because they are genetically most similar to wolves. This finding is 
consistent with the breed assignment based on DLA alleles. At higher values of K, 
all tumours were grouped in into a single cluster that is distinct from both dogs and 
wolves, thus confirming the monoclonal origin o f the CTVT.
To determine the specific origin of CTVT, additional clustering analysis was 
performed, focusing on the subset of individuals, that shows genetic similarity to 
CTVT (Fig 7.3). The model used allowed CTVT samples to have a mixed ancestry, 
so that if the ancestor was a mongrel dog, then CTVT ancestry should be spread 
across two or more breeds. In addition, to force the tumour samples to cluster with 
dog/wolf cluster(s), the PFROMPOPFLAGONLY was used. In this analysis, all
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individuals from Parker et al (2004) were correctly assigned to their respective 
original breed, whereas tumours were clustered more strongly with wolves, 
suggesting that CTVT possibly originated in wolves. Given that the wolf sample is 
larger than the dog samples (8 individuals versus 5), in order to check if this biases 
the clustering o f tumour samples with wolves, a set of 3 wolves was randomly 
dropped to rerun the structure analysis with the same parameters. In this case the 
posterior assigment o f tumour to the w olf cluster was slightly lower (at K= 4 from 
0.74 to 0.66).
A different additional analysis was performed using the Neighbour-Joining method, 
to build an unrooted tree based on the pairwise distance among genotypes 
(nonparametric clustering method). This analysis (Fig 7.4 a) again indicates the 
similarity between CTVT and wolves. The relationship between CTVT and wolves 
was confirmed when the tree was constructed using all dog and wolf populations 
(Fig 7.4 b).
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Figure 7.2. Structure analysis of the relationship between tumor genotypes and normal genotypes represented by 414 dogs of 
different breeds and 8 wolves, based on 73 microsatellite loci. Each panel shows the results from a model-based clustering 
algorithm, Structure, that assigns sampled individuals, based on their genotypes, to a pre-specified number K of clusters. Each 
tumor sample, or individual, is represented by a vertical line, with colored segments indicating the proportion of that 
individual's membership in each cluster. At K=2, the tumours cluster clearly with wolves and certain dog breeds; for larger K 
values, the tumors form a distinct group, indicating a common origin.
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Fig 7.3. Structure analysis of the individuals that appeared most closely related to CTVT (yellow at 
K=2 in Figure 6.1). In this analysis the 3 tumour genotypes (one each from India, Italy, Kenya) based 
on 73 dinucleotide markers, were forced to cluster to dog/wolf clusters without creating their own 
cluster. Structure runs were performed using an admixture model, with correlated frequency assuming 
different K values (2-6).
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Fig 7.4 Neighbor-Joining trees based 
on pairwise distance matrix obtained 
analyzing 3 CTVT samples (India, 
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that were clustered with CTVT 
sample using Structure analysis (Fig 
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7.2.3 Age of the CTVT
According to Coalescent theory, the extant alleles (DNA polymorphism) within a 
species or population derive from a common ancestral allele (Donnelly, 2001). 
Thanks to recent advances in theoretical population genetics, a variety of 
coalescence methods have been used to infer past evolutionary history in several 
species. This genealogical relationship between alleles within a population can be 
also used to infer the most recent common ancestor from the extant tumour cell 
lineages.
As discussed in the previous chapter regarding the monoclonal origin of the CTVT, 
phylogenetic analyses have shown that the extant tumours from several countries 
derive from a common ancestral clone. Therefore a coalescence approach can be 
applied, and the time of the most common ancestor (TMRCA) of CTVT can be 
inferred. The genetic variation between tumours was estimated by examining the 
level of microsatellite variation across tumours (Fig 7.5). The variability between 
tumours is much lower than variation o f wolves and dogs as a whole (8 wolves and 
414 dogs belonging to 85 breeds) and even less variable than the most inbred 
(Miniature Bull Terrier) of the 85 breeds studied by Parker et al (2004). The low 
variability of the CTVT seems suggests a recent origin of the extant clones of CTVT 
as transmissible parasite.
Seventeen o f 18 microsatellites genotyped show a single genotype in half of the 
tumours analysed. This was assumed to be the ancestral CTVT genotype. The 
analysis o f the distance between the ancestral genotype and tumours collected at 
different time points (29 years) do not show any correlation, suggesting that the time 
o f the most recent common ancestor is considerable higher than 30 years. The 
microsatellite variation analysis expressed as average expected heterozygosity (Fig 
7.5) shows a lower variability within CTVTs than within dogs in general and as a
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single breed, and within wolves. Although there is no direct information about the 
microsatellite mutation rate of CTVT, the genotyping results show a genetic 
stability at dinucleotide repeats, indicating that CTVT has an efficient mismatch 
repair mechanism.
Given the unclear estimates of the microsatellite mutation rate in the canid family, a 
mutation rate o f 10'3 to 10-4 per generation for typical loci, reported in humans was 
used (Huang et al., 2002) in order to estimate the time since divergence from a 
common tumour ancestral lineage. Assuming the absence o f back mutation (a small 
effect when most genotypes are identical), the probability that a genotype matches 
the ancestral genotype is exp(-mu t), where mu is the mutation rate, per genotype 
per year, and where t is the time in years since the common ancestor. If we suppose 
that genotype mutation rates of 10° to lO*4 /year are appropriate for CTVT, an age 
estimate ranging from 250 to 2500 years is obtained.
A further estimate o f the CTVT age was computed using the mt-DNA control 
region. A 580bp sequence obtained from 11 fresh specimens, and a shorter 257bp 
fragment obtained from 21 micro-dissected tumour cells from paraffin embedded 
specimens were analysed. In order to place our data in the context o f dog and wolf 
mt-DNA sequences, we analysed our data along with additional sequences obtained 
from previous studies of canid (Tsuda et al., 1997; Vila et al., 1997; Randi, 2002; 
Savolainen et al., 2002).
Two maximum likelihood trees were computed using the program PAUP* and 
analysing a subset of the tumour mt-DNA sequences (21 tumour haplotypes) and the 
previously obtained dog and wolf sequences (45 haplotypes). As noted before 
(Savolainen et al, 2002), there is considerable rate heterogeneity across sites within 
the sequence. This fact combined with the small number of substitutions separating 
most o f the sequences, means that there is considerable uncertainty in the estimated 
tree. Nonetheless, the tumours again fall into two main groups within clade A
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(Figures 7.7. and 7.8). The first maximum likelihood tree (Fig 7.7) was constructed 
by assuming that the tumour sequences are monophyletic. It is noteworthy that as 
noted in chapter 4, the tumours form two distinct clusters that correspond to haploid 
and diploid status at DQA1. Given that the branch lengths are proportional to the 
maximum likelihood times elapsed on each branch, this tree suggests that the 
common ancestor age of the haploid and diploid CTVT clades are each only slightly 
younger than the origin of dog clade A.
The second maximum likelihood tree (Fig 7.8) was constructed without assuming 
that the tumour sequences are monophyletic. This tree indicated that two tumour 
sequences 8C and 5F group separately from the main tumour clades. These tumour 
haplotypes are both short sequences obtained from fixed samples, and so there may 
be uncertainty about their true position on the tree. Moreover, contamination by host 
mt-DNA cannot be excluded. To estimate the time of origin of CTVT, the genetic 
variability within CTVT mt-DNA haplotypes relative to dog mt-DNA in general 
was determined (Fig 7.6). Savolainen et al. (2002) have previously estimated that 
the most recent common ancestor of dog clade A occurred about 41,000 years ago, 
assuming a unique single origin and a star-shaped genealogy (Savolainen et al., 
2002). Fig 7.6 shows that pairwise variability within CTVT is actually larger than 
the variability within dog Clade A (1.38% vs. 0.73% pairwise divergence). Within 
the two subclades defined by DQA1 status, pairwise variability is lower, but still 
comparable with that of the entire clade A (0.84% and 0.69% for the haploid and 
diploid clades respectively). Hence, on their own, the mt-DNA data argue for an 
extremely ancient origin of CTVT, roughly coincident with the domestication of 
dogs.
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Fig 7.5 Microsatellite average expected heterozygosity 
Miniature Bull terrier and Australian Sheperd represent the 
most and least heterozygous dog breeds respectively across 85 
dog breeds analyzed.
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Fig 7.6: mt-DNA pairwise sequence divergence
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Figure 7.7 Maximum likelihood (ML) tree of mt-DNA sequences from 2 1 
CTVT samples and 45 haplotypes representing dogs, wolves. A Coyote 
haplotype was used as outgroup. The ML tree was constructed subject to the 
constraint that the tumour sequences are monophyletic. The brackets indicate 
tumours samples with a haploid or diploid DQA l status. The red arrow indicates 
tumour haplotypes separated from the main two clusters.
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Figure 7.8 Maximum likelihood (ML) tree of mt-DNA sequences from 
21 CTVT samples and 45 haplotypes representing dogs, wolves. A 
Coyote haplotype was used as outgroup. The ML tree was constructed 
without assuming that the tumor sequences are monophyletic. The 
brackets indicate tumours samples with DQA1 haploid and diploid status. 
Red arrow indicates CTVT samples separated from the main tumour 
clades.
7.3 Discussion
The domestic dog (Canis familiaris) descends from grey wolf (Canis lupus), but the 
place and the origin of domestication have been much debated. Mitochondrial DNA 
analysis has been used to elucidate the relationship between dogs and wolves. 
Recent phylogenetic analysis was based on mt-DNA hypervariable region 1 (HVR1) 
group dogs in 6 clades (A-F) with 95 % o f dog haplotypes clustered on one o f three 
clades A, B and C (Savolainen et al., 2002). Although clades B and C appear to be 
derived from a single wolf female line, clade A has originated from several wolf 
haplotypes. Clade A contains almost exclusively dog haplotypes, and to date only 
five wolf mt-DNA haplotypes: 3 from East Asia and 2 from Bulgaria. Despite of 
numerous efforts to genetically link the majority o f the dog sequences to a particular 
wolf population, no match has been found, arguing for the extinction of the 
ancestral wolf population (Vila et al., 1997).
Phylogenetically CTVT mt-DNA haplotypes are grouped in two clusters within 
clade A, thus suggesting a probable origin in dogs. However given the presence of 
five wolf haplotypes within clade A, the wolf origin of CTVT cannot be excluded. 
Given the close genetic relationship between dogs and wolves, and the fact that dogs 
have coexisted with wolves until recent times across a diverse array of habitats, 
hybridisation between dogs and wolves occurred regularly. Wolf-dog hybrids have 
been reported in different countries such as USA, Italy, Spain and Israel (Vila and 
Wayne, 1999; Randi, 2002). However recent genetic studies based on the analysis 
o f mt-DNA indicate that the hybridisation between wolves and dogs is uncommon 
(Vila et al., 2003).
These observations raise the possibility that CTVT may have originated from a 
wolf-dog hybrid. However, the homozygosity present in the most polymorphic DLA 
class II genes suggests that both parents of the original CTVT host were related.
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A genetic comparison of the canine MHC class II genes between wolves, dogs and 
coyotes, shows that several DLA class II alleles are shared between these species 
(Seddon and Ellegren, 2002). Despite a recent domestication event from wolves, 
substantial allele sharing has been observed only at the DQA1 locus. It has been 
argued that the reduction o f shared DRB1 and DQB1 alleles between wolves and 
dogs may be due to the severe reduction of the wolf population size, with 
consequent genetic drift and loss of alleles, in conjunction with a large increase in 
the dog population size. Thus the DLA DRB1 and DQB1 alleles observed in dogs 
would have been present in ancestral wolf populations (Seddon and Ellegren, 2002).
The DLA-88 and DRB1 alleles present in CTVT have not been so far identified in 
any canid species, although the tumour DRB1 allele is close to alleles described in 
North American wolves and coyotes and Alaskan huskies. The CTVT DQB1 
present in the tumour has been described in North American and European wolves 
and in several dog breeds. The DQA1 allele present in the tumour has been so far 
described only in Huskies (allele 00402).
A recent investigation of the DLA class II haplotypes in over one thousand dogs 
representing 85 pure breeds shows an extensive inter-breed, but minimal intra-breed 
variation. It was also demonstrated that the level of homozygosity is high within 
breed for all three DLA class II genes, but only dogs belonging to rare breeds were 
homozygous at all three loci. In contrast to purebred dogs, feral dogs and large wolf 
populations show a high level of heterozygosity (Kennedy et al., 2002). Therefore 
DLA class II homozygosity present in CTVT indicates that the original CTVT host 
derived from an inbred population, possibly an isolated breed belonging to Spitz 
group or a wolf pack.
Because wolves live in packs that are primarily family units, there is considerable 
opportunity for incestuous mating. Yet some studies suggest that within wolf packs, 
mated wolves are rarely related as siblings or as parent-offspring (Seddon and
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Ellegren, 2004). This observation suggests that in general, wolf packs are 
established by unrelated or more distantly related wolves. Therefore despite of 
frequent opportunity, incestuous reproductive succession is not a common means to 
attain reproductive success. However several genetic studies suggest that incestuous 
mating in wolves occurs primarily where wolves are prevented from out-breeding, 
such as a population bottleneck or geographical isolation (Seddon and Ellegren, 
2004).
Savolainen et al. (2002) have shown from the comparison o f the mt-DNA control 
region in more than 100 dog breeds that there is low correlation between mt-DNA 
haplotype and breeds. Therefore although the mt-DNA analysis may resolve the 
difference between species, it cannot assign an individual at a specific breed 
(Savolainen et al., 2002). Phylogenetically CTVT tumours are grouped in two 
clusters within clade A. In cluster 1 there are tumours that share their haplotypes 
with a previous described haplotypes named A18 found in different breeds, whereas 
cluster 2 seems to be derived from haplotypes A22 also found in different breeds. 
Given that wolves are highly mobile and that up to few centuries ago were 
widespread throughout the Holarctic, the mitochondrial DNA shows a low 
geographical structure (Vila et al., 1999a). In contrast, some dog haplotypes show a 
correlation with their geographical origin. However the haplotypes A18-A22 are 
present in breeds o f different geographical origin.
Interestingly tumours within cluster 1 show a diploid DQA1 status, whereas 
tumours in cluster 2 posses a haploid DQA1 status. The DQA1 deletion present in 
the cluster 2 seems to indicate that cluster 1 is the original CTVT mt-DNA 
haplotype. However, the ancestral tumour haplotype may be extinct.
The inferred ancestral haplotype is genetically close to haplotype A31 that has been 
found only in West Laika dogs (a breed belonging to the Spitz group).
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Although more than one haplotype was found in some tumours, which were 
grouped in the same cluster, no tumour possessing both haplotype clusters (1 and 2) 
was found. Recently it has been shown that mt-DNA heteroplasmy is present both in 
tumour and normal cells, and that a mutated mt-DNA molecule may reach a 
homoplasmic status in a normal cell in seven days (Mambo et al., 2003). It has been 
suggested that homoplasmy occurs due to the selective advantage of the mutated 
haplotype (Bianchi et al., 2001). However theoretical studies have demonstrated that 
genetic drift could also explain this phenomenon (Bianchi et al., 2001; Coller et al., 
2001 ).
In contrast to mt-DNA analysis, microsatellites have been successfully used to 
assign dogs to their original population or breed. Phylogenetic analysis based on 
microsatellites showed divergence between breeds o f ancient origin that are closer 
to wolves, and breeds of presumed modern European origin (Parker et al., 2004). 
Recent studies aimed to analyse the differentiation and hybridisation between 
wolves and dogs using microsatellites markers have showed that wolves from 
different populations are more related compared to dogs o f different breeds (Randi, 
2002).
Genotyping analysis of microsatellites indicates that CTVT has originated in 
wolves. However, some caution is required due to the small sample sizes of each 
breed, and the fact that the available dog data were limited to pedigree breeds 
(Parker et al., 2004), so an origin in domestic dogs is not excluded. Moreover, the 
Structure assignment analysis indicates also that CTVT forms its own cluster. This 
might be due to the fact that CTVT derives from an unsampled wolf or dog 
population, or that during evolution CTVT has diverged from its original 
population. In contrast to wolf and dog populations as a whole, CTVT shows low 
microsatellite diversity. Generally the reduced microsatellite variability is due to 
several factor such as genetic isolation, bottleneck, or inbreeding (Ellegren et al., 
1996). Although the mechanism of mutation in microsatellites is due to slip-strand
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mispairing during replication, a further mechanism that increases genetic variability 
is recombination between homologous chromosomes during meiosis (Ellegren et al.,
1996). The lower genetic variability of CTVT may be due to selection or, given that 
CTVT reproduces asexually, by the absence o f recombination.
Development o f cancer in humans is due to accumulation and selection o f different 
mutations in at least six cancer associated genes (Hahn and Weinberg, 2002a). 
Given that tumours evolve within a finite lifetime, mutator mutations that accelerate 
the mutation rate are thought to contribute frequently to the carcinogenesis (Loeb 
and Loeb, 2000). However the reduced microsatellite diversity founded in CTVT 
indicates that CTVT is evolving with a normal mutation rate, thus suggesting a 
recent origin of the tumour.
Although an increased mutation rate may accelerate the accumulation of oncogenic 
mutation (positive clonal selection), it also affects other genes thus reducing the 
cellular fitness. These mutations may mediate the selective elimination (negative 
clonal selections) o f mutator clones (Beckman and Loeb, 2005). Recent theoretical 
studies have indicated the existence o f a mutation rate limit beyond which the 
negative clonal selection limits the survival of mutator clones (Sole and Deisboeck, 
2004; Beckman and Loeb, 2005).
Although the extant CTVTs are genetically stable, the remarkable constant 
chromosomal rearragments suggests that in the early stages of its evolution, CTVT 
exhibited chromosomal instability (CIN). Genetic defects in DNA damage repair 
genes have been associated with a variety of predisposition syndromes, such as 
hereditary non-polyposis colorectal carcinoma (HNPCC), Bloom Syndrome and 
ataxia-telengiectasia, and also with other tumours that possess a mutator phenotype, 
characterised by an high mutation rates, and consequently by genetic instability 
(Charames and Bapat, 2003).
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Recent studies indicate that besides the genetic defects, epigenetic mechanisms are 
also responsible in promoting the genetic instability by altering the genetic 
expression of DNA repair genes (Charames and Bapat, 2003). The epigenetic 
mechanisms involve both loss and gain of DNA methylation as well as alteration of 
histone modifications (acetylation and phosphorylation). Although epigenetic 
mechanisms can occur at any time during tumour progression they occur more 
frequently at the early stage of tumour development (Baylin and Ohm, 2006). In 
contrast to genetic alteration, epigenetic alteration can be reversed. From the above 
consideration, it can be argued that epigenetic mechanisms can be responsible for 
the genetic stabilization of CTVT. Therefore understanding how CTVT has 
stabilized its genome may have biological and therapeutic implications for cancer.
Although cancer cells die when their host dies, the advent of the mammalian cell 
culture and cloning allowed the development of immortalized cell lines able to live 
and spread in laboratory cultures. Human HeLa cells were cloned by Puck in 1952 
and since then are continually propagating (Weiss, 2005).
Novinsky made the first description of CTVT in 1876 in Petersburg. However a few 
years later CTVT has been described in several countries, thus suggesting an older 
emergence date. The impossibility to analyse ancient tumours makes difficult to 
calibrate a molecular clock for CTVT. However assuming a stable mutation rate of 
10  ^to 10*4 (at least since its emergence as a parasite) the genetic divergence of the 
dinucleotide repeats indicates that the tumour arose between 250 and 2500 years 
ago. Assuming that the tumour acquired the parasitic features from the begining, 
this date represents the time the tumour first arose. In contrast if the tumour has 
evolved as parasite in different hosts, this date could represent a later bottleneck, 
where the ancestral tumour parasite clone arose.
Savolainen et al (2002) using a substitution rate of 7.1 % per million years, and 
assumed a divergence time of one million years between coyotes and wolf, to
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suggest an approximate age of 41,000 ± 4000 years for clade A, assuming a single 
origin
In contrast to microsatellites, assuming a normal substitution rate, the mt-DNA data 
argue for an extremely ancient origin of CTVT, roughly coincident with 41,000 
years. These contrasting results may be due to the fact that the mt-DNA mutation 
rate in CTVT is higher than normal. Thus in CTVT the somatic mutations in mt- 
DNA do not associate with nuclear microsatellite instability.
Given that the mitochondrial genome does not posses its own repair mechanisms, 
nuclear genes are responsible in repairing the mt-DNA mutations (Bianchi et al.,
2001). In contrast to the nuclear genome, mt-DNA is more susceptible to 
electrophile and oxidant damage leading to rapid accumulation of homoplasmic 
mutations (Mambo et al., 2003). From the above considerations the estimated of the 
age of the most recent common ancestor of CTVT obtained by microsatellites seems 
to be more likely. Although the estimated date of between 250 and 2500 years 
represents a recent evolutionary origin, CTVT represent the oldest known 
immortalised somatic cell in continuous propagation, having undergone countless 
mitoses and animal to animal transfer since it arose in a progenitor.
181
Chapter 8
Conclusions
In vertebrates, genetic variation can be only inherited through germ cells, which are 
separated from somatic cells early in embryogenesis. It has been argued that this 
ontogenic separation o f the germ line limits competition between somatic and germ 
cells (Ridley, 2004a). Buss has pointed out that this kind of development known, as 
“Weismannist” is exceptional among diverse multicellular organisms, including 
colonial organisms where the generation of new individuals can be formed from 
somatic cells. In these organisms, cellular competition allows the emergence of 
super competitor or parasitic cells capable of reproducing themselves and spreading 
'infectiously' to the other member o f the colony by fusion, thus forming a chimera 
(Buss, 1982).
Natural selection operates upon biological entities that can be divided into different 
levels of organization from genes through chromosomes, cells, organs, and 
organisms, to groups within a species, and between species. In contrast to asexual 
organisms where selection between somatic cells can take place, In vertebrates 
natural selection is limited to germ cells (Ridley, 2004a). Recent studies have 
demonstrated that in the colonial ascidian Botryllus schlossery, the unit o f selection 
is the stem cell, which is able to produce both somatic and germ lineage cells. It has 
been also shown that these stem cell lineages may compete with stem cells of 
closely related colonies for access to gametic or blastogenic niches that will form a 
new individual (Laird et al., 2005).
In vertebrates the somatic cell lineages die when the organism dies, therefore 
limiting any form of selection to the germ lines that are transmitted by sex to form a 
new individual. Similarly somatic cancer cell lineages come to an end with the 
organism’s death. CTVT thus represents a special case, because somatic cancer cells
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have acquired the ability to spread naturally to other individuals acting like a 
parasite, thus, gaining independence from its original host.
In order to survive parasites evolve to increase their ability to propagate in the next 
host; thus the target of selection is transmission success (Frank, 1996; Weiss, 2002). 
Therefore a successful parasite may exploit its host resources in a prudent way 
without causing excessive damage, because a rapacious exploitation, although it 
increases the reproductive rate within a host, will reduce the probability of 
transmission among hosts. Furthermore, a limited resource may select the parasite 
for a prudent way of exploitation instead o f a rapid and rapacious way because it 
will reduce the total resource for the future progeny. Competition between parasites 
for limited resources influences virulence and therefore transmissibility (Frank, 
1996).
According to Kin Selection theory (Hamilton, 1964), cooperation between parasites 
(prudent exploitation of resources) is favoured by natural selection if the net 
reproductive value (total progeny in a susceptible population) among genetically 
related parasites is higher than the cost (reproductive value within the host). 
Therefore if genetically unrelated parasites use a limited resource, natural selection 
favours the parasite genotype that is capable of using a major quantity of resources 
to produce more progeny, thus increasing the conflict between parasites and the 
rapacious exploitation within a host (Frank, 1996). These observations suggest that 
individual selection favours short-term benefits while the kin selection favours long­
term benefits.
According to natural selection theory, no selection can take place between 
genetically identical cells. The genetic relatedness between cells is influenced by 
many factors; among them one of the most important is the mutation rate (Michod, 
1996). Cells o f somatic tissues may accumulate mutations that are naturally 
selected. According to the clonal evolution theory of cancer, somatic cells bearing
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mutations that increase the reproductive rates are expanded (Nowell, 1976; Greaves,
2002). While mutations in oncogenes and tumour suppressor genes enhance the 
reproductive rate, mutations in genetic instability genes increase mutation rates 
(Michor et al., 2003; Michor et al., 2004). Genetic instability is manifested as 
microsatellites instability (MSI) or chromosomal instability (CIN). Although 
enhanced mutation rates may slow down the growth rate due to the accumulation of 
lethal mutations, recent theoretical studies have demonstrated that genetic instability 
is a disadvantage only when clonal expansion is accelerated (Beckman and Loeb, 
2005; Nowak et al., 2005).
Although the debate on whether genetic instability plays an important role during 
the early stages o f a tumour progression or is just a late stage consequence o f the 
cancer evolution is still open (Sieber et al., 2005), the results obtained in this study 
show that CTVT is genetically stable. However, cytogenetic studies suggest that 
genetic instability might have played an important role in the early stages of the 
CTVT evolution.
Is has been suggested that due to the absence of recombination, asexual organisms 
can suffer from an effective accumulation of irreversible deleterious mutations 
throughout time, leading the finite population to extinction (Muller, 1964), called 
Muller’s ratchet. Although CTVT is an asexual reproducing cell it does not appear 
to be subject to Muller’s ratchet. This could be explained by the fact that CTVT may 
be not old enough to be affected by Muller’s ratchet (Gordo and Charlesworth, 
2000). However it has been shown that the reduction in population size during the 
parasite transmission bottleneck, accelerates the ratchet (Bergstrom et al., 1999). In 
contrast, weak purifying selection can lead to the complete cessation of the ratchet 
(Gordo and Charlesworth, 2000).
It can be argued that similar factors may also play an important role in CTVT. 
Recently it has been proposed that cell-cell fusion between tumour and normal cells
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or between tumour cells, might allow recombination between different genomes, 
thus contributing to cancer progression (Parris, 2006). However, in CTVT the 
constant rearranged karyotype and the genotyping results, suggest that 
recombination between different genomes is most unlikely to have played an 
important role during its evolution.
Another factor that influences relatedness between parasites is the bottleneck effect 
during the transmission event (the numbers of parasites that are transmitted from 
one host to the other). Therefore species with higher mutation rates are more prone 
to conflict than species with low mutation rates, and larger samples (number of 
parasites) during transmission decrease relatedness favouring competition between 
parasites (Bergstrom et al., 1999).
CTVT cells with their stabilized genome may reflect kinship selection and reduced 
virulence thus aiding host survival and onward tumour transmission. According to 
the theory o f somatic evolution, tumour cells typically evolve towards the 
selfishness that ultimately results in a more malignant phenotype with severe effects 
on the host’s fitness (Nunney, 1999; Greaves, 2002; Michor et al., 2004). In contrast 
for the evolution of the parasite, host conditions are extremely important, and 
virulence has to be modulated to limit host damage (Frank, 1996). CTVT is a 
sexually transmitted neoplastic disease; therefore the fitness of its host is essential 
for the tumour transmission, especially in a natural environment where the males 
compete to mate.
It is generally accepted that down-regulation of the MHC antigens represents the 
major mechanism for tumours to escape the immune surveillance system (Dunn et 
al., 2004a). Furthermore, it has been observed that MHC negative tumours tend to 
be more malignant (Kageshita et al., 1999). The lack o f expression of MHC antigens 
in CTVT seems to be in contrast to the reduced pathogenicity of CTVT, because 
assuming the evolution of a tumour within an individual, selection would increase
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tumour malignancy, thus decreasing host fitness (Frank, 1996). Therefore the within 
a host evolution is in conflict with the observed features of the CTVT, which have 
been selected to limit host damage. These parasite features may be explained 
assuming that CTVT has evolved through a multi-host evolutionary model. In an 
inbred population, the tumour could have been transplanted to a different host 
having the same DLA haplotype, so avoiding tumour rejection. In this first stage the 
tumour cells have been selected to maximise transplantability and transmission 
within a syngeneic population. Moreover, an infected female must survive and be 
fit enough to progress through a successful oestrous cycle in order to transmit the 
tumour to a new male.
The reproductive success of a parasite is correlated with the frequency of the 
encounters (susceptible hosts) present in the environment (Frank, 1996). Wolves are 
monogamous, where only the alpha male and females are allowed to breed, whereas 
dogs are more promiscuous. Therefore a successive step during CTVT evolution 
may have been to increase the range of susceptible hosts, from a syngeneic 
population to an allogeneic population. This process has been necessary because 
after tumour regression, the host is immune to CTVT reinfection so decreasing over 
a period of time the number of susceptible hosts.
It has been suggested that self/non-self recognition systems have evolved as defence 
against pathogens and somatic cell variants. From genetic studies applied to the 
cellular slime mould, Dictyostelium mucoroides. Buss proposed that the self/non­
self recognition system has evolved to limit the spread of somatic or germ cell 
parasites in colonial organisms (Buss, 1982). It may be argued that the driving 
selection for the evolution of the MHC system and cell mediated adaptive immunity 
in early-jawed vertebrates may have been as much to protect against spreading 
cancer cells as against infections, because invasive and metastatic tumours develop 
only in vertebrates, whereas infections are universal.
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In humans, cellular transmission of cancer has been observed in immuno-suppressed 
transplant recipients if the donor organ or tissue inadvertently contains occult 
tumour cells (Barozzi et al., 2003; MacKie et al., 2003). In contrast to the natural 
transmission of CTVT to immunocompetent dogs, the post-transplant tumour is not 
rejected because o f the immunosuppressive treatment. However many tumours in 
humans down regulate the MHC class I and II expression (Garrido and Algarra, 
2001; Khong and Restifo, 2002), and therefore MHC defective tumours might also 
proliferate in immunocompetent individuals. Similarly, the cellular transmission of 
MHC positive tumour cells, especially tumours o f genital tract, could be facilitated 
among AIDS patients. Therefore the possibility exists for tumour cells to survive 
and proliferate in different hosts from their original. It is not clear why parasitic 
tumours have not emerged more frequently.
However, the natural transmissibility o f CTVT may be not unique. From karyotype 
analysis Cooper et al (Cooper et al., 1964) reported that a transmissible hystiocytic 
tumour in inbred Syrian hamsters appears to be a case of cellular transmission. 
Recently, a tumour has been described in the Tasmanian devil called Devil Facial 
Tumour that based on cytogenetic analysis may also be a case of cellular 
transmission (Pearse and Swift, 2006). Recent genetic analysis of this endangered 
marsupial species has shown a very low degree of genetic diversity, which is 
consistent with a recent founder effect. It has been suggested that island effects and 
repeated periods of low population density may also have contributed to the low 
genetic variation within Tasmanian devil population (Jones et al., 2004). Although 
no MHC analysis has been performed, it can be argued that the Devil Facial Tumour 
may have emerged within a syngeneic population.
The foregoing discussion illustrates that CTVT represents a special case o f somatic 
cell parasitism. As a transmissible tumour cell, it is not entirely unique if the Syrian 
hamster and Tasmanian devil tumours are accepted to originate from transmissible 
cells. However, such tumour outbreaks may be self-limiting in local populations,
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such as hamsters within a single captive inbred colony, or Tasmanian devils within a 
small, partially inbred population. It is remarkable that as shown in this thesis, 
CTVT is a monoclonal tumour that has spread worldwide and has sustained 
transmission for at least 250 years, probably much longer.
In conclusion, CTVT is a most interesting biological phenomenon. It challenges us 
to think more deeply about genome stability in evolving tumour cell populations; 
how somatic cells may evade allograft rejection; and whether the evolution of 
adaptive cell-mediated immunity in vertebrates may have been driven in part by 
protection against allogeneic malignant cells.
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